

# PROGRAMME BOOK

# EVER 2013

September 18-21  
Science for Sight

# NICE

European Association for Vision and Eye Research



[www.ever.be](http://www.ever.be)

21 CME credits



Please join us for a  
scientific symposium

# Non-Infectious Uveitis

A **Short Look Back**  
and a **Long Look Forward**

Friday, 20 September  
18:15–19:15

Hermes Auditorium, Level 2  
Acropolis Convention Centre

## AGENDA

### Welcome

### Session 1

Epidemiology, immunopathology, and the role of cytokines in non-infectious uveitis

### Session 2

Classifying and stratifying patients to manage non-infectious uveitis and its complications

### Session 3

Where are we for treatment guidelines?

### Session 4

Scientific exchange



*Philippe KESTELYN  
EVER President 2013*

Dear EVER members,

As EVER president it is my pleasure and a privilege to invite you to the 2013 EVER meeting in Nice, France. Our 2012 meeting inaugurated this Congress venue, and judging from the broad attendance, one can only conclude that many EVER members consider this location to be a very convenient one.

During the last decade ophthalmology has witnessed many important changes: the pathogenesis of wet AMD is better understood and we start to have effective treatment; pharmacological interventions for vitreoretinal interface pathology are now a fact; thanks to innovative therapies we will be able to postpone or to avoid surgery in a substantial number of patients with keratoconus; cataract surgery will probably move from manual surgery to laser surgery in the near future; and last but not least, the first results of gene therapy for retinal dystrophies in humans have been published in the last years. These are just a few examples to illustrate how the constant progress in basic science and the results of translational and clinical research have a major impact on the way we tackle blindness and vision loss in our patients. The great thing about the EVER meeting is that it provides a platform for discussion to all those who participate in this complex process that leads to progress in Visual Science and Ophthalmology: from the basic scientist to the highly subspecialized clinician, from the young PhD student to the internationally renowned expert. The informal atmosphere at EVER and the ample opportunity for discussion during the conference create a favourable climate for dialogue and cross-fertilization.


It is our hope that future European collaborations and projects may be initiated at the EVER meetings.

This year's programme brings the usual combination of forty-five Special Interest Symposia from the eleven EVER sections; six Commercial Interest Symposia, eighteen Courses; Key Note lectures, some delivered by world class scientists; joint meetings with twelve other Groups, Clubs or Societies; and of course traditional poster sessions with opportunity for face-to-face discussion. It is not always easy to strike the right balance between basic science and clinical research, but the Board members are aware of this issue and will monitor it in the future.

While it is clear that the quality of the scientific programme is our prime concern, I am equally convinced that most EVER members will greatly appreciate the charms, the climate and the surroundings of Nice, an ideal setting for the social activities of the EVER meeting. The social programme in 2013 will include as a novelty a Farewell party on Saturday evening. I hope that this party will unite happy attendants, ready to go home with good memories of a memorable meeting. I look forward to share these moments with you!

Philippe Kestelyn  
President EVER 2013

# Targeting the mediators of inflammation<sup>1</sup>



## Long-lasting vision improvement<sup>2-4</sup>

These images are for illustrative purposes only and do not represent inflammatory mediator levels in the eye



**Ozurdex**<sup>®</sup>  
(dexamethasone intravitreal  
implant) 0.7mg

### OZURDEX<sup>®</sup> (Dexamethasone 700 micrograms intravitreal implant in applicator)

#### Abbreviated Prescribing Information

**Presentation:** Intravitreal implant in applicator. One implant contains 700 micrograms of dexamethasone. Disposable injection device, containing a rod-shaped implant which is not visible. The implant is approximately 0.46 mm in diameter and 6 mm in length. **Indications:** Treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). Treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis. **Dosage and Administration:** Please refer to the Summary of Product Characteristics before prescribing. OZURDEX must be administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is one OZURDEX implant to be administered intra-vitreally to the affected eye. Administration to both eyes concurrently is not recommended. Repeat doses should be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician's opinion may benefit from retreatment without being exposed to significant risk. Patients who experience and retain improved vision should not be retreated. Patients who experience a deterioration in vision, which is not slowed by OZURDEX, should not be retreated. There is only very limited information on repeat dosing intervals less than 6 months. There is currently no experience of repeat administrations in posterior segment non-infectious uveitis or beyond 2 implants in Retinal Vein Occlusion. Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs. No dose adjustment required for elderly population (>65 years). No special considerations required for renal or hepatic impairment. No relevant use in the paediatric population in macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). The safety and efficacy of OZURDEX in uveitis in the paediatric population have not been established. No data are available. Single-use intravitreal implant in applicator for intravitreal use only. The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). A broad spectrum topical antimicrobial should be given prior to and on the day of the injection procedure. Before the injection, the periorcular skin, eyelid and ocular surface should be disinfected (using for example drops of povidone iodine 5% solution on the conjunctiva as it was done in the clinical trials for the approval of OZURDEX) and adequate local anaesthesia should be administered. Remove the foil pouch from the carton and examine for damage. In a sterile field, open the foil pouch and gently place the applicator on a sterile tray. Carefully remove the cap from the applicator. Once the foil pouch is opened the applicator should be used immediately. Hold the applicator in one hand and pull the safety tab straight off the

applicator. Do not twist or flex the tab. With the bevel of the needle up away from the sclera, advance the needle about 1 mm into the sclera then redirect toward the centre of the eye into the vitreous cavity until the silicone sleeve is against the conjunctiva. Slowly press the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully pressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous. Immediately after injecting OZURDEX, use indirect ophthalmoscopy in the quadrant of injection to confirm successful implantation. Visualisation is possible in the large majority of cases. In cases in which the implant cannot be visualised, take a sterile cotton bud and lightly depress over the injection site to bring the implant into view. Following the intravitreal injection patients should continue to be treated with a broad spectrum antimicrobial. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Active or suspected ocular or periorcular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. Advanced glaucoma which cannot be adequately controlled by medicinal products alone. Aphakic eyes with rupture of the posterior lens capsule. Eyes with Anterior Chamber Intraocular Lens (ACIOL) and rupture of the posterior lens capsule. **Warnings/Precautions:** Any intravitreal injection can be associated with endophthalmitis, intraocular inflammation, increased intraocular pressure and retinal detachment. Proper aseptic injection techniques must always be used. Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients must be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay. All patients with posterior capsule tear, e.g. those with a posterior lens, and/or those who have an iris defect (e.g. due to iridectomy) with or without a history of vitrectomy, are at risk of implant migration into the anterior chamber. Other than those patients contraindicated where OZURDEX should not be used, OZURDEX should be used with caution and only following a careful risk benefit assessment. These patients should be closely monitored for any signs of implant migration. Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex and not be used in active ocular herpes simplex. The safety and efficacy of OZURDEX administered to both eyes concurrently have not been studied and is not recommended. OZURDEX is not recommended in patients with macular oedema secondary to RVO with significant retinal ischemia. OZURDEX should be used with caution in patients taking anti-coagulant or anti-platelet medicinal products. **Interactions:** No interaction studies have been performed. Systemic absorption is minimal and no interactions are anticipated. **Pregnancy:** There are

no adequate data from the use of intravitreally administered dexamethasone in pregnant women. OZURDEX is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus. **Lactation:** Dexamethasone is excreted in breast milk. No effects on the child are anticipated due to the route of administration and the resulting systemic levels. However OZURDEX is not recommended during breast feeding unless clearly necessary. **Driving/Use of Machines:** Patients may experience temporarily reduced vision after receiving OZURDEX by intravitreal injection. They should not drive or use machines until this has resolved. **Adverse Effects:** RVO in clinical trials the most frequently reported adverse events were increased intraocular pressure (24.0%) and conjunctival haemorrhage (14.7%). Increased intraocular pressure (IOP) with OZURDEX peaked at day 60 and returned to baseline levels by day 180. Elevations of IOP either did not require treatment or were managed with the temporary use of topical IOP-lowering medicinal products. The following adverse events were reported: **Eye disorders** Very common ( $\geq 1/10$ ) Intraocular pressure increased, conjunctival haemorrhage\* Common ( $\geq 1/100$  to  $< 1/10$ ) Ocular hypertension, vitreous detachment, cataract, subcapsular cataract, vitreous haemorrhage\*, visual disturbance, vitreous opacities\* (including vitreous floaters), eye pain\*, photopsia\*, conjunctival oedema\*, anterior chamber cell\*, conjunctival hyperaemia\* Uncommon ( $\geq 1/1,000$  to  $< 1/100$ ) Retinal tear\*, anterior chamber flare\* **Nervous system disorders** Common: Headache. **Uveitis** In clinical trials the most frequently reported adverse events in the study eye were conjunctival haemorrhage (30.3%), increased intraocular pressure (25.0%) and cataract (11.8%). The following adverse events were reported: **Nervous system disorders** Common: Migraine **Eye disorders** Very common: Increased intraocular pressure, cataract, conjunctival haemorrhage\* Common: Retinal detachment, Myodesopsia, vitreous opacities, blepharitis, sclera hyperaemia\*, visual impairment, abnormal sensation in the eye\*, eyelid pruritis. (\*Adverse reactions considered to be related to the intravitreal injection procedure rather than the dexamethasone implant). Please refer to Summary of Product Characteristics for full information on side effects. **Marketing Authorisation number:** EU/1/10/638/001 **Marketing Authorisation Holder:** Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, Co. Mayo, Ireland. **Legal Category:** POM. **Date of Preparation:** October 2012.

Adverse events should be reported to your local Allergan office and to your Regulatory Authority.

**References:** 1. Nehme A & Edelman J. Invest Ophthalmol Vis Sci. 2008;49(5):2030-2038. 2. Haller JA et al. Ophthalmol. 2010;117:1134-1146. 3. Haller JA et al. Ophthalmol. 2011;118:2453-2460. 4. Lowder C et al. Arch Ophthalmol. 2011;129:545-553.

Date of preparation: December 2012

EU/0689/2012







Word from the President .....	1
About EVER .....	5
Board 2013.....	6
General Information .....	8
Grants.....	11
Partnership.....	12
About the Programme Book .....	14
Programme Committee 2013 .....	15
Floor plan .....	16
Exhibition.....	17
<b>Industry Sponsored Symposia overview.....</b>	<b>18</b>
<b>Courses overview .....</b>	<b>19</b>
<b>Wednesday, September 18.....</b>	<b>21</b>
Morning session.....	22
Lunchtime session: Industry-sponsored symposium 1 .....	25
First afternoon session.....	26
Second afternoon session.....	30
Opening Ceremony .....	33
<b>Thursday, September 19.....</b>	<b>35</b>
First morning session.....	36
Keynote Lecture: Balwantray CHAUHAN .....	39
Second morning session .....	40
Lunchtime session: Industry-sponsored symposium 2.....	43
Ophthalmic Research Lecture: Neville OSBORNE.....	44
First afternoon session.....	45
Poster session 1.....	48
Second afternoon session.....	52
<b>Friday, September 20.....</b>	<b>57</b>
First morning session.....	58
Keynote Lecture: Alfredo SADUN .....	60
Second morning session .....	61
Lunchtime session: Industry-sponsored symposium 3.....	64
First afternoon session.....	65
Poster session 2.....	69
Business Meetings of the Scientific Sections.....	73
Second afternoon session.....	74
Evening session: Industry-sponsored symposium 4.....	77
<b>Saturday, September 21 .....</b>	<b>79</b>
First morning session.....	80
Keynote Lecture: Nicholas BAZAN .....	83
Second morning session .....	84
Lunchtime session: Industry-sponsored symposium 5.....	87
First afternoon session.....	88
Poster session 3.....	92
Second afternoon session.....	97
Evening session: EVER General Assembly and Prize Giving.....	101
Presenting first authors .....	105
Presenting authors by country .....	111
Congress Time Schedule .....	112
Sponsors.....	back cover



## L'innovation en Ophtalmologie va bien au-delà des médicaments

Chez Novartis, compléter l'innovation scientifique par le service, c'est notre philosophie de partenariat.  
Découvrez ViaOpta, un ensemble de services que Novartis a conçu pour vous, ainsi que pour vos patients.

-  Rétina Base, une grande médiathèque numérique de la rétine mise à disposition des ophtalmologistes
-  Espace documentation et outils pour vos patients
-  Informations professionnelles innovantes et entretiens d'experts
-  Agenda des congrès nationaux et internationaux

Pour plus d'informations,  
retrouvez cette offre de services sur le site [www.viaopta.fr](http://www.viaopta.fr)

The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the largest European scientific organization which covers all subspecialties of ophthalmology and visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress.

**Membership**

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research.


Applications for membership - available on [www.ever.be](http://www.ever.be) - may be submitted at any time, membership is on calendar year basis and starts on January 1.

Every member must select one of the 11 Scientific Sections that best represents his or her primary area of interest.

**The benefits of EVER membership are:**

- submission of abstracts to EVER annual meeting
- reduced registration fee for EVER annual meeting
- organizing Special Interest Symposia (SIS) and courses during the EVER annual meeting
- participating in the EBO review courses
- EACCME granted 21 European CME credits (ECMEC) recognized by the American Medical Association- for the EVER annual meetings
- voting rights for the election of the Board Members (except members-in-training and emeritus members)
- 12 travel grants for best abstracts to attend the EVER annual meeting
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.3)
- quarterly E-Newsletter

**Participants:**



Clinical with or without research: 73 %  
 Research only: 27 %

**Elections**

This year new representatives of the scientific sections

- Lens / Cataract
- Retina / Vitreous

will be elected through electronic voting. Voting 2013 will close on September 20, midnight.

The result of the elections will be announced at the General Assembly on Saturday September 21, 2013.


The scientific sections will hold their Business Meetings on Friday, September 20, 2013 from 16:00 - 16:40. The agenda is available on page 73.

The following 3 sections will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2014:

- Anatomy / Cell Biology
- Electrophysiology/ physiological Optics/ Vision Sciences
- Molecular Biology / Genetics / Epidemiology

The statutes and by-laws are available on the website: [www.ever.be](http://www.ever.be) » about » statutes.

**MEMBERS ACCORDING TO SCIENTIFIC SECTIONS**





**Philippe  
KESTELYN**

• President



**Catherine  
CREUZOT**

• Secretary  
General



**Jean-Jacques  
GICQUEL**

• Treasurer



**Marcela  
VOTRUBA**

• Programme  
Secretary



**Constantin  
POURNARAS**

• President Elect



**Thierry  
ZEYEN**

• Vice President



**Alfred  
WEGENER**

• Vice-President  
Elect



**Leopold  
SCHMETTERER**

• Past President

EXECUTIVE COMMITTEE



**Marlene  
VERLAECKT**

• Executive Officer



**Lies  
VAN EYCKEN**

• Executive Assistant



**Brecht  
SPILEERS**

• Junior Executive Officer



**Paul  
MOERS**

• Webmaster

OFFICE

Kapucijnenvoer 33, 3000 Leuven, Belgium - tel +32 16 233 849, fax +32 16 234 097 - ever@ever.be



SECTION CHAIRS



**Nadja  
KNOP**

- Anatomy / Cell Biology



**Thomas  
FUCHSLUGER**

- Cornea / Ocular Surface



**Werner  
SPILEERS**

- Electrophysiology, Physiological Optics, Vision Sciences



**Alain  
BRON**

- Glaucoma



**Andrew  
DICK**

- Immunology / Microbiology



**Alfred  
WEGENER**

- Lens and Cataract



**Bart  
LEROY**

- Molecular Biology / Genetics / Epidemiology



**Aki  
KAWASAKI**

- Neuro-ophthalmology / Strabismology / Paediatric / History



**Laurence  
DESJARDINS**

- Pathology / Oncology



**Gerhard  
GARHÖFER**

- Physiology / Biochemistry / Pharmacology



**Constantin  
POURNARAS**

- Retina / Vitreous



**Bozena  
ROMANOWSKA-  
DIXON**

- East Europe

REGIONAL  
REPRESENTATIVE



**Jean-Pierre  
CAUJOLLE**

- Nice, France

LOCAL  
REPRESENTATIVE

### Venue

EVER 2013 will be held at the Acropolis Convention Center in Nice, France

→ visit the website on [www.nice-acropolis.com](http://www.nice-acropolis.com)

The scientific programme of the EVER congress starts on Wednesday, September 18 at 11:00 and concludes on Saturday, September 21 at 19:30 with a Farewell Cocktail.

### Registration

Everyone attending the scientific sessions - whether or not an EVER member, invited speaker, accompanying person or presenter - must register and pay the registration fee.

On-site registration starts on Wednesday, Sept 18, 09:00.

#### Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-care, Technician or Nurse, you need to prove your status with a document signed by the Head of your Department

### Registration fees on-site

	EUR	EUR
EVER member / SIS & Course-invited speaker	455	390 *
Member-in-training	250	200 *
Non-member	800	645 *
Non-member-in-training	400	310 *
Eye-Care / Technician / Nurse	200	180 *
Congress Dinner (member / non-member)	90	90
Congress Dinner (in training)	60	60

\* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunisia, Ukraine

### Cancellation policy

Refunds - up to 75% of the advance registration fee will be granted for cancellation received in writing prior to Sept 1, 2013. Refunds will not be granted for later cancellations or no-shows.

### Website

The EVER website [www.ever.be](http://www.ever.be) has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2013 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended

### Housing / Travel

#### ADVANCEDFAIR

AdvancedFair has negotiated special rates for accommodation in several categories of hotels.

The Nice Côte d'Azur Airport is located 15 minutes from the Acropolis, at 7 km from the city centre.

The tramway line connects most of the hotels with the Acropolis Convention Center.

### Weather

Nice enjoys an exceptional microclimate. A Mediterranean city opening onto the sea, it is protected from the main winds by its mountains. It is renowned for its mild climate in winter and its sunshine.

### Tourist information

The city of Nice is located on the French Riviera in Provence-Alpes-Côte d'Azur. Blessed by a sunny, temperate climate, Nice attracts visitors from around the world. Among its many attractions are its beautiful beaches, lovely seaside promenade, interesting museums, famous city landmarks and other tourist attractions.

Day excursions are available from Nice to Antibes, Juan-les-Pins, Monte Carlo, Cannes and to other towns.



**EVER 2014**  
**NICE**

**OCTOBER 1-4**  
**SCIENCE FOR SIGHT**  
[www.ever.be](http://www.ever.be)

### Welcome Reception

The Welcome Reception is open for all participants

- **Wednesday 19:00 - 21:00**  
in Exhibition area, Acropolis Convention Center

### Congress Dinner

Registration for the Congress Dinner is required.

Members/non-members: 90 EUR

Members in training: 60 EUR

Space is limited.

- **Friday 20:30 in Hotel NEGRESCO**  
37, promenade des Anglais, 06000 Nice

### Coffee

Included in the registration fee are the coffee/tea and soft drinks offered throughout the whole meeting.

### Internet access

Wi-Fi internet access is available in the Convention Center.

### Photographs



It is strictly forbidden to take photographs or videos of the presentations in all lecture halls.

### Publication of the abstracts

The abstracts of the EVER 2013 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

### Business Meetings

EVER Business Meetings of the scientific sections  
Friday, 16:00 - 16:40

- ACB ..... Gallieni 1 & 2
- COS ..... Rhodes 1
- EOVS ..... Hermes
- G ..... Hermes
- IM ..... Rhodes 1
- LC ..... Rhodes 4
- MBGE ..... Gallieni 5
- NSHP ..... Rhodes 3
- PO ..... Rhodes 2
- PBP ..... Athena
- RV ..... Athena

Agenda see page 73

### EVER General Assembly and Prize Giving

Saturday, 18:00 - 19:30 in room Hermes

Agenda see page 101

### Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request the permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 1, 2013.

### No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

### CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 21 European CME credits (ECMEC) to the EVER 2013 congress on Sept 18-21 in Nice, France.

CME credit certificates can be printed from the EVER website after the congress.

### Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

### Poster Prizes

A poster prize of 200 EUR will be awarded for the best poster in each section. One additional EOVS poster prize will be generously sponsored by the Alta Eficacia Tecnologia, SL, Spain.

The winners will be chosen by the poster moderators and will be announced in the General Assembly and followed by the prize giving ceremony on Saturday September 21. Please make sure to attend.

No prize will be given after the congress.

### EVER 2013 congress App









### Travel grants for best abstract

We are pleased to announce that the following 11 members have received a travel grant of 500 EUR each, from the 11 EVER sections:

- **ACB - Marialaura AMADIO - Italy**  
4662 - ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human ARPE-19 cells
- **COS - Amy LYNCH - Ireland**  
3436 - Influence of growth factors on keratocyte phenotype in serum free media
- **EOVS - Markus WIRTH - Germany**  
T028 - Keep an eye on the Pi – Using the Raspberry Pi as inexpensive, yet powerful platform for vision research
- **G - Yuka AOYAMA - Japan**  
T032 - The prediction error of the visual field sensitivity is large at the steep 'border' of glaucomatous scotoma
- **IM - Benjamin PENAUD - France**  
3454 - Mid-term efficacy and safety of adalimumab in refractory pediatric uveitis: A retrospective monocentric study
- **LC - Gah-Jone WON - Canada**  
S077 - The effects of actomyosin inhibitors on cytoskeletal distributions in the lens
- **MBGE - Audrey GIOCANTI-AUREGAN - France**  
T071 - Profiling miRNAs in a hyperglycemic and hypo-insulinemic Ins2Akita mouse model
- **NSPH - Gonzague FACON - France**  
F068 - Definition of a normative basis for peripapillary nerve fibers thickness in childhood with sd-oct
- **PBP - Houda TAHIRI - Canada**  
4774 - Retinal pigment epithelium cell-derived micro-particles mediate oxidative stress-induced retinal cells dysfunction
- **PO - Zita STEIBER - Hungary**  
S092 - Expression of stem cell markers in human uveal melanoma
- **RV - Guillaume DEBELLEMANIÈRE - France**  
3464 - Evaluation of cone photoreceptor density using adaptive optics retinal imaging in patients under treatment with hydroxychloroquine



### Alta Eficacia Tecnología SL, Spain, travel grant

Alta Eficacia Tecnología is pleased to announce a travel grant of 500 EUR for the best paper in the EOVS section

- **Dorota POJDA-WILCZEK - Poland**  
1666 - Possibility of visual prognosis based on flash visual evoked potential in cases of early brain damage

The prize will be presented by Professor Celia SANCHEZ RAMOS at the General Assembly.



3 grants of 500 EUR each supported by Quartett for best paper in COS

- Translation Medicare
- Basic Research
- Clinical Research

The papers will be chosen during the congress.  
The grants will be handed over during the General Assembly.



[www.ever.be](http://www.ever.be)

### EVER - European Association for Vision and Eye Research

We aim to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has members from over 50 countries and is represented by 11 scientific sections. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.



[www.ever-f.eu](http://www.ever-f.eu)

### EVERf - EVER Foundation

In 2010, the EVER Foundation was created to raise money to organize EVERf Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

## In CONCORDIA pro VISU

The following societies collaborate with EVER to unify European ophthalmology by promoting quality education in ophthalmology and its scientific foundations (the societies are listed in alphabetical order):



[ebo-online.org](http://ebo-online.org)

### EBO - European Board of Ophthalmology

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress. See pages 23, 27.

From this year on and in order to evaluate the level of knowledge, a pre-test will be proposed online. Each speaker will extensively review the answers during his presentation.



[www.eupo.eu](http://www.eupo.eu)

### EUPO - European University Professors of Ophthalmology

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe.

In 2014 the EUPO course on RETINA will be organized prior the EVER congress in Nice, France on Sept 30 - Oct 1.



[www.soevision.org](http://www.soevision.org)

### SOE - Societas Ophthalmologica Europea

SOE aims to promote ophthalmology in Europe and to stimulate co-operation between European ophthalmologists and between their National Societies. Today, its mission is to become a central point in European ophthalmology through education and by fostering collaboration with subspecialty societies and supranational organisations both within Europe and beyond.

The 2015 SOE Congress will take place from 6-9 June, 2015 in Vienna Austria.



**Acta Ophthalmologica**[eu.wiley.com](http://eu.wiley.com)**ACTA OPHTHALMOLOGICA - EVER's journal**

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.3)

[www.arvo.org](http://www.arvo.org)**ARVO - Association for Research in Vision and Ophthalmology**

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. See page 75.

[www.europeaneyebanks.org](http://www.europeaneyebanks.org)**EEBA - European Eye Bank Association**

The EEBA is a technical-scientific organization comprising individual members from 83 eye banks from 25 European countries. Founded with the simple objective of sharing information regarding eye-banking, the Association is today the leading pan-national association in Europe dedicated to the advancement of eye-banking and an authoritative reference point for eye banks wishing to work according to quality standards. The EEBA is collaborating with EVER since 2012. See page 47.

[www.fan-int.org](http://www.fan-int.org)**FAN - European Fluorescein Angiography Club**

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. See page 88.

[www.fro-online.org](http://www.fro-online.org)**FRO - Belgian Fund for Research in Ophthalmology**

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. See pages 24 and 29.

**GOA - Groupe Ophtalmo Allergo**

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated. See page 59.

[www.kpro.org](http://www.kpro.org)**KPro Study Group**

The KPro Study Group was established in 1990 to foster clinical and basic research on keratoprosthesis, synthetic corneas and artificial corneal implants. This International Group aims to foster the development and improvement of keratoprosthesis worldwide for the benefit of eyecare and patients. The KPro Study Group is collaborating with EVER since 2004. See pages 88 and 97.



**OOG - The Ophthalmic Oncology Group**

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multi-center studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. See pages 85, 89 and 98.

[www.soie-soif.org](http://www.soie-soif.org)**SOIE - Society for Ophthalmo-Immunoinfectiology in Europe**

The aims are to form an association of ophthalmologists and other doctors or scientists having an interest in the field of ophthalmo-Immuno-Infectiology and to share mutual experiences in order to contribute to the progress of each member in this field, to promote education by organising or sponsoring symposia or courses or by contributing to publications in this field and to promote contacts between clinical centres in order to realise collaborative studies. SOIE is collaborating with EVER since 2008. See pages 37 and 86.

This programme book is organised chronologically



## The sessions are colour-coded



FP = Free Paper session

SIS = Special Interest Symposium

CIS = Commercial Interest Symposium

 = EVER travel grant recipient

 = Alta Eficacia Tecnología SL, Spain, travel grant recipient

*rf* = Rapid Fire presentation

★ Conflict of interest disclosed

## Scientific sections

ACB	=	Anatomy/Cell Biology
COS	=	Cornea/Ocular Surface
EOVS	=	Electrophysiology, Physiological Optics, Vision Sciences
G	=	Glaucoma
IM	=	Immunology/Microbiology
LC	=	Lens and Cataract
MBGE	=	Molecular Biology/Genetics/ Epidemiology
NSPH	=	Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology
PBP	=	Physiology/Biochemistry/Pharmacology
PO	=	Pathology/Oncology
RV	=	Retina/Vitreous



*Programme Committee meeting, June 2013*

## Programme secretary, Marcela VOTRUBA

### Section programme secretaries

ACB	Anatomy/Cell Biology	Ulla AAPOLA
COS	Cornea/Ocular Surface	Jean-Jacques GICQUEL
EOVS	Electrophysiology, Physiological Optics, Vision Sciences	Miguel CASTELO-BRANCOO
G	Glaucoma	Sayeh POURJAVAN
IM	Immunology/Microbiology	Piergiorgio NERI
LC	Lens and Cataract	Ralph MICHAEL
MBGE	Molecular Biology/Genetics/Epidemiology	Marzena GAJECKA
NSPH	Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/ History of Ophthalmology	Dominique BREMOND-GIGNAC
PBP	Physiology/Biochemistry/Pharmacology	Neville OSBORNE
PO	Pathology/Oncology	Karin LÖFFLER
RV	Retina/Vitreous	Anita LEYS



## LEVEL 2 RHODES



# LEVEL 2 RHODES

## EXHIBITORS

- Alimera Sciences
- Allergan
- ARVO
- Charles River
- EyeTechCare
- Horus Pharma
- Iris Pharma
- Novartis France
- Ocuscience
- OphtaBiotech
- Théa
- Toxikon
- Ursapharm
- Wisepress



# INDUSTRY-SPONSORED SYMPOSIA OVERVIEW

The Commercial Interest Symposia throughout the EVER 2013 congress:

## Wednesday, September 18



Industry-sponsored symposium 1:

### Glaucoma and the Ocular Surface

12:30 - 13:30 in room Rhodes 2 ..... 25

## Thursday, September 19



Industry-sponsored symposium 2:

### Micronutrition: Part of the retinal specialists' armamentarium?

12:35 - 13:35 in room Rhodes 2 ..... 43

## Friday, September 20



Industry-sponsored symposium 3:

### Enhanced Oxidative Stress and ocular surface

12:35 - 13:35 in room Hermes ..... 64



Industry-sponsored symposium 4:

### Non-infectious uveitis. A short look back and a long look forward

18:15 - 19:15 in room Hermes ..... 77

## Saturday, September 21





Industry-sponsored symposium 5:

### Aflibercept: an innovation in health care for a chronic condition

12:35 - 13:35 in room Rhodes 2 ..... 87

The 18 courses throughout the EVER 2013 congress:

## Wednesday, September 18

<b>Course 1</b>	<b>11:00 - 12:30</b>	RV: Macular hole .....	22
<b>Course 2</b>	<b>11:00 - 12:30</b>	G: Glaucoma? Yes I can! .....	23
<b>Course 3</b>	<b>11:00 - 12:30</b>	IM: EBO review course: Intraocular Inflammation and Infection - Part I 	23
<b>Course 4</b>	<b>13:30 - 15:00</b>	COS: The amniotic membrane: new regenerative therapies and their potential impact on the clinical management of ocular surface diseases .....	26
<b>Course 5</b>	<b>13:30 - 15:00</b>	IM: EBO review course: Intraocular Inflammation and Infection - Part II 	27
<b>Course 6</b>	<b>15:05 - 16:35</b>	RV: Retinal detachment .....	30
<b>Course 7</b>	<b>15:05 - 16:35</b>	COS: An update on corneal infectious diseases .....	30
<b>Course 8</b>	<b>15:05 - 16:35</b>	EOVS: Visual electrophysiology .....	32

## Thursday, September 19

<b>Course 9</b>	<b>11:05 - 12:35</b>	PO: The management of pigmented fundus lesions .....	41
<b>Course 10</b>	<b>14:15 - 15:45</b>	COS: An update on corneal procedures.....	45
<b>Course 11</b>	<b>16:30 - 18:00</b>	PO: Practical ophthalmic pathology - basics, updates and new insights .....	53

## Friday, September 20

<b>Course 12</b>	<b>08:30 - 10:00</b>	ACB: Cell biological techniques for eye research .....	59
<b>Course 13</b>	<b>11:00 - 12:30</b>	PO: Don't panic: Hitchhiker's guide to statistics .....	62
<b>Course 14</b>	<b>11:00 - 12:30</b>	NSPH: Visual Fields: Back to Basics .....	63
<b>Course 15</b>	<b>13:40 - 15:10</b>	COS: Corneal Dystrophies – from molecular basis to therapeutic approach .....	65
<b>Course 16</b>	<b>16:45 - 18:15</b>	COS/ ACB: Stem cells for treatment of eye diseases.....	75

## Saturday, September 21

<b>Course 17</b>	<b>08:30 - 10:00</b>	RV: Pseudophakic retinal detachment .....	80
<b>Course 18</b>	<b>16:15 - 17:45</b>	LC: Femtosecond laser cataract surgery .....	98





Lined writing area consisting of approximately 28 horizontal lines spaced evenly down the page.



The background features a complex pattern of thin, overlapping lines in shades of light blue and white, creating a sense of motion and depth. A large, white, angular shape is positioned on the left side of the page, partially overlapping the text area.

**WEDNESDAY  
SEPTEMBER 18  
2013**

WEDNESDAY

Advanced

**Course 1 Macular hole**  
**RV**

Georgios PAPPAS

Athena

Macular Hole Surgery is almost 25% of macular surgery. The pathophysiology of this condition is getting clearer using new diagnostic tools. There are many controversies though regarding best treatment and the tools used for the treatment of this condition. This course aims to give answers and directions for the optimal treatment of the condition.

11:00	1411	Pathophysiology of macular hole and diagnostic tools STAPPLER T—Liverpool
11:12	1412	ILM peeling or not - The best dye POURNARAS JA—Lausanne
11:24	1413	Posture face-down or not? The best tamponade FRIMPONG-ANSAH K—Plymouth
11:36	1414	20g, 23g, 25g or 27g - The best forceps GOTZARIDIS S—Athens
11:48	1415	Partial thickness macular holes and pharmacological treatment GEORGALAS I—Athens
12:00	1416	What are we doing in difficult cases (Not closed, Myopic, Large)? PAPPAS G—Heraklion
12:12	1417	Mechanism of macular hole closure REPPUCCI V—New York

**SIS** **Update on limbus disorders in children**

COS/NSPH

Dominique BREMOND-GIGNAC, Jean-Jacques GICQUEL

Hermes

11:00	1421	Update on ocular surface disorders in aniridia BREMOND-GIGNAC D—Amiens
11:22	1422	Update on corneal dystrophies in children CHIAMBARETTA F—Clermont Ferrand
11:44	1423	LSCD - What clues does the infant limbus hold? YEUNG A—Nottingham
12:06	1424	Update on ocular surface burn in children GICQUEL JJ—Poitiers

## Course 2 Glaucoma? Yes I can!

Rhodes 1

Beginner

G Alain BRON

This course is designed for beginners in glaucoma who are mostly interested in daily clinical practice. It is really possible to improve your own glaucoma management with basic examinations. After this course you probably will better use your slit lamp to find useful clinical signs for glaucomas. Gonioscopy is a key step in the diagnosis and the management of the glaucomas as well. Clinical examination of the optic disc is determinant for the diagnosis and the evaluation of progression. A better understanding of functional and structural tests is mandatory when you have to order those tests. Five teachers, all glaucoma experts will lead you during this course with very simple and clear recommendations. They would like to provide you with a ready-to-use clinical tool kit for glaucomas.

11:00	1431	My basic slit-lamp? Yes I can! BRON A—Dijon
11:18	1432	Gonioscopy? Yes I can! HOMMER A—Vienna
11:36	1433	Clinical examination of the optic disc? Yes I can! JONAS J—Mannheim
11:54	1434	Function in glaucoma? Yes I can! ZEYEN T—Leuven
12:12	1435	Structure in glaucoma? Yes I can! SUNARIC MEGEVAND G—Geneva

## SIS PBP Ocular imaging

Rhodes 2

Gerhard GARHOFER, Leopold SCHMETTERER

11:00	1441	Doppler optical coherence tomography SCHMETTERER L—Vienna
11:22 ★	1442	Retinal oximetry methodology HARDARSON S—Reykjavik
11:44	1443	Determination of macular pigment BERENDSCHOT T—Maastricht
12:06	1444	In vivo cell-scale imaging of the human retina by adaptive optics PAQUES M—Paris

## Course 3 EBO review course: Intraocular Inflammation and Infection - Part I

Rhodes 3

Intermediate

IM Bahram BODAGHI, Carl P HERBORT



The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

11:00	1451	Pathophysiology of uveitis DICK A—Bristol
11:15	1452	Classification of uveitis ANDROUDI S—Thessaloniki
11:30	1453	Signs and symptoms of uveitis NERI P, CAPUANO V, PIRANI V, ARAPI I, MARIOTTI C, GIOVANNINI A—Ancona
11:45	1454	Laboratory work-up and specialized investigations PLEYER U—Berlin
12:00	1455	Imaging in uveitis: techniques and indications HERBORT C—Lausanne
12:15	1456	Therapeutic management of uveitis DICK A—Bristol



WEDNESDAY

**SIS  
EOVS****Doctor, the eyes won't keep still**

Graham HOLDER

**Rhodes 4**

11:00	1461	The initial consult SPILEERS W—Leuven
11:20	1462	Genetically determined causes of eye movement disorders LEROY B—Ghent
11:40	1463	The neurological approach KAWASAKI A—Lausanne
12:00	1464	The role of electrophysiology HOLDER G—London

**Joint M. FRO - Belgian Fund for Research in Ophthalmology - part 1**

Marie - José TASSIGNON, Laure CASPERS

**Gallieni 1 & 2**

11:00	1471	The effect of local rock-inhibition on uveitis HOLLANDERS K—Leuven
11:12	1472	Identification of the gene signature of retinal endothelial cells during classical experimental autoimmune uveitis, Th1- and Th17-dependent uveitis LIPSKI D
11:24	1473	Evaluating hyaluronic acid as a coating strategy for intravitreally injected nanomedicines for retinal gene therapy MARTENS T—Ghent
11:36	1474	Examining the optical qualities of explanted IOLs NI DHUBGHAILL S
11:48	1475	Development of a classification system for normal and keratoconic human corneas to assist in the detection of early keratoconus through a machine learning algorithm RUIZ HIDALGO I
12:00	1476	Potential implications of epigenetic changes in human retinal pigmented epithelium during diabetic retinopathy SALIK D—Bruxelles
12:12	1477	Complementary effects of mitomycin-c and anti-fibrotic agents on surgical outcome after glaucoma filtration surgery VAN BERGEN T—Leuven
12:24	1478	Endothelial recovery by novel rock-inhibitors in the cornea SIJNAVE D—Leuven

INDUSTRY-SPONSORED SYMPOSIUM **Rhodes 2****Glaucoma and the Ocular Surface**

Moderator: Alain BRON

12:30		Welcome
12:35	1541	Glaucoma and the ocular surface BRON A–Dijon
12:47	1542	How to recognize and decide if a patient suitable for PF therapy GONI F–Barcelona
12:59	1543	PF Monotherapy ROSSETTI L–Milano
13:11	1544	PF Combo therapy SUNARIC MEGEVAND G–Geneva
13:23		Q & As

WEDNESDAY

**SIS** **Dietary fatty acids: from mechanisms to epidemiology and clinical application in the prevention of Age-related Macular Degeneration (AMD)**

Athena

**RV** Lionel BRETILLON



13:30 ★	1611	Dietary fat consumption and AMD: Epidemiological facts DEL COURT C–Bordeaux
13:48	1612	Omega-3 fatty acids and prevention of cardiovascular events DALLONGEVILLE J–Lille
14:06	1613	The mechanisms of the action of omega-3s in the retina ACAR N–Dijon
14:24	1614	Prospects: Dietary -3 polyunsaturated fatty acids, CCR2+ monocyte recruitment, and AMD? SENNLAUB F–Paris
14:42	1615	How to handle the dietary requirements in clinical practice in ophthalmology CREUZOT C–Dijon

Intermediate

**Course 4** **The amniotic membrane: new regenerative therapies and their potential impact on the clinical management of ocular surface diseases**

Hermes

**COS** Jean-Jacques GICQUEL, Andrew HOPKINSON

The Amniotic Membrane (AM) story is pretty much at a conclusion. Over the last 10 years, AM transplantation has dramatically changed our approach of the treatment of ocular surface diseases. Nowadays, new AM based regenerative therapies have been developed and they may once again have a significant impact on how we manage our patients. We propose to an intermediate audience, an update on the many new technologies being developed, including corneal mimetic constructs, decellularised corneas and innovative stem cells technologies.

13:30	1621	Amniotic membrane transplantation: Implications for corneal wound healing GICQUEL JJ, DUA HS–Poitiers, Nottingham
13:48	1622	Intra and inter donor variations of amniotic membrane GICQUEL JJ–Poitiers
14:06	1623	The new clinical applications of dried amniotic membrane HOPKINSON A, ALLEN C, DUA HS–Nottingham
14:24	1624	Challenges in manufacturing an amniotic membrane alternative for corneal regeneration WILSON S, HOPKINSON A–Nottingham
14:42	1625	Amniotic membrane as a tissue engineering substrate BRANCH M–Nottingham

**FP COS** **Free papers COS 1/5: Corneal inflammation and wound healing** **Rhodes 1**  
Philippe KESTELYN, Dominique BREMOND-GIGNAC

13:30	1631	Healing of a resistant corneal neurotrophic ulcer using a new matrix therapy agent (RGTA) PISON A, HAY A, DETHOREY G, BREZIN A, BOURGES JL—Paris
13:42	1632	New matrix therapy in chronic corneal ulcers resistant to conventional therapies HUGNY LARROQUE C, DERRIEN S, COCHENER B—Brest
13:54	1633	A RHO kinase inhibitor, AMA0526 improves corneal wound healing after alkali burn injury SIJNAVE D, HOLLANDERS K, VAN BERGEN T, VAN DE VELDE S, VANDEWALLE E, MOONS L, STALMANS I—Leuven
14:06	1634	Diagnostic traps based on nomenclature of inflammatory changes in corneal confocal microscopy in vivo SMEDOWSKI A, WYLEGALA E, WOJCIK L—Katowice
14:18	1635	Short-time reproducibility of tearfilm osmolarity measurement assessed with electrical impedance SCHMIDL D, KAYA S, NEPP J, SCHMETTERER L, GARHOFER G—Vienna
14:30	1636	Corneal Langerhans cell and dry eye examinations in ankylosing spondylitis MARSOVSZKY L, NEMETH J, RESCH MD, TOLDI G, LEGANY N, KOVACS L, BALOG A—Budapest, Szeged
14:42	1637	Experimental evidence of fluid secretion of rabbit lacrimal gland ductal epithelia TOTH-MOLNAR E, KATONA M, FACSKO A, VENGLOVECZ V, NEMETH L, HEGYI P—Szeged

**SIS PBP** **Neuroprotection: past and future strategies** **Rhodes 2**  
Gerhard GARHOFER, Neville OSBORNE

13:30	1641	Pharmacological strategies related to ocular neuroprotection GARHOFER G—Vienna
13:50	1642	Importance of taurine in maintaining retinal function PICAUD S, FROGER N—Paris
14:10	1643	Clinical neuroprotection in relation to ophthalmology ROSSETTI L—Milano
14:30	1644	Possible reasons for a miss match between animal neuroprotection studies and clinical findings OSBORNE N—Oviedo

**Course 5 IM** **EBO review course: Intraocular Inflammation and Infection - Part II** **Rhodes 3**  
Bahram BODAGHI, Carl P HERBORT

Intermediate



The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

13:30	1651	B27-associated uveitis, Fuchs uveitis WILLERMAIN F—Bruxelles
13:45	1652	Infectious uveitis PLEYER U—Berlin
14:00	1653	Behçet disease, VKH, sarcoidosis KHAIRALLAH M, KAHLOUN R—Monastir
14:15	1654	White dot syndromes HERBORT C—Lausanne
14:30	1655	Pediatric uveitis BODAGHI B—Paris
14:45		Conclusions





**FP  
EOVS**

**Free papers EOVS 1/1: Visual function and neurophysiology**

**Rhodes 4**

Miguel CASTELO-BRANCO, Werner SPILEERS

13:30	1661	Motion-onset visual evoked potentials - Important tool in vision and eye research KUBOVA Z, KUBA M, KREMLACEK J, LANGROVA J, SZANYI J, VIT F, CHUTNA M—Hradec Kralove
13:42	1662	Pure neuroretinal dysfunction in diabetic retinopathy occurring prior to endothelial and vascular damage REIS A, MATEUS C, MELO P, FIGUEIRA J, CUNHA-VAZ J, CASTELO-BRANCO M—Coimbra
13:54	1663	Ophthalmic care – Reaching out to the ageing population. Experiences in Sweden MARTIN L—Eskilstuna
14:06	1664	Characterization of human corneal grafts' transparency by optical coherence tomography and scattering measurements HOFFART L—Marseille
14:18	1665	Optic disc hamartomas in a family with heterozygous mutation in the VMD2 gene: Clinical, diagnostic and molecular genetic findings TODOROVA M, SCHORDERT DF, VALMAGGIA C—Basel, Sion, St. Gallen
14:30	1666	Possibility of visual prognosis based on flash visual evoked potential in cases of early brain damage POJDA-WILCZEK D—Katowice

**Joint M.**

**FRO - Belgian Fund for Research in Ophthalmology - part 2**

**Gallieni 1 & 2**

Marie - José TASSIGNON, Laure CASPERS



13:30	1671	Identification of a novel gene for autosomal dominant retinitis pigmentosa by combined linkage analysis and whole VAN CAUWENBERGH C—Ghent
13:42	1672	The Role of ROCK Inhibition in the Pathogenesis of Glaucoma VAN DE VELDE S—Leuven
13:54	1673	The effect of aging on the regenerative potential of the zebrafish retina: insights in mammalian retinal regeneration VAN HOUCKE J—Leuven
14:06	1674	Unraveling molecular and cellular mechanisms underlying inflammation- and aging-induced blood-retinal barrier disruption VAN HOVE I—Leuven
14:18	1675	Histology and immunohistochemistry of the vitreolenticular interface in developmental cataracts VAN LOOVEREN J—Edegem
14:30	1676	Functional characterization of ECSIT, a candidate disease gene for primary congenital glaucoma (PCG) on chromosome 19p13.2 VERDIN H—Ghent
14:42	1677	Self aligning recombinant human collagen scaffolds for corneal tissue engineering ZAKARIA N—Edegem

WEDNESDAY

Beginner

### Course 6 Retinal detachment RV

Catherine CREUZOT, Jean-Paul BERROD

Athena

The aim of this course is to present the signs and the treatment of different clinical cases of retinal detachment. The indication of vitrectomy or scleral buckling will be considered. Cases of retinal detachment occurring in myopic patients or exudative retinal detachment will be presented. Finally, the problem of tractional retinal detachment will be considered.

15:05 1711 Retinal detachment without PVR  
CREUZOT C–Dijon

15:23 1712 Retinal detachment with PVR  
BERROD JP–Nancy

15:41 1713 DR in myopic patients  
TADAYONI R–Paris

15:59 1714 Exudative retinal detachment  
DE SMET MD–Lausanne

16:17 1715 Tractional retinal detachment  
MASSIN P–Paris

Intermediate

### Course 7 An update on corneal infectious diseases COS

Jean-Jacques GICQUEL, Dominique BREMOND-GIGNAC

Hermes

Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we'll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections. We will also see how new techniques such as Amniotic Membrane Transplantation and Crosslinking can help the clinician, when facing severe cases.

15:05 1721 Corneal bacterial infections: A practical approach  
GICQUEL JJ–Poitiers

15:27 1722 Herpes and Zoster infections update  
LABETOUILLE M, ROUSSEAU A–Le Kremlin Bicêtre

15:49 1723 The particularities of corneal infectious diseases in children  
BREMOND-GIGNAC D–Amiens

16:11 1724 New emerging treatments in severe corneal infectious diseases  
GICQUEL J, DUA HS–Poitiers, Nottingham

**SIS** **New frontier in glaucoma surgery: Trans-trabecular meshwork** **Rhodes 1**  
**G/ACB** K. Sheng LIM, Sayeh POURJAVAN

15:05 ★	1731	iStent implant AU L—Manchester
15:27	1732	Trabectome surgery LONGSTAFF S—Sheffield
15:49 ★	1733	Other trans-trabecular meshwork implants LIM K—London
16:11	1734	Basic science behind trabecular meshwork surgeries OVERBY D—London

**FP** **Free papers PBP 1/2: Neuroprotection and ocular blood flow** **Rhodes 2**  
**PBP** Gerhard GARHOFER, Jonathan CROWSTON

15:05	1741	Rod microglia is absent from microglial changes in mice retina contralateral to experimental glaucoma GALLEGO B, DE HOZ R, RAMIREZ AI, SALAZAR JJ, ROJAS B, TRIVINO A, RAMIREZ JM—Madrid
15:17	1742	Neuropeptide Y Y1 receptor is neuroprotective and modulates microglia reactivity in the rat retina AMBROSIO AF, ELVAS F, MADEIRA M, BRUDZEWSKY D, MARTINS J, MARTINS T, CAVADAS C, SANTIAGO AR—Coimbra
15:29	1743	Effect of neuroprotective statins in retina: A hypercholesterolemic rabbit model NAVARRO J, GALLEGO BI, DE HOZ R, RAMIREZ AI, SALAZAR JJ, ROJAS B, TRIVINO A, RAMIREZ JM—Madrid
15:41	1744	Modified connexin43 mimetic peptide shows higher efficacy in reducing retinal ganglion cell loss and vessel leak after retinal ischemia RUPENTHAL I, CHEN YS, TEAGUE R, PERRETT J, DANESH-MEYER H, TOTH I, GREEN C—Auckland, Brisbane
15:53	1745	Effect of breathing 12% oxygen in nitrogen on retinal blood flow and oxygen saturation PALKOVITS S, TOLD R, BOLTZ A, SCHMIDL D, NAPORA K, GARHOFER G, SCHMETTERER L—Vienna
16:05	1746	Optic nerve head autoregulation during changes in arterial blood pressure BOLTZ A, TOLD R, PALKOVITS S, SCHMIDL D, NAPORA KJ, GARHOFER G, SCHMETTERER L—Vienna

**SIS** **How biologic agents are changing the story of uveitis:** **Rhodes 3**  
**IM** **anti-TNF- $\alpha$  agents and more**  
 Piergiorgio NERI, Andrew DICK

15:05	1751	The evolution of monoclonal antibodies DICK A—Bristol
15:23	1752	What I should do before considering biologic agents WILLERMAIN F—Bruxelles
15:41	1753	Long-term clinical outcomes in patients with refractory uveitis associated with Behçet's disease treated with infliximab ABU EL ASRAR A—Riyadh
15:59	1754	Rescue therapy with subcutaneous anti-TNF- $\alpha$ agents for idiopathic non-infectious uveitis NERI P, ARAPI I, PIRANI V, CAPUANO V, GIOVANNINI A, MARIOTTI C—Agugliano, Ancona
16:17	1755	The "strange story" of Interferon- $\alpha$ : A very peculiar biologic agent BODAGHI B—Paris



WEDNESDAY

Intermediate

**Course 8 Visual electrophysiology**  
**EOVS**

Graham HOLDER, Bart LEROY

Rhodes 4

To discuss the clinical applications of visual electrophysiology.

15:05	1761	A general introduction to the tests and abnormality localisation LEROY B–Ghent
15:27	1762	Electrophysiology in acquired disease HOLDER G–London
15:49	1763	Electrophysiology in inherited disease LEROY B–Ghent
16:11	1764	Electrophysiology and imaging HOLDER G–London

**FP**  
**PO****Free papers PO 1/2: New insights into uveal melanoma**

Martine J JAGER, Nathalie CASSOUX

Gallieni 1 &amp; 2

15:05	1771	Effect of hypoxic stress on induction and plasticity of tumour-induced immune cells in uveal melanoma BRONKHORST IHG, JEHS TML, DIJKGRAAF EM, LUYTEN GPM, VAN DER VELDEN PA, VAN DER BURG SH, JAGER MJ–Leiden
15:17	1772	Targeting the hypoxia pathway in uveal melanoma cells ASNAGHI L, LIN MH, LIM KS, LIM KJ, BAR EE, EBERHART CG–Baltimore, Cleveland
15:29	1773	Epigenetic regulation of the epithelial phenotype in uveal melanoma VERSLUIS M, DE LANGE MJ, VAN PELT S, LUYTEN GPM, JAGER MJ, VAN DER VELDEN PA–Leiden
15:41	1774	Gain of chromosome 6 status does not influence HLA-expression in uveal melanoma VAN PELT S, VAN ESSEN TH, BRONKHORST IHG, VERSLUIS M, LUYTEN GPM, VAN HALL T, VAN DEN ELSEN PJ, VAN VELDEN PA, JAGER MJ–Leiden
15:53	1775	A new and standardized method to sample and analyse vitreous biopsies by the Cellient® automated cell block system VAN GINDERDEUREN R, VAN CALSTER J–Leuven
16:05	1776	Ophthalmic histopathology samples – are we sending enough? DEV BORMAN A, HASSANI M, KESHARAJU R, NADERI K, GHAZI-NOURI S–Chelmsford, Plymouth, Colchester
16:17	1777 <i>rf</i>	Orbital melanocytosis and OTA naevus DE KEIZER RJW, LAUWERS N, DE GROOT V–Antwerp

WEDNESDAY



16:45

Welcome by the President EVER 2013  
Philippe KESTELYN - President 2013

Athena

**WELCOME**



17:15

EVER 2013 Lecture: Advances in OCT imaging  
Leopold SCHMETTERER - Past-President  
Introduction by Philippe KESTELYN

Athena

**EVER lecture**



17:50  
**European  
Ophthalmic  
Heritage Lecture**

Major Central European contributions to  
international ophthalmology  
Andrzej GRZYBOWSKI  
Introduction by Marcela VOTRUBA

Athena



18:25  
**EVER/ACTA  
Lecture**

Telomere maintenance and retinal vascularisation  
Tero KIVELÄ  
Introduction by Einar STEFANSSON  
Award presentation

Athena

**Acta Ophthalmologica**



19:00 - 21:00

**WELCOME  
RECEPTION**

EVER Welcome Reception

Exhibition area

Reception opened by Philippe Kestelyn  
EVER 2013 President



The background features a complex pattern of thin, overlapping lines in shades of light blue and white, creating a sense of motion and depth. A large, white, rectangular area is positioned in the upper right, serving as a backdrop for the text. The text is rendered in a bold, dark blue, sans-serif font.

**THURSDAY  
SEPTEMBER 19  
2013**

THURSDAY

**SIS RV**      **Macular edema**      **Athena**  
Catherine CREUZOT, Pascale MASSIN

08:30 ★	2211	Pathophysiology of macular edema JONAS J—Mannheim
08:48	2212	Can we quantify macular edema outcome? MASSIN P—Paris
09:06	2213	Functional assessment of macular edema MIDENA E—Padova
09:24 ★	2214	How to select our treatments? CREUZOT C—Dijon
09:42	2215	How to organise the follow-up of patients with macular edema? POURNARAS CJ—Genève

**SIS G**      **Dealing with advanced glaucoma**      **Hermes**  
Ejaz ANSARI

08:30	2221	Definition and diagnosis of advanced glaucoma ZEYEN T—Leuven
08:52	2222	Treatment of advanced glaucoma BRON A—Dijon
09:14	2223	Differential diagnosis ANSARI E—Maidstone
09:36	2224	Counselling in advanced glaucoma ANSARI E—Maidstone

**SIS**      **ME and retinal disease**      **Rhodes 1**  
Susan LIGHTMAN, Anat LOEWENSTEIN



08:30	2231	ME and Retinal Disease AMBATI J—Lexington
08:42	2232	ME and Visual Acuity TADAYONI R—Paris
08:54	2233	ME and RVO LOEWENSTEIN A—Tel Aviv
09:06	2234	ME and Uveitis LIGHTMAN S—London
09:18		Discussions and Close



**SIS PO**      **Non-Graves' orbital Inflammation**      **Rhodes 2**  
 Pierre Yves ROBERT, RJW DE KEIZER

08:30	2241	Rationale for a diagnostic approach GAVARD-PERRET A, ROBERT PY–Nice, Limoges
08:52	2242	Clinics, biopsy and pathology ROBERT P–Limoges
09:14	2243	Inflammatory orbital lesions (IOI) DE KEIZER RJW, BIJLSMA WR–Edegem, Utrecht
09:36	2244	Orbital biopsies - the pathologist's perspective COUPLAND S–Liverpool

**Joint M. IM**      **Improved monitoring and treatment of endogenous uveitis is modifying disease management/outcomes I: VKH disease**      **Rhodes 3**  
 Piergiorgio NERI, Carl P HERBERT



08:30	2251	Pathophysiology of the development of intraocular inflammation in VKH HERBERT C–Lausanne
08:45	2252	ICGA features in VKH BOUCHENAKI N, HERBERT CP–Geneva, Lausanne
09:00	2253	OCT for VKH NAKAI K–Suita
09:15	2254	Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids ABU EL ASRAR A–Riyadh
09:30	2255	Vogt-Koyanagi-Harada disease: Sunset-glow fundus is not a fatality any more HERBERT C–Lausanne
09:45	2256	The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease ABU EL ASRAR A–Riyadh

THURSDAY

**SIS** **Mitochondria and the eye: mitochondrial dysfunction and disease** Rhodes 4  
 MBGE/ NSPH Marcela VOTRUBA, Alfredo SADUN



08:30	2261	Oxidative-induced RGC-5 cell death culture involves mitochondrial dysfunction and can be attenuated by hydrogen sulphide OSBORNE N–Oviedo
08:48	2262	Advancing age and mitochondrial dysfunction impair optic nerve recovery after IOP challenge CROWSTON JG–Melbourne
09:06	2263	The expanding clinical spectrum of dominant optic atrophy YU-WAI-MAN P–Newcastle upon Tyne
09:24	2264	Sensorineural hearing loss in OPA1-linked disorders BONNEAU D, MILEA D, LERUEZ S, DEFOORT-DHELLEMMES S, CROCHET M, LAMBLIN J, LENAERS G, PROCACCIO V, REYNIER P, BONNEAU-AMATI P–Angers, Lille, Montpellier
09:42	2265	The unsolved genetics of LHON: Beyond mtDNA primary mutations what else? CARELLI V–Bologna

**SIS** **Clearance systems in the RPE cells-implications to AMD** Gallieni 1 & 2  
 ACB Kai KAARNIRANTA, Hannu UUSITALO



08:30	2271	The endolysosomal system and AMD: Insights from a novel genetically engineered mouse model SINHA D, VALAPALA M, ZIGLER JS, HOSE S–Baltimore
09:00	2272	Crosstalk of proteasomes and autophagy in RPE cells KAARNIRANTA K–Kuopio
09:30	2273	A novel role for the immunoproteasome in retinal function FERRINGTON D–Minneapolis



## KEYNOTE LECTURE

Hermes

Balwantray CHAUHAN

10:15		Introduction by Alain Bron
10:25	2321	Why what you have been taught about the optic disc may not be entirely true CHAUHAN B-Halifax
10:55		Award of the EVER certificate of honour

THURSDAY

**FP** **Free papers RV 1/4: Surgical retina** **Athena**  
**RV** Zachariah KOSHY, Ramin TADAYONI

11:05	2411	Postoperative quality of life in macula-off rhegmatogenous retinal detachment patients and its relation to visual function VAN DE PUT M, WANDERS W, NOLTE I, HOOYMANS J, LOS L—Groningen
11:17	2412	Posterior vitreous detachment in highly myopic eyes undergoing vitrectomy PHILIPPAKIS E, GUALINO V, GAUCHER D, GAUDRIC A, MASSIN P, TADAYONI R—Paris, Strasbourg
11:29	2413	Epiretinal membrane surgery in highly myopic eyes a case control study BERROD JP, FAVEL C, BATTÀ B, SELTON J, TRECHOT F, CONART JB—Nancy
11:41	2414	Baseline characteristics and vitreoretinal interface features in patients with vitreomacular traction associated with macular hole from the MIVI-TRUST clinical program KOSHY Z, LABOURDETTE A, DUCHATEAU L, LESCRAUWAET B—Ayr, Toulouse, Ghent, Leuven
11:53 ★	2415	Baseline characteristics predictive of pharmacologic vitreomacular adhesion resolution in the ocriplasmin MIVI-TRUST program GANDORFER A—Munich
12:05	2416 <i>rf</i>	Baseline characteristics and vitreoretinal interface features in patients with vitreomacular traction without macular hole from the MIVI-TRUST clinical program KOSHY Z, LABOURDETTE A, DUCHATEAU L, LESCRAUWAET B—Ayr, Toulouse, Ghent, Leuven
12:11	2417 <i>rf</i>	Intravitreal drug dispersion and needle gauge PEREZ-MARTIN S, MONTERO J, MERINO A—Valladolid

**SIS** **Myths and misconceptions in glaucoma** **Hermes**  
**G** Sayeh POURJAVAN

11:05	2421	Myths and misconceptions about glaucoma blindness HONDEGHEM K—Antwerp
11:27	2422	Misconception about the intraocular pressure POURJAVAN S—Brussels
11:49	2423	Generics are the same or similar? STEVENS AM—Gent
12:11	2424	Myths and misconceptions in treatment adherence KOTECHA A—London

**SIS**      **Developments in corneal regeneration – NEXCR (Network of Excellence in Corneal Regeneration)**      **Rhodes 1**

**COS**      Herbert VAN ESSEN, Marie - José TASSIGNON



11:05	2431	Novel strategies for angioregression at the ocular surface BOCK F, CURSIEFEN C—Cologne
11:23	2432	Mesenchymal stem cells and corneal regeneration HOPKINSON A, BRANCH M—Nottingham
11:41	2433	Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation ZAKARIA N, KOPPEN C, TASSIGNON MJ—Antwerp
11:59	2434	Transcriptional profiling of human corneal epithelium using laser capture microdissection and massive parallel sequencing BATH C, MUTTUVELU D, EMMERSEN J, VORUM H, HJORTDAL J, ZACHAR V—Aalborg, Aarhus
12:17 ★	2435	Suitability of a fish scale-derived collagen matrix (FSCM) as artificial cornea VAN ESSEN TH, VAN ZIJL L, SPARKS SJ, CHEN G, LIN CC, LAI HJ, LUYTEN GPM, GHALBZOURI AEL, JAGER MJ—Leiden

**Course 9 The management of pigmented fundus lesions**

**Rhodes 2**

**PO**      Laurence DESJARDINS, Bertil DAMATO

Intermediate

The course will cover benign and malignant, congenital and acquired pigmented lesions of the fundus. Congenital pigmented lesions of the fundus are rare and can sometimes be confused with naevus or melanoma. The clinical aspects and pathology of all these lesions will be described. The differential diagnosis between benign naevi and suspicious naevi and the description and follow up of such lesions will allow the audience to get precise guidelines for the management of choroidal naevi. Focus will then be made on malignant uveal melanoma, including clinical aspects with the prognostic factors and treatment options. Radiotherapy techniques and surgical techniques will be developed in details.

11:05	2441	Congenital and other pigmented fundus lesions CAUJOLLE JP—Nice
11:23	2442	Suspicious choroidal naevi KIVELÄ T—Helsinki
11:41	2443	Malignant melanoma of the uvea: Diagnosis, characterization and prognosis MIDENA E—Padova
11:59	2444	Malignant melanoma of the uvea: Radiotherapy techniques DESJARDINS L—Paris
12:17	2445	Malignant melanoma of the uvea: Surgical techniques DAMATO B—Liverpool



THURSDAY

**SIS** **Inflammation and glaucoma: good or bad?** **Rhodes 3**  
**IM/G** Francois WILLERMAIN, Heping XU, Alain BRON

11:05	2451	Uveitis and glaucoma: A practical approach BODAGHI B—Paris
11:27	2452	Autoimmune mechanisms in primary open angle glaucoma GRUS F—Mainz
11:49	2453	Role of glial activation in neuroprotection of the retina VIDAL-SANZ M, GALINDO C, GALLEGO B, ROJAS B, DE HOZ R, RAMIREZ AI, SALAZAR JJ, TRIVINO A, AVILÉS M, AGUDO M, VILLEGAS-PÉREZ MP, RAMIREZ JM—Murcia, Madrid, Universidad de Murcia
12:11	2454	How inflammatory reactions affect POAG topical and surgical treatment? LABBE A, BAUDOUIN C—Paris

**SIS** **Grand rounds in ophthalmic genetics** **Rhodes 4**  
**MBGE** Bart LEROY, Christian HAMEL

This SIS will provide a forum for researchers and clinicians alike to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics. The format is simple and is comparable to that of the Grand Rounds in departments of ophthalmology around the World. Both SIS organisers will be present, together with other leaders in the field of ophthalmic genetics. Because of the format of the SIS, there will be no formal speakers set in stone from the outset, as all EVER participants will be free to submit cases during the meeting prior to this session. As such, the format will be similar to the FAN Club meeting.

**FP** **Free papers ACB 1/2: Modelling corneal epithelium and cell biology of retina** **Gallieni 1 & 2**  
**ACB** Roger BEUERMAN, Goran PETROVSKI

11:05	2471	Restoration of keratocyte cell phenotype through epithelial-stromal cell interactions in a 3D hydrogel model WILSON SL—Nottingham
11:17	2472	Culture optimisation of CD34-positive corneal stromal stem cells and transdifferentiation into corneal epithelial cells SIDNEY LE, BRANCH MJ, HASHMANI K, DUA HS, HOPKINSON A—Nottingham
11:29 ★	2473	Small molecule induction promotes corneal epithelial cell differentiation from human pluripotent stem cells SKOTTMAN H, MIKHAILOVA A, UUSITALO H, ILMARINEN T—Tampere
11:41	2474	Computational model of Ca <sup>2+</sup> wave propagation in human retinal pigment epithelium VAINIO I, ABU KHAMIDAKH A, PACI M, SKOTTMAN H, JUUTI-UUSITALO K, HYTTINEN J, NYMARK S—Tampere
11:53	2475	Scara5 involvement in retinal iron metabolism MENDES-JORGE L, VALENÇA A, RAMOS D, LOPEZ-LUPPO M, CATITA J, PIRES VMR, NACHER V, NAVARRO M, CARRETERO A, RODRIGUEZ-BAEZA A, RUBERTE J—Lisboa, Barcelona
12:05	2476 <i>rf</i>	Glucocorticoid modulation of agonist induced microvascular endothelial permeability SHAMS F, HUDSON N, OCKRIM Z, TUROWSKI P—London
12:11	2477 <i>rf</i>	Comparative gene expression analysis of corneal stroma mesenchymal stem cell-like cells, limbal epithelial stem cells and bone marrow-derived mesenchymal stem cells VEREB Z, POLISKA SZ, ALBERT R, OLSTAD OK, MOE MC, FESUS L, PETROVSKI G—Debrecen, Oslo

INDUSTRY-SPONSORED SYMPOSIUM **Rhodes 2****Micronutrition:  
Part of the retinal specialists' armamentarium?**

Moderator: Catherine CREUZOT

12:35	2541	Micronutrition; Opinion and use among European Ophthalmologists ASLAM T–Manchester
12:55	2542	New evidence on nutritional supplements CREUZOT C–Dijon
13:15	2543	How to go further? From fundamental research to clinical practice DELMAS D, LAYANA A–Dijon



# OPHTHALMIC RESEARCH LECTURE

Hermes

Neville OSBORNE

Ophthalmic  
Research  
Journal for Research in  
Experimental and  
Clinical Ophthalmology

13:40

Introduction by Uwe Pleyer

13:45

2621

The neuroscience of glaucoma in relation to the possibility for neuroprotection  
OSBORNE N—Oviedo

**SIS RV** **Vitreoretinal interface disorders** **Athena**  
Jean - Antoine C POURNARAS, Ramin TADAYONI

14:15	2611	Normal and abnormal vitreoretinal interface conditions POURNARAS CJ—Genève
14:30	2612	Assessment and classification of vitreoretinal interface disorders TADAYONI R—Paris
14:45	2613	Natural history of vitreoretinal interface disorders POURNARAS JA—Lausanne
15:00 ★	2614	Medical management of vitreoretinal interface disorders LE MER Y—Paris
15:15	2615	Surgical management of vitreoretinal interface disorders WOLFENSBERGER TJ—Lausanne
15:30	2616	Case study POURNARAS JA—Lausanne

**SIS G** **New angles in glaucoma- neuroprotection** **Hermes**  
Miriam KOLKO, M Francesca CORDEIRO

14:15	2621	The potential of regenerative strategies in glaucoma CORDEIRO M—London
14:45	2622	The potential role of endothelin in glaucoma CHAUHAN B—Halifax
15:15	2623	The role of low-grade inflammation in glaucoma KOLKO M—Copenhagen

**Course 10** **An update on corneal procedures** **Rhodes 1**  
**COS** Jean-Jacques GICQUEL, Rita MENCUCCI

Intermediate

This course will offer a practical and comprehensive update on modern corneal surgical procedures. It should be of interest for ophthalmologists in training as well as for the more experienced ophthalmologists who wants to increase their skills.

14:15	2631	Step by step limbal stem cell transplantation techniques GICQUEL J, DUA HS—Poitiers, Nottingham
14:37	2632	Indications and practical use of corneal crosslinking MENCUCCI R—Florence
14:59	2633	Modern indications and limitations of amniotic membrane transplantation YEUNG A—Birmingham
15:21	2634	Bloodless and painless pterygium surgery GICQUEL JJ—Poitiers

THURSDAY

**FP** **Free papers PO 2/2: Diagnostic tools in eyelid and orbital pathology** **Rhodes 2**  
**PO** Steffen HEEGAARD, Edoardo MIDENA

14:15	2641	Agreement between in vivo confocal scanning laser microscopy with a handheld microscope and histology in eyelid and conjunctival tumours ESPINASSE M, GRIVET D, CAMPOLMI N, CINOTTI E, PERROT JL, LABELLE B, CAMBAZARD F, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G—Saint-Etienne
14:27	2642	Mohs surgery of eyelid tumours assisted by ex vivo confocal microscopy and a new "open book" method for tissue preparation GRIVET D, CAMPOLMI N, CINOTTI E, FOREST F, ESPINASSE M, PERROT JL, LABELLE B, CAMBAZARD F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G—Saint-Etienne
14:39	2643 <i>rf</i>	A novel imaging approach to periocular basal cell carcinoma: In vivo optical coherence tomography and histological correlates PELOSINI L, SMITH HB, SCHOFIELD J, DHITAL A, KHANDWALA M—Maidstone, Kent
14:45	2644 <i>rf</i>	Unique morphology of the human orbit among the Hominoidea DENION E, HITIER M, GUYADER V, DUGUE AE, MOURIAUX F—Caen
14:51	2645 <i>rf</i>	Strabismus and diplopia revealing rhabdomyosarcoma in a 7-year-old girl AZIZ A, MATONTI F, FAKHOURY O, DENIS D—Marseille
14:57	2646	Non graves orbital inflammations: Rationale for a diagnostic approach FISCH AL, GAVARD PERRET A, LAGIER J, ROBERT PY—Nice, Limoges
15:09	2647	Repair of orbital implants exposures using muller muscle flaps ROBERT PY, DELMAS J, ADENIS JP—Limoges

**FP** **Free papers IM 1/2: Ocular infections "pole to pole":** **Rhodes 3**  
**IM** **new perspectives**  
 Piergiorgio NERI, Andrew DICK

14:15	2651	Inhibition of the DNA damage response blocks herpes simplex virus infection in corneal epithelium ALEKSEEV O, AZIZKHAN-CLIFFORD J—Philadelphia, PA
14:27	2652	Small molecule design strategy to overcome antibiotic resistance BEUERMAN R—Singapore
14:39	2653	Pharmaceutical failure mechanism of the worldwide ReNu with MoistureLoc-related fusarium keratitis epidemic of 2004-2006 BULLOCK J—Kettering, Ohio
14:51	2654	Recurrence of toxoplasmic retinochoroiditis: Analysis of cases proven by initial analysis of aqueous humor MATET A, FARDEAU C, TERRADA C, CASSOUX N, PARIS L, LEHOANG P, BODAGHI B—Paris
15:03	2655	Reduced Th17 type inflammation associated with enhanced Th1, Th2 and Treg responses in a model of reactivation of congenital ocular toxoplasmosis SAUER A, BOURCIER T, CANDOLFI E, PFAFF AW—Strasbourg
15:15	2656	Anatomical and visual outcome after pars plana vitrectomy in acute postcataract endophthalmitis CHIQUET C, CAMPOLMI N, COMBEY DE LAMBERT A, CORNUT PL, ROUBEROL F, PALOMBI K, APTEL F, THURET G, CREUZOT C—Grenoble, Saint Etienne, Lyon, Dijon

**SIS Mitochondrial dysfunction in optic neuropathies: from disease mechanisms to therapeutic strategies**

Rhodes 4

MBGE/NSPH Marcela VOTRUBA, Patrick YU-WAI-MAN



14:15	2661	Genetic analyses of autosomal optic neuropathies reveal novel physiopathological pathways involved in optic nerve degeneration LENAERS G, HALLOY F, HIEU N, MEGY C, DELETTRE C, MEUNIER I, ROUBERTIE A, HAMEL CP—Montpellier
14:33	2662	OPA1 in mitochondrial quality control and its implications for RGC degeneration ALAVI M—San Francisco
14:51	2663	Mitochondrial dynamics in mitochondrial optic neuropathies POULTON J, LIAO C, ASHLEY N—Oxford
15:09 ★	2664	New concepts of treatment for LHON and other genetic mitochondrial optic neuropathies SADUN A—Los Angeles
15:27 ★	2665	Raxone (idebenone) in LHON - An update MEIER T—Liestal

**Joint M. EEBA symposium: storage and processing of donor tissue before transplantation**

Gallieni 1 & 2

**COS** Vincent BORDERIE



14:15	2671	Hypothermic storage or organ culture? PONZIN D—Venice
14:27	2672	Consequences of storage on the donor corneal tissue ARMITAGE J—Bristol
14:39	2673	The fate of the corneal endothelium during storage: apoptosis/necrosis/survival ARMITAGE J—Bristol
14:51	2674	Evaluation of the donor tissue during storage BORDERIE V—Paris
15:03	2675	Preparing donor tissue for DSEK DICKMAN M—Maastricht
15:15	2676	Descemet's membrane preparation in eye banks for DMEK BACHMANN B, KRUSE FE—Erlangen
15:27	2677	Revisiting corneal storage using an innovative bioreactor THURET G, HE Z, BERNARD A, NAIGEON N, NANGOUM-FOSSO T, NEFZAQUI C, PISELLI S, ACQUART S, GARRAUD O, CAMPOLMI N, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P—Saint Etienne, Paris



THURSDAY

**Anatomy / Cell Biology****Moderators:****Hannu UUSITALO, Debasish SINHA**

- T001** *rf* Comparative gene expression analysis of corneal stroma mesenchymal stem cell-like cells, limbal epithelial stem cells and bone marrow-derived mesenchymal stem cells  
VEREB Z, POLISKA SZ, ALBERT R, OLSTAD OK, MOE MC, FESUS L, PETROVSKI G—Debrecen, Oslo
- T002** *rf* Proteasome dysfunction in retinal pigment epithelium during aging contributes to the pathogenesis of Age-Macular related Degeneration  
GIRAO H, MARQUES C, SOARES A, FERNANDES R, PEREIRA P—Coimbra
- T003** Bafilomycin A1 enhances the production of IL-1b induced by the proteasome inhibitor MG-132 but not that of IL-8  
PIIPPO N, HYTTI M, KINNUNEN K, SALMINEN A, KAARNIRANTA K, KAUPPINEN A—Kuopio
- T004** AICAR promotes cleansing of MG-132-induced protein aggregates in ARPE-19 cells  
MARCHESI N, VIIRI J, PASCALE A, AMADIO M, KAARNIRANTA K—Pavia, Kuopio
- T005** Hypoxia stimulates the release of Brain Natriuretic Peptide (BNP) from RPE cells  
ARJAMAA O, KINNUNEN K, KAARNIRANTA K, AALTONEN V—Turku, Kuopio
- T006** PKC activation affects, via ELAVL1/HuR protein, VEGF expression in pericytic/endothelial coculture  
AMADIO M, OSERA C, LUPO G, MOTTA C, DRAGO F, GOVONI S, PASCALE A—Pavia, Catania
- T007** *rf* ★ The effect of hyperglycaemia on permeability and tight junction components in human retinal and choroidal endothelial cells  
STEWART EA, SAKER S, AMOAKU WM—Nottingham
- T008** *rf* Glucocorticoid modulation of agonist induced microvascular endothelial permeability  
SHAMS F, HUDSON N, OCKRIM Z, TUROWSKI P—London
- T009** Macro and microglial retinal cells in rat organotypic cultures  
GALLEGO B, ROJAS B, SALAZAR JJ, RAMIREZ AI, DIERSTEIN M, DE HOZ R, TRIVINO A, RAMIREZ JM, UEFFING M, ARANGO-GONZÁLEZ B—Madrid, Tübingen
- T010** A new automatic method for microglial-cell quantification in whole-mount mouse retinas  
DE HOZ R, GALLEGO BI, ROJAS B, RAMIREZ AI, SALAZAR JJ, TRIVINO A, DE GRACIA PACHECO P, RAMIREZ JM—Madrid
- T011** Characterisation of diabetic retinal neuropathy in Ins2Akita mice  
ROMERO J, CHEN M, XU H—Belfast
- T012** Müller cell response during degenerative retinopathy in mice  
MENDES-JORGE L, VALENÇA A, PIRES VMR, CATITA J, RAMOS D, LOPEZ-LUPPO M, NACHER V, NAVARRO M, CARRETERO A, RODRIGUEZ-BAEZA A, RUBERTE J—Lisboa, Barcelona
- T013** Cellular senescence is increased in human retinal microaneurysms during aging  
MENDES-JORGE L, LOPEZ-LUPPO M, NACHER V, RAMOS D, NAVARRO M, CARRETERO A, RODRIGUEZ-BAEZA A, RUBERTE J—Lisboa, Barcelona
- T014** The fractal properties of the retinal vascular architecture  
VEKRIA P, CUBBIDGE R, HEITMAR R—Birmingham
- T015** Evaluation of central retinal thickness and subfoveal choroidal thickness in normal eyes  
LEE DW, KIM J, KIM CG, LEE TG—Seoul, Milwaukee
- T016** Assessment of macular retinal thickness and volume in normal eyes and highly myopic eyes with spectral optical coherence tomography  
CHEBIL A, BEN ACHOUR B, KORT F, CHAKER N, EL MATRI L—Tunis

**Electrophysiology, physiological Optics, Vision Sciences**

Moderators:

Miguel CASTELO-BRANCO, Celia SANCHEZ RAMOS, Werner SPILEERS, Aldina Susana REIS

- T017 Macula of retina - spherical calotte with its focus. Right image on the retina. Applications: Biophotonics Laser Holographic Theory of Vision. Apparatus for the study of human vision  
★ MANU MD, PLESU GH-Iasi
- T018 Biological lasers theory, vol.II vision holographic theory - Eye and vision  
★ MANU MD, PLESU GH-Iasi
- T019 The activity of the "when" pathway during visual motion  
KENGO T, SHU M-Umami-naka, Koryo-cho, Kitakatsugun, Nara
- T020 Evaluation of direct and consensual accommodation of fellow eyes using binocular open field auto refracto/keratometer WR-5100K  
TARUTTA E, TARASOVA N-Moscow
- T021 The relationship between halo size and intraocular light scatter in normal healthy subjects  
PUELL MC, PEREZ-CARRASCO MJ, PALOMO-ALVAREZ C, BARRIO AR-Madrid
- T022 Simultaneous VEP and EOG in dyslexic children  
HERAVIAN J, SOBHANI D, LARI YAZDI S, AZIMI A, KHOSHISMA MJ, HOSSEINI YAZDI SH, OSTADI MOGHADDAM H, YEKTA AA-Mashhad, Tehran
- T023 Retinal vessel oxygen saturation in retinitis pigmentosa patients  
TÜRKSEVER C, VALMAGGIA C, ORGUEL S, SCHORDERT DF, TODOROVA MG-Basel, St. Gallen, Sion
- T024 Hyperstereopsis is attenuated by the addition of secondary visual cues  
PRIOT AE, PHILIPPE M, SALASC CA, NEVEU P, PLANTIER J, ROUMES C-Brétigny-sur-Orge
- T025 Analysis of retinal and cortical response to electrical stimulation by subretinal implant in rodent  
MATONTI F, ROUX S, MARRE O, PICAUD S, CHAVANE F-Marseille, Paris
- T026 VEP evidence of significant differences in motion perception in children  
KUBOVA Z, KUBA M, KREMLACEK J, LANGROVA J, SZANYI J, VIT F, CHUTNA M-Hradec Kralove
- T027 Effects of Quensyl on the ERG a-wave amplitude from the isolated superfused vertebrate retina  
SIAPICH SA, GOEBEL A, WALTER P-Aachen
- T028 Keep an eye on the Pi – Using the Raspberry Pi as inexpensive, yet powerful platform for vision research  
★ WIRTH M, WEICHMANN F, SCHAEFFEL F, ZRENNER E, STRASSER T-Augsburg, Tuebingen
- T029 Differential diagnosis of endogeneous visual phenomena  
KRASTEL H, UDODOV E, GOLUBKINA L, HARDER B, KOLLING G, JONAS J-68167 Mannheim, Nesvizh, Mannheim, Heidelberg
- T030 Upper hemiretinal occult retinopathy  
KRASTEL H, BEUTELSPACHER S, ROSER O, UDODOV E, SCHLICHTENBREDE F, JONAS J-Mannheim, Ettlingen, Heidelberg, Nesvizh
- T031 The effect of vitreous opacities on stray light measurements  
DE SMET MD, CASTILLA M-Lausanne

**Glaucoma**

Moderators:

James MORGAN, Aachal KOTECHA, M. Francesca CORDEIRA

- T032 The prediction error of the visual field sensitivity is large at the steep 'border' of glaucomatous scotoma  
★ AOYAMA Y, MURATA H, TAHARA M, YANAGISAWA M, HIRASAWA K, MAYAMA C, ASAOKA R-Tokyo
- T033 Progression of visual field in patients with primary open-angle glaucoma (1): Preliminary results  
APTEL F, GIRAUD JM, ARYAL-CHARLES N, EL CHEHAB H, MAY F, CHIQUET C, ROMANET JP, RENARD JP-Grenoble, Paris
- T034 Secondary glaucoma in familial amyloid polyneuropathy  
ROUSSEAU A, BARREAU E, KASWIN G, CAUQUIL C, THEAUDIN M, ADAMS D, LABETOUILLE M-Le Kremlin-Bicêtre
- T035 Pituitary macroadenoma misdiagnosed as advanced normal tension glaucoma  
POPA CHERECHEANU A, COMAN CI, IANCU R, PARVULESCU RA, STANA D, DASCALU AM-Bucharest
- T036 Effectiveness of the glaucoma screening in employees of the University Hospital St. Luc, UCL, in Brussels  
STINGLHAMBER A, POURJAVAN S-Brussels
- T037 24-hour intraocular pressure rhythm in young healthy subjects evaluated with continuous monitoring using contact lens sensor  
MOTTET B, APTEL F, ROMANET JP, HUBANOVA R, PEPIN JL, CHIQUET C-Grenoble
- T038 Sleep apnea syndrome screening in patients with normal-tension glaucoma  
AGARD E, DESMAIZIERES C, RUSSO A, RACTMADOUX G, COSTE O, DOT C-Lyon
- T039 Comparing the use of steroid vs artificial tears following selective laser trabeculoplasty  
ALI ALJASIM L-Riyadh
- T040 Comparative effectiveness of bimatoprost 0.03% preservative free for the treatment of open-angle glaucoma and ocular hypertension  
BRERETON N, STRADWICK S, HARVEY B, SHERGILL C, PATEL V, WONG W-Sheffield, Marlow, Irvine
- T041 Comparative effectiveness of bimatoprost 0.03% / timolol 0.5% preservative free fixed combination (BTFC PF) for the treatment of open-angle glaucoma and ocular hypertension  
BRERETON N, STRADWICK S, HARVEY B, SHERGILL S, WONG W-Sheffield, Marlow, Irvine
- T042 Comparative analysis of hyperaemia rate between preservative-free latanoprost and preserved prostaglandin eyedrops. An adjusted indirect comparison meta-analysis  
★ ROULAND J, CUCHERAT M-Lille, Lyon
- T043 Removal of preservative from Ganfort improves intraocular pressure (IOP) lowering in patients – A timolol dose-response phenomenon  
★ SHEN J, BEJANIAN M, SCHIFFMAN R-Irvine
- T044 SYL040012, a siRNA for the treatment of glaucoma  
★ PAÑEDA C-Tres Cantos, Madrid

## THURSDAY

- T045 Patient behavior when prescribed non-affordable glaucoma medication in the medical unit, National Research Center, Cairo, Egypt  
*rf*  
SAEED IBRAHIM A—Cairo
- T046 Outcome of fornix-based versus limbal-based conjunctival flaps in trabeculectomy  
IBANEZ J, PEREZ GARCIA D, ASCASO PUYUELO FJ, PINILLA I, JIMENEZ DEL RIO B, CRISTOBAL JA—Zaragoza
- T047 Ultrasonic circular cyclo coagulation in patients with primary open-angle glaucoma: A multicenter clinical trial  
★  
APTEL F, DENIS P, ROULAND JF, NORDMANN JP, LACHKAR Y, RENARD JP, SELLEM E, BAUDOUIN C, BRON A—Grenoble, Lyon, Lille, Paris, Dijon
- T048 Comparison of Esnoper® implant placement in non penetrating deep sclerectomy  
IBANEZ J, PEREZ GARCIA D, ASCASO PUYUELO FJ, CRISTOBAL JA—Zaragoza
- T049 Treatment of refractory glaucoma using UC3 procedure with HIFU (High Intensity Focused Ultrasound). Prospective series  
★  
ROULAND J, APTEL F—Lille, Grenoble
- T050 Argon laser trabeculoplasty (ALT) for advanced glaucoma: A 12 months follow-up study  
*rf*  
PELOSINI L, FAYEMI A, ANSARI E—Maidstone, Kent
- T051 Neovascular glaucomas after central retinal artery occlusions  
DEGOUMOIS A, MIOCCQUE S, DENION E—Caen
- T052 Imaging of the optic nerve (oct rnfl and ganglion cells analysis) in monitoring the child's congenital glaucoma  
BOUAKAZ S, RUPIN A, LABALETTE P, ROULAND JF—Lille
- T053 Hemifield pattern electroretinogram, frequency doubling technology and optical coherence tomography for detection of early glaucomatous optic neuropathy in ocular hypertensive patients  
CELLINI M, FINZI A, STROBBE E, CAMPOS E—Bologna
- T054 Backwards compatibility of HRT3 and HRT II before and after cataract surgery and intraocular lens implantation  
FALCK A, SAARELA V—Oulu
- T055 Structure function relationship: Specific index of ganglion cell complex assessment of 2 spectral domain OCT and standard automated perimetry  
EL CHEHAB H, DELBARRE M, FENOLLAND JR, MARECHAL M, ZERROUK M, FRANCOZ M, OUANEZAR S, GIRAUD JM, MAY F, RENARD JP—Paris
- T056 Ganglion cell complex measurement and glaucoma diagnosis using two SD-OCT  
FRANCOZ M, EL CHEHAB H, FENOLLAND JR, DELBARRE M, MARECHAL M, OUANEZAR S, GIRAUD JM, MAY F, RENARD JP—Paris
- T057 Analyse of segmented macular inner layers by spectral domain optical coherence tomography in glaucoma  
DELBARRE M, EL CHEHAB H, FRANCOZ M, ZERROUK R, MARECHAL M, OUANEZAR S, GIRAUD JM, MAY F, RENARD JP—Paris
- T058 Comparaison of two anterior segment OCT: CASIA (Tomey) versus OCT Visante (Zeiss)  
GIMBERT A, CAMPOLMI N, THURET G, GAIN P, ROMANET JP, CHIQUET C, APTEL F—Saint-Etienne, Grenoble
- T059 Inter-test variability in normals and glaucomatous patients tested by Optopol PTS-910, Glaucoma program  
POPA CHERECHEANU A, DASCALU AM, STANA D, SERBAN D—Bucharest
- T060 Choroidal thickness in open-angle glaucoma  
STEINMETZ P, JONAS JB—Mannheim
- T061 Cognitive function associated with larger optic nerve heads  
*rf*  
JONAS J, XU L, WANG YX, LI JJ—Mannheim, Beijing
- T062 Spectral analysis of ocular pulse amplitude recordings obtained using a contact lens sensor  
*rf*  
HIRN C, RUSSELL RA, LAMPARTER J, LASCARATOS G, HO T, GARWAY-HEATH DF—Zurich, London, Mainz
- T063 Correlation between retinal ganglion cell count and morpho-functional parameters in glaucoma  
MILANO G, LOMBARDO S, DISTANTE P, TINELLI C, LANTERI S, VERTICCHIO VERCELLIN AC, CUTOLO CA, RAIMONDI M, ROLANDO M, ROSSI GCM—Pavia
- T064 Progression of visual field in patients with primary open-angle glaucoma (2): Level of progression  
GIRAUD JM, EL CHEHAB H, APTEL F, ARYAL-CHARLES N, MAY F, CHIQUET C, ROMANET JP, RENARD JP—Paris, Grenoble
- T065 Ocular Pulse Amplitude is associated with ocular blood flow velocities in healthy subjects and patients with primary open angle glaucoma, but not normal tension glaucoma  
PINTO L, VANDEWALLE E, STALMANS I—Lisbon, Leuven
- T066 Motion perception in early glaucoma  
*rf*  
FRANCOZ A, CARLINI A, CREUZOT C, POZZO T, BRON AM—Dijon
- T067 Validation of Testvision, an internet-based test for the detection of visual field loss  
*rf*  
OLSEN AS, LA COUR M, SERUP L, ALBERTI M, DAMATO B, KOLKO M—Copenhagen, San Francisco

**Molecular Biology / Genetics / Epidemiology**

**Moderators:**

**Jo POULTON, Marzena GAJECKA, Guy LENAERS**

**T068** Primary health care model for detection of ophthalmological visual disturbances in a population of employees of Universidad de Tarapaca, Chile  
 CHAVEZ C, VETTERLEIN V, RAMIREZ JM, DE HOZ R—Arica, Madrid

**T069** Distribution of ocular biometric parameters during the eye growth  
 YEKTA A, HASHEMI H, OSTADIMOGHADDAM H, JAFARZADEHPOUR E, KHABAZKHOOB M, REZVAN F—Mahhad, Tehran, Mashhad

**T070** Eye problems in deaf children: A case-control study  
 OSTADIMOGHADDAM H, MIRHAJIAN H, SOBHANI D, YEKTA A, HERAVIAN J, KHABAZKHOOB M—Mashhad, Tehran

**T071** Profiling miRNAs in a hyperglycemic and hypoinsulinemic *Ins2Akita* mouse model  
 GIOCANTI-AUREGAN A, AHN L, TSANG SH, SANCHO-PELLUZ J, KISS S, ROSENBLATT MI, TUSCHL T, PENA JTG, D'AMICO DJ—Paris, New York, Valencia

**T072** Visual function changes in an animal model of retinitis pigmentosa  
 SEGURA CALVO F, LOPEZ DE LA FUENTE C, SANCHEZ-CANO A, FUENTES-BROTO L, PEREZ GARCIA D, PINILLA I—Zaragoza

**T073** Influence of refractive error and axial length on retinal vessel geometric characteristics  
 LIM LS, CHEUNG C, LIM X, MITCHELL P, WONG TY, SAW SM—Singapore, Sydney

**T074** Early dietary therapy in preventing progression of retinopathy in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency caused by the homozygous G1528C mutation  
 ROOMETS E, KIVELÄ T, TYNI T—Tallinn, Helsinki

**T075** A cone-rod dystrophy patient with a homozygous RP1L1 mutation  
 KAMEYA S, KIKUCHI S, GOCHO K, KABUTO T, SUGAWARA Y, YAMAKI K, TAKAHASHI H—Inzai, Chiba, Yurihonjo, Akita, Sendagi, Tokyo

**T076** Hunter Syndrome after 12 months of enzyme replacement treatment: A case report  
 HERRERA L, CRUZ N, CARAMELLO C, ZABADANI K, PINILLA I, ASCASO FJ, CRISTOBAL JA—Zaragoza

**T077** Interleukin-8 promoter polymorphism is associated with the initial repose to bevacizumab in AMD treatment  
 IMMONEN I, HAUTAMÄKI A, KIVIOJA J, VAVULI S, KAKKO S, SAVOLAINEN ER, SAVOLAINEN M, LIINAMAA MJ, SEITSONEN S, ONKAMO P, JÄRVELÄ I—Helsinki, Oulu

**T078** Clinical findings in a Roma family with autosomal dominant cone-rod dystrophy  
 KOEV K, CHERNINKOVA S, KAMENAROVA K, GEORGIEV R, KANEVA R—Sofia

**T079** Examination of colour vision deficiency in different types retinitis pigmentosa  
 KOEV K, GEORGIEV R, CHERNINKOVA S—Sofia

**T080** Retigabine-induced retinal dystrophy: First reported case  
 ASCASO FJ, MAURI JA, MATEO J, CAMACHO JL, DEL BUEY MA, IBANEZ J, PÉREZ D, CRISTOBAL JA—Zaragoza

**T081** Alu retrotransposon quantification in the retina and plasma: Mechanism-based risk assessment in age-related macular degeneration  
 FOWLER B, KERUR N, GELFAND B, BASTOS-CARVALHO A, AMBATI J—Lexington

**T082** Angiotensin-like protein 2 contributes to pathogenesis of diabetic retinopathy  
 ITO Y, OIKE Y, TANIHARA H—Kumamoto

**T083** Photoreceptor integrity and visual acuity in retinitis pigmentosa  
 EL MATRI L, CHEBIL A, LARGUECHE L, CHAKER N, CHARFI H—Tunis

**T084** DNA methyltransferases are differentially expressed in human eyes  
 BONNIN N, BLANCHON L, BELVILLE C, CHIAMBARETTA F, SAPIN V—Clermont Ferrand

**T085** Analysis of mitochondrial sequences in patients with keratoconus  
 NOWAK DM, KAROLAK JA, MACHTEL P, POLAKOWSKI P, SZAFLIK JP, SZAFLIK J, GAJECKA M—Poznan, Warsaw

**T086** Genotype-phenotype correlation in two patients with posterior polymorphous corneal dystrophy 3  
 LISKOVA P, PALOS M, HARDCASTLE A, VINCENT A—Prague, London, Auckland

**T087** Association between endothelin receptor type A gene polymorphisms EDNRA (C+70G, C+1222T) and the endothelin-1 plasma concentration in patients with normal tension glaucoma  
 WROBEL-DUDZINSKA D, KOSIOR-JARECKA E, LUKASIK U, KOCKI J, ZARNOWSKI T—Lublin

**T088** Intraocular foreign bodies on the Island of Sealand, a preventable serious eye disease  
 MELSOM H, LA COUR M—Glostrup, Copenhagen

**T089** Choroidal thickness in retinitis pigmentosa using EDI OCT  
 AKNIN I, MELKI L—Golfe Juan, Cannes

THURSDAY

**SIS** **Controversies in the pathogenesis and treatment of retinal vein occlusion** **Athena**

**RV** Andrzej GRZYBOWSKI, Francisco ASCASO

16:30	2711	Controversies in the pathogenesis of RVO – Local perspective ASCASO F–Zaragoza
16:45	2712	Controversies in the pathogenesis of RVO – Systemic perspective GRZYBOWSKI A–Poznan
17:00	2713	Anti-VEGF agents in the treatment of RVO REHAK MATUS–Leipzig
17:15 ★	2714	Intravitreal steroids to treat the RVO-associated macular edema CREUZOT C–Dijon
17:30	2715	The role of autologous plasmin enzyme in the therapy of macular edema secondary to RVO UDAONDO P
17:45	2716	Controversies in the surgical treatment of RVO - Associated macular edema GARCIA - ARUMI J, VELAZQUEZ VILLORIA D–Barcelona

**FP** **Free papers G 1/4: IOP measurements / Epidemiology** **Hermes**

**G** Jost B JONAS, Philippe KESTELYN

16:30	2721	24 hour continuous ocular tonography Triggerfish and biorhythms of the cardiovascular system functional parameters in healthy and glaucoma populations WASILEWICZ R, WASILEWICZ P, CZAPLICKA E, KOCIECKI J, BLASZCZYNSKI J, MAZUREK C, SLOWINSKI R–Poznan
16:42	2722	The therapeutic impact of office-hours diurnal pressure measurements in the management of glaucoma patients LAMPE M, POURJAVAN S–Brussels
16:54	2723	Pseudoexfoliation: normative data and associations. The Central India Eye and Medical Study JONAS J, NANGIA N–Mannheim, Nagpur
17:06	2724	Intraocular pressure and central corneal thickness in an old French population: The MONTRACHET study BRON AM, FRANCOZ A, FIET C, BONYTHON KOPP C, BINQUET C, TZOURIO C, ACAR N, BRETILLON L, CREUZOT C–Dijon, Bordeaux
17:18	2725	Dependence of the origin of pain in the eyes with terminal stage of glaucoma from chemical composition of vitreous ERMOLAEV A, RENDEL E, KASCHEEVA N–Moscow
17:30	2726 <i>rf</i>	Cognitive function associated with larger optic nerve heads JONAS J, XU L, WANG YX, LI JJ–Mannheim, Beijing
17:36	2727 <i>rf</i>	Spectral analysis of ocular pulse amplitude recordings obtained using a contact lens sensor HIRN C, RUSSELL RA, LAMPARTER J, LASCARATOS G, HO T, GARWAY-HEATH DF–Zurich, London, Mainz

**SIS**      **The quality of vision: the new frontier of modern ophthalmology**      **Rhodes 1**  
**COS**      Jean-Jacques GICQUEL, Pierre Jean PISELLA

16:30	2731	Why is a precise assessment of the quality of vision essential in dry eye patients? PISELLA P–Tours
16:48	2732	3D or not 3D: The binocular tolerance to higher order aberrations GICQUEL JJ–Poitiers
17:06 ★	2733	Should our decision to practice cataract surgery be only based on visual acuity? VAN DEN BERG TJTP–Amsterdam
17:24	2734	Spherical aberration: Friend or foe? VANDERMEER G, NOCHEZ Y, PISELLA PJ–Tours
17:42	2735	The effectiveness of wavefront-guided refractive laser treatment SULEMAN H, FARES U, AL-AQABA MA, OTRI AM, SAID DG, DUA HS–Nottingham

**Course 11 Practical ophthalmic pathology - basics, updates and new insights**      **Rhodes 2**  
**PO**      Sarah COUPLAND, Steffen HEEGAARD

Intermediate

This aim of this course is to provide a basic overview of ophthalmic pathology, its continuing role in modern ophthalmology, and to provide practical guidelines for the evaluation of ocular specimens of varying types (e.g. diagnostic vitrectomies, conjunctival-, orbital- and chorio-retinal biopsies, enucleated eyes as well as exenteration specimens).

Furthermore, the course will cover newer technologies and methodologies in molecular diagnostics, and how these can be incorporated into the diagnostic panel in ophthalmic pathology.

This course will be based on routine examples and will be given by experienced clinicians/pathologists from a practical rather than theoretical point of view. It is aimed at ophthalmologists with an interest in pathology, as well as at pathologists and basic researchers specialising in ocular pathology.

16:30	2741	Tips and tricks in grossing & processing specimens COUPLAND S–Liverpool
16:45	2742	Overview of conjunctival and eyelid tumours VAN GINDERDEUREN R–Leuven
17:00	2743	Anterior to posterior “tour” of ocular disease processes VAN GINDERDEUREN R–Leuven
17:15	2744	Overview of adult and paediatric orbital pathology HEEGAARD S–Copenhagen
17:30	2745	Molecular techniques in ocular pathology COUPLAND S–Liverpool
17:45	2746	Comparative ocular pathology and animal models used in eye research HEEGAARD S–Copenhagen



THURSDAY

**SIS** **Neuro-ophthalmic complications in the patient with cancer** **Rhodes 3**  
**NSPH** Aki KAWASAKI, Gabriella SZATMARY

16:30	2751	Neuro-ophthalmic complications of cancer chemotherapy KAWASAKI A—Lausanne
16:48	2752	Paraneoplastic syndromes SZATMARY G, POLGAR TATJA—Hattiesburg
17:06	2753	Meningeal carcinomatosis SZATMARY G—Hattiesburg
17:24	2754	Anterior pathway meningiomas KAWASAKI A, BOSCHI A—Lausanne, Brussels
17:42	2755	Radiation optic neuropathy BORRUAT F—Lausanne

**FP** **Free papers MBGE 1/2: Genetics; Genotypes and Phenotypes** **Rhodes 4**  
**MBGE** Christian HAMEL, Jochen GRAW

16:30	2761	The eye screen of the German Mouse Clinic (GMC) – New genetic insights into eye development and ocular disorders PUK O, FUCHS H, GAILUS-DURNER V, HRABE DE ANGELIS M, GRAW J—Neuherberg
16:42	2762	High resolution retinal image analysis of unilateral retinitis pigmentosa using adaptive optics GOCHO K, KIKUCHI S, KABUTO T, AKEO K, KAMEYA S, YAMAKI K, TAKAHASHI H—Inzai, Tokyo
16:54	2763	Pilot study in Polish keratoconus patients using next generation sequencing GAJECKA M, KAROLAK JA, NOWAK DM, POLAKOWSKI P, SZAFLIK JP—Poznan, Warsaw
17:06	2764	Role of O-GlcNAcylation of Sp1 in the pathogenesis of diabetic retinopathy DONOVAN K, ALEKSEEV O, AZIZKHAN-CLIFFORD J—Philadelphia
17:18	2765	Global microarray analysis and metabolic pathway profiling of a transgenic model of conditional, selective Müller cell ablation CHUNG SH, SHEN W, YANG J, JAYAWARDANA K, GILLIES MC—Sydney
17:30	2766 <i>rf</i>	Genotype-phenotype correlation in two patients with posterior polymorphous corneal dystrophy 3 LISKOVA P, PALOS M, HARDCASTLE A, VINCENT A—Prague, London, Auckland
17:36	2767 <i>rf</i>	Analysis of mitochondrial sequences in patients with keratoconus NOWAK DM, KAROLAK JA, MACHTEL P, POLAKOWSKI P, SZAFLIK JP, SZAFLIK J, GAJECKA M—Poznan, Warsaw

**SIS** **Mechanisms of wound healing** **Gallieni 1 & 2**  
**ACB** Hannu UUSITALO, Roger BEUERMAN



16:30	2771	Wound healing in health and disease UUSITALO H—Tampere
16:52	2772	The role of wound healing in cornea BEUERMAN R—Singapore
17:14	2773	The mouse model of glaucoma filtration surgery: from understanding the wound healing response to applications as a tool for validating anti-fibrotics LI-FONG LF, WONG TT—Singapore
17:36 ★	2774	Cell biological mechanisms of wound healing JÄRVINEN T—Tampere

INDUSTRY-SPONSORED SYMPOSIUM **Rhodes 2****Ocular surface and corneal damages: new outcomes**

Moderators: Leopold SCHMETTERER, Marc MURAINÉ

18:00	2841	Dry eye associated with ocular surface damages SCHMETTERER L–Vienna
18:30	2842	Confusing corneal ulcerations: Management of neurotrophic ulcers MURAINÉ M–Rouen
19:00	2843	New therapy for persistent epithelial defects - report of the first cases UDZIELA M–Warsaw





**FRIDAY  
SEPTEMBER 20  
2013**

FRIDAY

**SIS** **Recent advances in OCT exploration of choroid in normal and diseases** **Athena**  
**RV** Gabriel COSCAS, Constantin POURNARAS

08:30	3211	Choroidal thickness measurements and variations with age, gender in normal, myopia and high myopia COSCAS G—Creteil
08:45	3212	Choroidal circulation measurements by laser Doppler flux metry POURNARAS CJ—Genève
09:00	3213	Changes in choroidal thickness in adult onset foveomacular vittelliform dystrophy versus exudative AMD COSCAS F, PUCHE N, SOUIED E, COSCAS G—Créteil
09:15	3214	Evaluation of posterior limits of choroid UZZAN J—Rouen
09:30	3215	Comparison of choroidal thickness between central serous choroidopathy and polypoidal choroidal vasculopathy PUCHE N, COSCAS F—Paris
09:45	3216	Variations of choroidal thickness in exudative AMD before and after treatment MAUGET-FAYSSE M, COSCAS G—Paris

**SIS** **Intelligent follow-up for glaucoma** **Hermes**  
**G** David F GARWAY-HEATH, Balwantray CHAUHAN

08:30	3221	Using 'big data' to examine visual field follow up in glaucoma CRABB D—London
08:48	3222	Visual field testing in clinical practice - The role of age, stage and follow-up duration JANSONIUS NM—Groningen
09:06	3223	Is there any place for non-standard automated perimetry in glaucoma monitoring? CHAUHAN B—Halifax
09:24	3224	How imaging can be used for clinical decision-making? GARWAY-HEATH D—London
09:42	3225	Clinically sensible follow-up for glaucoma LEMIJ H—Rotterdam

**FP** **Free papers COS 2/5: Eye banking and corneal bioengineering** **Rhodes 1**  
**COS** Gilles THURET, Christopher LIU

08:30	3231	Conception and optimization of a corneal bioreactor TRONE MC, CAMPOLMI N, GAUTHIER AS, NEFZAOUI C, BERNARD A, NAIGEON N, NANGOUM-FOSSO T, PISELLI S, GARRAUD O, ACQUART S, THURET G, GAIN P—Saint-Etienne
08:42	3232	Setting up organ-cultured corneas pre-cutting by a French blood center-eye bank CAMPOLMI N, GAUTHIER AS, MONTARD R, ACQUART S, THEILLIERE C, PEIRERA S, GARRAUD O, HE Z, PISELLI S, THURET G, DELBOSC B, GAIN P—Saint-Etienne, Besançon
08:54	3233	Optical measurement of dioptric power and transparency of cornea stored in bioreactor PATAIA G, GAUTHIER AS, TRONE MC, CAMPOLMI N, BERNARD A, NAIGEON N, NANGOUM-FOSSO T, PISELLI S, ACQUART S, LEPINE T, DELBOSC B, THURET G, GAIN P—Saint-Etienne, Besançon
09:06	3234	Endothelial and stromal quality control of corneas stored in an innovative bioreactor GAUTHIER A, TRONE MC, CAMPOLMI N, NEFZAOUI C, BERNARD A, NAIGEON N, NANGOUM-FOSSO T, PISELLI S, DELBOSC B, ACQUART S, THURET G, GAIN P—Saint-Etienne, Besançon

**SIS PO**      **Tumours and pseudo-tumours of the pigment epithelium**      **Rhodes 2**  
 Leonidas ZOGRAFOS, Ann SCHALENBOURG

08:30	3241	Congenital hypertrophy of the retinal pigment epithelium (RPE) ZOGRAFOS L–Lausanne
08:42	3242	Isolated and combined hamartomas of the RPE SCHALENBOURG A–Lausanne
08:54	3243	Congenital hypertrophy of the RPE related to familial adenomatous polyposis DESJARDINS L–Paris
09:06	3244	Irido-ciliary tumours of the pigmented and non-pigmented ciliary epithelium DAMATO B–Liverpool
09:18	3245	Controversies in the surgical treatment of combined hamartomas of the retina and retinal pigment epithelium GARCIA-ARUMI J, VELAZQUEZ VILLORIA D–Barcelona
09:30	3246	Debate: Challenging cases of retinal pigment epithelium lesions: How to diagnose? How to manage? GARCIA-ARUMI J, DAMATO B, DESJARDINS L, SCHALENBOURG A, ZOGRAFOS L–Barcelona

**Course 12**      **Cell biological techniques for eye research**      **Rhodes 3**  
**ACB**      Hannu UUSITALO, Ulla AAPOLA

Intermediate

In vitro techniques and models of disease are an essential part of basic and translational eye research. They are widely used when novel cellular mechanisms or pathogenesis of ocular diseases are studied. This techniques are important means to detect new therapeutic and diagnostic modalities for various eye diseases. The course is designed to give practical information and advice on selected methods of eye research. This year the course will focus on the techniques used in RPE cell and retinal angiogenesis and in retinal diseases like AMD. The staff will give detailed practical advice and detailed instructions of their techniques in their course material.

08:30	3251	The role of in vitro studies in eye research UUSITALO H–Tampere
08:50	3252	How to study heterophagy in RPE cells SINHA D–Baltimore
09:10	3253	Techniques to demonstrate immunoproteasome in retinal functions FERRINGTON D–Minneapolis
09:30	3254	Techniques for studying mechanisms of autophagy in RPE cells KAARNIRANTA K–Kuopio

**Joint M. NSPH**      **GOA**      **Gallieni 1 & 2**  
 Jean-Luc FAUQUERT



08:30	3271	Conjunctival provocation test in ophthalmology daily practice FAUQUERT J–Clermont-Ferrand
09:00	3272	Allergy and vernal keratoconjunctivitis: Results of a 251 children cohort CHIAMBARETTA F–Clermont Ferrand
09:30	3273	What's new in atopic keratoconjunctivitis BREMONT-GIGNAC D–Amiens



## KEYNOTE LECTURE

Hermes

Alfredo SADUN

- |       |      |  |
|-------|------|--|
| 10:10 |      | Introduction by Aki Kawasaki   |
| 10:20 | 3321 | Why is the optic nerve the canary in the coal mine of mitochondrial diseases?<br>SADUN A—Los Angeles |
| 10:50 |      | Award of the EVER certificate of honour  |



**SIS** **Retinal vein occlusions: new concepts for clinical management** **Athena**  
**RV** Michel PAQUES

11:00	3411	RVO: A complex disease PAQUES M—Paris
11:18	3412	Is there a need for a general workup of RVO patients? HERON E—Paris
11:36	3413	The issue of chronic macular edema GIRMENS JF—Paris
11:54	3414	Toward a new classification of RVOs? PAQUES M—Paris
12:12	3415	Discussion of clinical cases in real-life practice MAUGET-FAYSSE M—Paris

**SIS** **Patient Perceptions in Glaucoma - what the doctor (thinks he) knows, and what the patient can tell us** **Hermes**  
**G** Aachal KOTECHA, Pradeep RAMULU

11:00	3421	What research tells us about the impact of glaucoma on the patient RAMULU P—Baltimore
11:22	3422	Methods used to measure patient perceptions RUBIN GS—London
11:44	3423	The art of healthcare: the importance and impact of effective Patient and Public Involvement (PPI) PORTEOUS C—London
12:06	3424	What glaucoma means to me: The patient's perspective KOTECHA A—London

**FP** **Free papers COS 3/5: Keratoconus and corneal diseases** **Rhodes 1**  
**COS** Vincent BORDERIE, María Fideliz DE LA PAZ

11:00	3431	Fitting tips and tricks of challenging cases of keratoconus ABOU SAMRA W—Mansoura
11:12	3432	Current phenotype of keratoconus patients at King Khaled Eye Specialist Hospital AL-SWAILEM S, YIU S, AL ASSIRI A, ASGHAR N, AL QASSIMI A—Riyadh, Baltimore
11:24	3433	Corneal refractive power after anterior lamellar versus penetrating keratoplasty BORDERIE VM, SANDALI O, GEORGEON C, BORDERIE M, TOUZEAU O, BOUHERAOUA N, LAROCHE L—Paris
11:36	3434	Recurrence of anterior corneal dystrophies after keratoplasty DE LA PAZ M, BARRAQUER RI, ALVAREZ DE TOLEDO JP, BUIGUES A, MICHAEL R, BARRAQUER J—Barcelona
11:48	3435	Very low risk of light-induced retinal damage during Boston Keratoprosthesis surgery SALVADOR CULLA B, BEHLAU I, SAYEGH RR, STACY RC, DOHLMAN CH, DELORI F—Boston
12:00	3436	Influence of growth factors on keratocyte phenotype in serum free media LYNCH A, O'SULLIVAN F, AHEARNE M—Dublin



FRIDAY

Intermediate

### Course 13 Don't panic: Hitchhiker's guide to statistics

Rhodes 2

PO Tero KIVELÄ, Bertil DAMATO

This course will widen your comfort zone in statistics. It highlights pearls not to be missed and pitfalls to be circumvented in using and interpreting the most common statistical methods and tests. Good science and evidence-based practice depends on accurate communication of research results and their correct interpretation by the readership. Because some authors do not seek statistical advice when planning and analysing their study and most journals do not submit their manuscripts to statistical review, the scientific reviewer is often responsible for spotting at least elementary deviations from good statistical practice. For many, this means stepping out of their comfort zone. The experience of the instructors as senior writers, reviewers and editorial board members is used to guide the participants into being more agile in the exciting field of statistical analysis whether they produce or peruse research. The items discussed are based on live examples from recent published literature.

11:00	3441	Introduction to study design DAMATO B–Gayton - Wirral
11:20	3442	Matching analysis with your study design KIVELÄ T–Helsinki
11:40	3443	Communicating your research and presenting your data DAMATO B–Liverpool
12:00	3444	Pearls and pitfalls KIVELÄ T–Helsinki
12:20		Discussion

FP  
IM

### Free papers IM 2/2: Hot topics in ocular immuno-infectiology

Rhodes 3

Francois WILLERMAIN, Heping XU

11:00	3451	Retinal pigment epithelial (RPE) cells convert bone marrow derived macrophages into myeloid suppressor cells with novel phenotype XU H, ZHAO J, LUO C, CHEN M–Belfast
11:12	3452	Ocular Syphilis: Beware of the great imitator! VELDMAN E, MEENKEN C, HALABY T, KOOTSTRA G–Enschede, Amsterdam
11:24	3453	Intraocular rubella virus detection as a diagnostic tool for atypical forms of Fuchs cyclitis BOUILLLOT A, FEL A, TOUITOU V, LE HOANG P, LABETOUILLE M, ROZENBERG F, BODAGHI B–Paris, Kremlin-Bicêtre
11:36	3454	Mid-term efficacy and safety of adalimumab in refractory pediatric uveitis: A retrospective monocentric study PENAUD B–Paris
11:48	3455	Tocilizumab for uveitic macular edema MESQUIDA M, LLORENÇ V, ADAN A–Barcelona
12:00	3456	3 months results of intravitreal dexamethasone implant in non infectious uveitis DARUGAR A, CHAMPION E, TOUITOU V, FARDEAU C, LE HOANG P, BODAGHI B–Paris

FP  
RV

**Free papers RV 2/4: Retina imaging 1**

Rhodes 4

Melanie BIDAUT GARNIER, Catherine CREUZOT

11:00	3461	Three-dimensional analysis of HSV colour space to distinguish small retinal haemorrhages, hard exudates and photocoagulation marks from dust artefacts SUZUKI N, YAMANE K—Higashi-Hiroshima, Hiroshima
11:12	3462	Reliability of the cone counts by an Adaptive Optics Retinal Camera BIDAUT GARNIER M, FLORES M, TUMAHAI P, MEILLAT M, DEBELLEMANIERE G, PUYRAVEAU M, SCHWARTZ C, MONTARD M, DELBOSC B, SALEH M—Besançon
11:24	3463	Quantification of cone loss after macula-involving retinal detachment using the RTX-1 Adaptive optics camera FLORES M, DEBELLEMANIERE G, MEILLAT M, TUMAHAI P, SCHWARTZ C, MONTARD M, DELBOSC B, SALEH M—Besançon
11:36	3464	Evaluation of cone photoreceptor density using adaptive optics retinal imaging in patients under treatment with hydroxychloroquine DEBELLEMANIERE G, TEA S, TUMAHAI P, MEILLAT M, FLORES M, BIDAUT GARNIER M, SCHWARTZ C, MONTARD M, DELBOSC B, SALEH M—Besançon
11:48 ★	3465	Comparison of macular pigment optical density measured by autofluorescence and reflectometry: The LIMPIA study CREUZOT C, DELYFER MN, ROUGIER MB, SAVEL H, CHENE G, DELCOURT C, KOROBELNIK JF—Dijon, Bordeaux
12:00	3466 <i>rf</i>	Autofluorescence patterns and visual acuity in macular telangiectasia type 2 BALASKAS K, LEUNG I, SALLO FB, CLEMONS TE, BIRD AC, PETO T—London, Rockville, Maryland
12:06	3467 <i>rf</i>	Evaluation of ultra-widefield fundusautofluorescence in non-infectious posterior uveitis KERNT M, REZNICEK L, THURAU S, KAMPIK A—Munich
12:12	3468	The effect of posterior subtenon injection of triamcinolone acetonide for diabetic macular edema refractory to intravitreal bevacizumab injection SOO GEUN JOE, MOON HAEIN, CHAE JB—Seoul, Cheongju

**Course 14 Visual fields: back to basics**  
NSPH

Aki KAWASAKI, François-Xavier BORRUAT

Gallieni 1 & 2

Beginner

This course focuses on basic understanding and interpretation of visual fields. Basic anatomy and relevance to visual field patterns are reviewed. Principles and usage of automated and kinetic perimetry are discussed. Case illustrations and unknowns are presented to facilitate open interaction.

11:00	3471	Anatomy of afferent visual pathway KAWASAKI A—Lausanne
11:22	3472	Principles of automated perimetry SZATMARY G—Hattiesburg
11:44	3473	How to perform confrontational visual fields, tangent screen and manual kinetic perimetry KAWASAKI A, BORRUAT FX—Lausanne
12:06	3474	Cases and visual field examples and discussion KAWASAKI A, BORRUAT FX, SZATMARY G—Lausanne, Hattiesburg

## INDUSTRY-SPONSORED SYMPOSIUM

Hermes



## Enhanced Oxidative Stress and ocular surface

12:35	3521	Reduction of oxidative stress: Importance for age-related diseases GARHOFER G–Vienna
12:50	3522	Clinical results on the anti-oxidative effect of oral vitamin and mineral supplementation (on impaired retinal vascular reactivity) GARHOFER G–Vienna
13:10		New therapy options for dry eye. First cases and perspectives - TBD

**SIS RV**      **Fluid accumulation in the retina**      **Athena**  
 Gisèle SOUBRANE, Anat LOEWENSTEIN

13:40	3611	Mechanism of fluid accumulation WOLFENSBERGER TJ—Lausanne
13:58	3612	Fluid of choroidal origin SOUBRANE G—Paris
14:16	3613	Fluid from the retinal origin WOLF-SCHNURRBUSCH U
14:34 ★	3614	Anti VEGF: When, which effect? LOEWENSTEIN A, FLEISSIG E—Tel Aviv
14:52	3615	Steroids: How does it work? BEHAR-COHEN F—Paris

**SIS G**      **Retinal ganglion cell degeneration and dysfunction in glaucoma**      **Hermes**  
 James Edwards MORGAN

13:40	3621	Retinal ganglion cell degeneration: events in the human retina THANOS S—Munster
14:02	3622	Retinal ganglion cell degeneration and dysfunction in glaucoma LEUNG C—Kowloon City
14:24	3623	Psychophysical effects of RGC damage: What tests could we use clinically? REDMOND T—Cardiff
14:46	3624	RGC degenerations. A neural substrate for reversing glaucomatous damage? MORGAN J—Cardiff

**Course 15**      **Corneal Dystrophies – from molecular basis to therapeutic approach**      **Rhodes 1**

Intermediate

**COS**      Edward WYLEGALA, Anna NOWINSKA

Corneal dystrophies are the group of hereditary disorders affecting all corneal layers. Since 2008 when IC3D classification was published there are new advances in diagnosis and treatment. During this course we would like to present the current methods of diagnosis including genetic testing and different treatment options.

13:40	3631	Introduction, Surgical treatment options for corneal dystrophies WYLEGALA E—Katowice
13:55	3632	Genetics of the stromal corneal dystrophies NOWINSKA A—Katowice
14:10	3633	Classification of corneal dystrophies (IC3D) NIELSEN K—Aarhus C
14:25	3634	Imaging methods of the corneal dystrophies JANISZEWSKA D—Katowice
14:40	3635	Genetics of the posterior corneal dystrophies DOBROWOLSKI D—Katowice
14:55	3636	Meesmann dystrophy in Denmark NIELSEN K—Aarhus C

FRIDAY

**SIS** **FNAB for the diagnosis and management of intraocular tumours** **Rhodes 2**  
**PO** Nathalie CASSOUX, Laurence DESJARDINS

13:40	3641	Diagnosis FNAB for orbital and intraocular tumours from a cytologist point of view KLIJANIENKO J
13:58	3642	Long term result of transcleral FNAB for genetic analysis of uveal melanoma MIDENA E–Padova
14:16	3643	Curie experience with transvitreal and transcleral FNAB CASSOUX N–Paris
14:34	3644	Incisional trans-scleral biopsy of choroidal melanoma DAMATO B–Liverpool
14:52	3645	How to handle ophthalmic biopsy specimen to optimize the results COUPLAND S–Liverpool

**FP** **Free papers NSPH 1/2: Pediatric ophthalmology** **Rhodes 3**  
**NSPH** Carl ARNDT, Bahram BODAGHI

13:40	3651	Minocycline as a new neuroprotective agent in a rodent model of NAION FEL A, SIMONUTTI M, FROGER N, IVKOVIC I, LEHOANG P, BERNSTEIN SL, BODAGHI B, SAHEL JA, PAQUES M, PICAUD S, TOUITOU V–Paris, Baltimore
13:52	3652	Retinal ganglion cell impairment in Leber Optic Neuropathy carriers triggers cortical compensatory plasticity in extrastriate cortex CASTELO-BRANCO M, MATEUS C, D' ALMEIDA O, REIS A, SILVA E–Coimbra
14:04	3653	incidence of Diabetic Macular Edema in type 1 Diabetes LUJAIN I–Jeddah
14:16	3654	Telemedicine screening for diagnosis of retinopathy of prematurity in clinical practice LUX AL, LASTENNET F, DENION E–Caen, Le Havre
14:28	3655 <i>rf</i>	Refractive error after intravitreal bevacizumab for threshold disease in retinopathy of prematurity: Two-years follow-up JONAS J, HARDER B, SCHLICHTENBREDE F, VON BALTZ S–Mannheim
14:34	3656 <i>rf</i>	Wide field imaging in patients treated with vigabatrin ARNDT C, BRUGNIART C, BURSTZYN J, MOTTE J, DUCASSE A, BENISTY D–Reims, Paris
14:40	3657 <i>rf</i>	Utility of systematic ophthalmological screening in congenital toxoplasmosis: Epidemiological study of a French cohort between 1990 and 2011 SAUER A, CANDOLFI E, ESCANDE B, SPEEG-SCHATZ C, SUBILIA-GUIGNIER A–Strasbourg, Colmar
14:46	3658 <i>rf</i>	Quality of life among children with severe and chronic ophthalmic conditions AZIZA A, MATONTI F, FAKHOURY O, DENIS D–Marseille

**SIS LC**      **Functional indicators for cataract surgery**      **Rhodes 4**  
 Rafael I. BARRAQUER, Ralph MICHAEL

13:40	3661	Experience with straylight in the cataract clinic COCHENER B–Brest
13:58	3662	Objectivity and reliability of the C-Quant in a clinical setting GICQUEL JJ–Poitiers
14:16	3663	Multiparameter cataract indication approach REUS NJ–Rotterdam
14:34 ★	3664	Inclusion effects if straylight is added to the indication for cataract surgery VAN DEN BERG TJTP–Amsterdam
14:52	3665	Cataract morphology, visual function and quality of life: A prospective observational study of surgical section ASPINALL P, KLIJN S, REUS NJ, DHILLON B–Edinburgh

**FP COS**      **Free papers COS 4/5: Infected and ocular inflammatory surface**      **Gallieni 1 & 2**  
 Philippe KESTELYN, Marc MURAINÉ

13:40	3671	A unilateral chronic conjunctivitis as onset of a systemic sarcoidosis TARIGHT N, SMAIL A, SEVESTRE H, MILAZZO S, BREMOND-GIGNAC D–Amiens
13:52	3672	Lithium increases p63 levels in cultured human limbal epithelial stem cells MOE MC, JOHNSEN E, NESS CH, SHAHDADFAR A, NICOLAISSEN B, NOER A–Oslo
14:04 ★	3673	Simple novel surgical device to facilitate preparation of endothelial grafts for DMEK MURAINÉ M, GUEUDRY J, TOUBEAU D, LEFEVRE S, AFFRIAT M–Rouen, Reims
14:16	3674	Allergic conjunctivitis related to cat and dog dander ALMALIOTIS D, MICHAILOPOULOS P, GIOULEKA P, GIOULEKAS D, NAKOS E, XANTHOPOULOU E, KARAMPATAKIS V–Thessaloniki
14:28	3675	Identification of infected corneal epithelial cells using an innovative in vivo fluorescent multilaser confocal microscope: Proofs of concept NAIGEON N, VERHOEVEN P, BOURLET T, SOULIER H, POZZETTO B, HE Z, CAMPOLMI N, CINOTTI E, PISELLI S, GAIN P, THURET G–Saint-Etienne
14:40	3676 <i>rf</i>	Various epithelial manifestation of herpetic keratitis in corneal confocal microscopy imaging WOJCIK L, WYLEGALA E, SMEDOWSKI A–Katowice





**Physiology / Biochemistry /  
Pharmacology**

**Moderators:**

**Gerhard GARHOFER, Neville OSBORNE**

- F001 Inflammatory cytokines decrease viability and alter ganglioside profile in retinal pigment epithelium cells  
MASSON EA, DOSSARPS D, BERDEAUX O, BRON A, CREUZOT C, BRETILLON L—Dijon
- F002 Blue light toxic action spectrum on A2E-loaded RPE cells in sunlight normalized conditions  
BIGOT K, BARRAU C, GONDOUIN P, VILLETTE T, SAHEL JA, PICAUD S—Paris, Charenton-le-Pont
- F003 Chicken peptidylarginine deiminase type I and III are constitutively expressed in the retinal neuron  
SHIMIZU A, HONDA T, KOJIMA T, KOHSAKA T, TAKAHARA H—Tokyo, Ibaraki, Shizuoka
- F004 Does cyclodextrin affect penetration of diclofenac sodium through amniotic membrane?  
RESCH M, MARSOVSZKY L, BUDAI-SZUCS M, SOOS J, BERKO SZ, SIPOS P, NEMETH J, SZABO-REVESZ P, CSANYI E—Budapest, Szeged
- F005 Assessment of polyesteramide of PEA Microparticles for in vivo intraocular injections  
DE HOZ R, ROJAS B, RAMIREZ AI, SALAZAR JJ, GALLEGU BI, TRIVINO A, ANDRÉS-GUERRERO V, HERRERO R, MIHOV G, DIAS A, ZONG M, RAMIREZ JM—Madrid, Geleen
- F006 A drug-induced central retinal vein occlusion  
BAUDOT A, TRECHOT F, BATA B, ANGIOI K—Nancy
- F007 Aquaporin expression in the human retinal pigmented epithelial cell line ARPE-19  
SALIK D, MOTULSKY E, PERRET J, CASPERS L, DELPORTE C, WILLERMAIN F—Brussels
- F008 Serum concentrations of infliximab in patients with Behçet's disease  
TAGUCHI C, INOUE R, YAMAKAWA R—Kurume
- F009 Suppression of TRPV 1 channels activity is a possible way in treatment of ophthalmic diseases  
MIRONOVA E, GRISHIN E, PCHELINTSEVA O, KOROLKOVA U—Moscow
- F010 Effect of systemic hyperoxia on retinal oxygen saturation  
TOLD R, PALKOVITS S, BOLTZ A, NAPORA KJ, SCHMIDL D, GARHOFER G, SCHMETTERER L—Vienna
- F011 Reproducibility of retrobulbar blood flow velocity measurements using two different colour Doppler imaging devices  
VERTICCHIO VERCELLIN AC, CUTOLO CA, DELLAFIORE C, LAVA M, RAIMONDI M, LANTERI S, ROLANDO M, LOMBARDO S, DISTANTE P, BOSSOLESI L, TINELLI C, MILANO G—Pavia
- F012 Angiogenic role of glycerol in laser-induced choroidal neovascularization  
YASUMA R, YASUMA T, KIM Y, GELFAND B, FOWLER B, KERUR N, BASTOS CARVALHO A, MIZUTANI T, AMBATI J—Lexington
- F013 IL18 does not reduce choroidal neovascularization and causes retinal dysfunction in mice  
YASUMA T, HIRANO Y, KIM Y, YASUMA R, FOWLER B, CARVALHO A, GELFAND B, AMBATI J—Lexington

- F014 Circulating blood glutathione levels influence retinal microvascular function in healthy individuals  
SESHADRI S, QIN L, MROCKZKOWSKA S, PATEL S, GHERGHEL D—Birmingham
- F015 RESVEGA, by the presence of Resveratrol, inhibits retinal endothelial tube formation  
★  
OLMIERE C, CLERC A, LECONTE L—Clermont-Ferrand, Paris
- F016 Correlation between SD-OCT, immunocytochemistry and functional findings in an animal model of retinal degeneration  
PINILLA I, FERNANDEZ-SANCHEZ L, SEGURA CALVO F, SANCHEZ-CANO A, SAUVE Y, TAMARIT JM, LOPEZ DE LA FUENTE C, FUENTES-BROTO L, HERRERA LX, CUENCA N—Zaragoza, Alicante, Edmonton, Valencia
- F017 Fundus autofluorescence, OCT thickness evaluation, angiography and immunohistochemistry correlation in albino P23H rats  
PINILLA I, FERNANDEZ-SANCHEZ L, SEGURA CALVO F, SANCHEZ-CANO A, FUENTES-BROTO L, TAMARIT JM, LOPEZ DE LA FUENTE C, PEREZ GARCIA D, RAMIRO P, CUENCA N—Zaragoza, Alicante, Valencia
- F018 Ocular and systemic distribution of MRZ-99030 in pigmented mouse, rat, rabbit and non-human primate by quantitative tissue analysis  
STRUBLE C, PRESCOTT E, KLEIN KU, WEGENER N—Madison, Wisconsin, Frankfurt
- F019 Proteomic analysis of the retina in mice deficient in glial fibrillary acid protein and vimentin  
MANDAL N, HONORÉ B, VORUM H, PEREZ MT—Lund, Aarhus, Aalborg

FRIDAY

**Retina / Vitreous****Moderators:****Constantin POURNARAS, Anita LEYS,  
Tina XIROU**

- F020** The frequency of idiopathic retinal detachment has seasonal variation and correlated with climate – A survey in Japan  
TAKETANI Y, INAMOCHI K, MAYAMA C, ASAKA R, MURATA H, NOMOTO Y–Asahi, Chiba, Tokyo
- F021** Outcomes of vitrectomy for vitreous haemorrhage (VH) in patients with presumed choroidal neovascularization (CNV)  
KOH L, LAUDE A–Singapore
- F022** Simultaneous SD-OCT and fundus autofluorescence imaging of the macula after successful repair of rhegmatogenous retinal detachment  
CHAKER N, MGHAIETH F, BOURAOUI R, GHRIBI H, EL MATRI L–Tunis
- F023** Cytologic analysis in vitreo-retinal surgery  
BENISTY D, HAYATE F, BOULAGNON C, DUCASSE A, ARNDT C–Reims
- F024** Long-term results and prognostic factors for visual acuity after diabetic vitrectomy: A 10-year follow-up study  
OSTRI C–Copenhagen
- F025** Idiopathic macular hole closure toward the optic disc after internal limiting membrane peeling  
OHTA K, SATO A, FUKUI E–Shiojiri
- F026** Intravitreal drug dispersion and needle gauge  
*rf* PEREZ-MARTIN S, MONTERO J, MERINO A–Valladolid
- F027** Baseline characteristics and vitreoretinal interface features in patients with vitreomacular traction without macular hole from the MIVI-TRUST clinical program  
*rf* KOSHY Z, LABOURDETTE A, DUCHATEAU L, LESCRAUWAET B–Ayr, Toulouse, Ghent, Leuven
- F028** Late results of sclera reconstructive surgery aimed at preventing the progression of myopic macular dystrophies  
MARKOSSIAN G, TARUTTA E, IOMDINA E, KRUSHKOVA G–Moscow
- F029** Live retinal image mosaicking during fundus examination with a computer-assisted slit-lamp prototype  
★ GUILLEMOT C, RICHA R, COMUNELLO E, VON WANGENHEIM A, SCHNITZLER JY, WASSMER B, HAGER G, TAYLOR R, THURET G, GAIN P–Saint-Etienne, Florianopolis, Clermont-Ferrand, Baltimore MD
- F030** Phacoemulsification with intravitreal bevacizumab injection in patients with cataract and diabetic clinically significant macular edema  
CHEBIL A, CHAKER N, KORT F, JEDIDI L, LARGUECHE L, EL MATRI L–Tunis
- F031** Evaluation of choroidal thickness depending on the stage of diabetic retinopathy by SD-OCT  
CHAKER N, MGHAIETH F, DALLELI F, CHEBIL A, BOURAOUI R, MRABET A, EL MATRI L–Tunis
- F032** Association of OCT parameters with HbA1c level and diabetes duration in early stage of diabetic retinopathy  
OSHITARI T, NONOMURA S, ARAI M, YAMAMOTO S–Chiba
- F033** Purtscher-like retinopathy associated with acute pancreatitis at Vilnius University Hospital Santariskiu Klinikos  
PAULAVICIENE R, STRELKAUSKAITE E, ASOKLIS R, STRUPAITE R–Vilnius
- F034** Branch retinal vein occlusion and vitreovascular traction: An SD-OCT case-control study  
ASCASO FJ, PADGET E, VILLÉN L, HUERVA V, ZABADANI K, DEL BUEY MA, CRISTOBAL JA–Zaragoza, Lleida
- F035** Intravitreal ranibizumab following bevacizumab for macular edema due to retinal vein occlusion  
DURIEUX P, LABALETTE P–Lille
- F036** Spectral-domain optical coherence tomography (SD-OCT) patterns in macular edema associated with retinal vein occlusion  
CHEOUR M, BROUR J, HACHICHA F, LAJMI H, MEHANAOU D, SAFRA I, MAZLOUT H, KRAIEM A–Montfleury
- F037** Hypertensive retinopathy complicated with bilateral retinal neovascularization: PRP versus intravitreal anti-VEGF treatment  
XIROU T, BATSOS G, GEORGIADIS O, XIROU V, FERETIS E, KABANAROU SA–Athens
- F038** Intravitreal aflibercept (IVT-AFL) for macular edema secondary to CRVO: Results of COPERNICUS and GALILEO studies  
*rf* ★ CREUZOT C–Dijon
- F039** Wide field imaging in Coat's disease  
*rf* ARNDT C, BENISTY D, MASSE S, VARDI K, DUCASSE A, ZAMBROWSKI O–Reims
- F040** Optic disk changes in retinal vein occlusion and correlated factors  
★ SOO GEUN JOE, SUNG KR, LEE KS, LEE JR, CHAE JB–Seoul
- F041** Autofluorescence patterns and visual acuity in macular telangiectasia type 2  
*rf* BALASKAS K, LEUNG I, SALLO FB, CLEMONS TE, BIRD AC, PETO T–London, Rockville, Maryland
- F042** Response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory ranibizumab  
OGATA N, HASEGAWA T, YAMASHITA M, OKAMOTO M–Kashihara, Nara
- F043** AMD Drusenoid deposits characterization: Interest of OCT, OCT en FACE  
GONZALEZ C–Toulouse
- F044** Neovascular AMD with high recurrences and atrophic areas - Potential relationship between neovascular complication and atrophy  
GONZALEZ C–Toulouse
- F045** Clinical manifestation of retinal pigment epithelial tear after age-related macular degeneration treatment  
CHAE JB, JOE SG–Cheongju, Seoul
- F046** Multispectral retinal image analysis (MRIA) for the assessment of subretinal fibrosis in neovascular age-related macular degeneration (nAMD)  
CALCAGNI A, STYLES IB, PALMER AD, SHEN Y, BARTLETT H, EPERJESI F, GIBSON JM, CLARIDGE E–Birmingham
- F047** Choroidal thickness in dry age-related macular degeneration  
ZABADANI K, ASCASO FJ, HERRERA L, PADGETT E, NUÑEZ E, CRISTOBAL JA–Zaragoza
- F048** Retinal tubulations in geographic atrophy associated with age-related macular degeneration  
RUIZ MORENO JM, LUGO FL, RUIZ-MEDRANO J, MONTERO JA, DONATE J–Albacete, Alicante, Madrid, Valladolid

F049 Intercellular trafficking of Alu RNAs causes geographic atrophy expansion in AMD  
BASTOS CARVALHO A, KERUR N, KIM Y, FOWLER B, GELFAND B, AMBATI J—Lexington, KY

F050 New diagnostic and therapeutic strategies in acute and chronic central serous chorioretinopathy  
FRUSCHELLI M, DENARO R, ESPOSTI G, FREZZOTTI P, TORCHIA R, ESPOSTI PL—Siena, Belvedere Marittimo

F051 Central serous chorioretinopathy in pregnancy: A report of two cases  
CARAMELLO C, HERRERA L, CRUZ N, ZABADANI K, PINILLA I, ASCASO J, CRISTOBAL JA—Zaragoza

F052 Leopard-spot pattern of yellow-orange subretinal deposits in central serous chorioretinopathy  
DE ZAEYTIJD J, SCHELFHOUT V, LEROY BP—Ghent, Wetteren

F053 Effect of intravitreal bevacizumab for chronic, recurrent, or atypical central serous chorioretinopathy  
SONG JH, CHUNG YR, KIM MH, LEW HM—Suwon

F054 Choroidal thickness in eyes with idiopathic epiretinal membrane  
ZABADANI K, ASCASO FJ, PADGETT E, HERRERA L, MATEO J, CRISTOBAL JA—Zaragoza

F055 Topographic distribution of vascular and neurodegenerative signs in type 2 idiopathic macular telangiectasia  
SALLO F, LEUNG I, BALASKAS K, PAULEIKHOFF D, BIRD AC, PETO T—London, Muenster

F056 Choroidal thickness changes determined by SS OCT following intravitreal bevacizumab  
RUIZ MORENO JM, MONTERO JA, RUIZ-MEDRANO J, FLORES-MORENO I, LUGO F—Albacete, Valladolid, Madrid, Alicante

F057 Evaluation of ultra-widefield fundus autofluorescence in non-infectious posterior uveitis  
KERNT M, REZNICEK L, THURAU S, KAMPIK A—Munich

F058 Swept source optical coherence tomographic findings in a case of bilateral macular coloboma  
CHENG C, CHAN JH, CHEUNG G—Singapore

F059 Retinal arteriolar diameter response to flicker light provocation - A useful marker for risk stratification in cardiovascular disease?  
HEITMAR R, BLANN A, SUMMERS AJ—Birmingham

F060 Variation of online Amsler grid from mobile apps, YouTube and Google  
LUK S, CHEN K, DAVIES N—London

F061 HMGB1 is a potent inducer of choroidal angiogenesis through a MyD88-dependent manner  
KIM Y, KERUR N, LI S, AMBATI J—Lexington

**Neuro-ophthalmology / Strabismology / Paediatric / History**

**Moderators:**

**François-Xavier BORRUAT, Valerio CARELLI**

F062 Refractive error after intravitreal bevacizumab for threshold disease in retinopathy of prematurity: Two-years follow-up  
JONAS J, HARDER B, SCHLICHTENBREDE F, VON BALTZ S—Mannheim

F063 Wide field imaging in patients treated with vigabatrin  
ARNDT C, BRUGNIART C, BURSTZYN J, MOTTE J, DUCASSE A, BENISTY D—Reims, Paris

F064 Utility of systematic ophthalmological screening in congenital toxoplasmosis: Epidemiological study of a French cohort between 1990 and 2011  
SAUER A, CANDOLFI E, ESCANDE B, SPEEG-SCHATZ C, SUBILIA-GUIGNIER A—Strasbourg, Colmar

F065 Quality of life among children with severe and chronic ocular conditions  
AZIZ A, MATONTI F, FAKHOURY O, DENIS D—Marseille

F066 Ocular morpho-functional analysis: Comparison between prematurely-born and born at term children  
SPALLONE L, LOMBARDO S, RUBERTO G, BIANCHI PE, TINELLI C, GUAGLIANO R—Pavia

F067 Choroidal thickness measurement in children using optical coherence tomography  
BIDAUT GARNIER M, SCHWARTZ C, PUYRAVEAU M, MONTARD M, DELBOSC B, SALEH M—Besançon

F068 Definition of a normative basis for peripapillary nerve fibers thickness in childhood with sd-oct  
FACON G, DEFOORT-DHELLEMMES S, LABALETTE P, ROULAND JF—Lille

F069 Functional vision of young adults with type 1 diabetes since childhood  
SIISKONEN M, JÄRVINEN K, HAUTALA N, FALCK A—Oulu

F070 The socio-economic status of young adults with type 1 diabetes since childhood  
HANNULA V, HAUTALA N, FALCK A—Lahti, Oulu

F071 Differential diagnostic of eye morphometric parameters in patients with refractive and axial myopia  
BUSHUYEVA NN, MALIIVA EV—Odessa, Kiev

F072 Changes in protein composition of tear fluid in schoolchildren with high progressing myopia  
IOMDINA E, TARUTTA E, KURYLEVA I, AKSENOVA Y, SURINA E, BOGACHUK A—Moscow

F073 Epidemiology of patients undergoing strabismus surgery at adult age: Retrospective study of 221 patients  
PROMELLE V, BREMOND-GIGNAC D, MILAZZO S—Amiens

F074 Screening of visual disorders among high school students without expressed complaint  
KOVARSKI C, CARLU C, PORTALIER S, FAUCHER C, DUFIER JL, ROCHE O, ORSSAUD C—Lyon, Paris, Québec

F075 Prevalence of binocular anomalies among preschool children in Mashhad, Iran  
YEKTA AA, HAGHIGHI B, HASHEMI H, SHAFIEE H, REZVAN F, OSTADIMOGHADDAM H, HERAVIAN J, AZIMI A, YEKTA R, KHABAZKHOOB M, RASHID TORABI M—Mashhad, Tehran

## FRIDAY

- F076** Change in the antioxidative capacity of extraocular muscles in patients with exotropia  
JUNG S–Seoul
- F077** Incidence of associated other oculomotor disturbances with internuclear ophthalmoplegia  
VILA J, BORRUAT FX–Lausanne
- F078** Optical coherence tomography as a progression marker in mild cognitive impairment and Alzheimer's disease  
HERRERA L, CRUZ N, ZABADANI K, CARAMELLO C, ASCASO FJ, MINGUEZ E, CASAS P, CRISTOBAL JA–Zaragoza
- F079** Evaluation of optical features of the macula in multiple sclerosis  
★  
VARGA BE, TATRAI E, LAURIK L, OLVEDY V, SIMO M, NEMETH J, SOMFAI GM, DEBUC D–Budapest, Miami, FL
- F080** Visual evoked potentials, short wave-length automated perimetry, standard automated perimetry, contrast sensitivity and stereoacuity testing in visually asymptomatic eyes of patients with multiple sclerosis  
HERAVIAN J, NAJJARAN M, FOROUGHIPUR M, AZIMI A, SABER MOGHADDAM A, OSTADIMOGHADDAM H, YEKTA A, KHOSHISIMA J–Mashhad
- F081** Neuromyelitis optica (devic's disease): The use of the spectral domain optical coherence tomography (OCT) in the follow up of the disease  
XIROU T, PORTALIOU D, BOURANTANI S, PANOUSOPOULOU A, KOURENTIS C, KABANAROU SA–Athens
- F082** Retinal nerve fibre layer thickness as a neurological dysfunction marker in fibromyalgia patients  
CARAMELLO C, ASCASO FJ, GARCIA-MARTIN E, HERRERA L, HERRERA P, GARCIA-CAMPAYO J, PABLO L, CRISTOBAL JA–Zaragoza
- F083** Optical coherence tomography and electrophysiology to evaluate Parkinson disease severity  
GARCIA MARTIN E, SATUE M, FUERTES I, OTIN S, ALARCIA R, HERRERO R, BAMBO MP, SERAL M, POLO V, LARROSA JM, PABLO L, ASCASO J–Zaragoza
- F084** Relevance of contrast sensitivity for the diagnosis and monitoring of early stages of Alzheimer's disease  
GARCIA MARTIN E, ROJAS B, DE HOZ R, GIL P, YUBERO R, RAMIREZ JM–Madrid
- F085** Retinal layer segmentation: Non-invasive technique demonstrating hyperplasia of nerve fibers and ganglion cells in the Ataxia of Charlevoix-Saguenay  
GARCIA MARTIN E, BAMBO MP, SATUE S, HERRERO R, OTIN S, GAZULLA J, ALFARO J, VELA A, LARROSA JM, POLO V, PABLO LE, ASCASO J–Zaragoza
- F086** Optic disc drusen and peripapillary subretinal neovascular membranes in children  
BENNAI D, BENZERROUG M, BENHAMANA A, BREMOND-GIGNAC D, MILAZZO S–Amiens
- F087** Accuracy of fluorescein angiography (FA) based diagnosis for retinopathy of prematurity: Expert versus non expert graders evaluation  
GUAGLIANO R, BARILLA D, BERTONE C, MAFFIA A, PERITI F, SPALLONE L, ANSELMETTI G, GIACOSA E, TINELLI C, BIANCHI PE–Pavia, Torino
- F088** A case of cortical blindness due to cerebral ischemia during OPCAB surgery and later recovery  
GUTIÉRREZ BONET R, QUIJADA ANGELI S, SANTOS VICENTE E–Madrid
- F089** Adult-onset aqueductal stenosis: A case report  
BATTA B, TRECHOT F, CLOCHE V, MAALOUF T, ANGIOI K–Nancy
- F090** Presumed eosinophilic granuloma of the orbital roof in an adult man  
BLASETTI F, MAIORE I, BRUNDU E, PINNA A–Sassari
- F091** Eye and optic tract function in patients with cavernous sinus meningioma undergoing CyberKnife robotic radiosurgery  
ORSKI M, TARNAWSKA D, WYLEGALA E–Katowice
- F092** Glaucomatous optic neuropathy in congenital glaucoma  
KATARGINA L, MAZANOVA E, TARASENKOV A–Moscow
- F093** First outcomes of silicon rod frontalis suspension prospective follow-up in congenital blepharoptosis  
GRIVET D, NEZAR H, CAMPOLMI N, REYMOND M, THURET G, GAIN P–Saint-Etienne, Clermont-Ferrand
- F094** The Leonardo Da Vinci Program in the ophthalmological formation of residents  
JANUSCHOWSKI K, ZARZO-VARGAS MONICA M, SOLE GONZALEZ L, DELGADO MIRANDA JOSE–Tuebingen, Santa Cruz

## Business meetings of the scientific sections

- ACB - Anatomy / Cell Biology ..... Gallieni 1 & 2
- COS - Cornea / Ocular Surface ..... Rhodes 1
- EOVS - Electrophysiology, Physiological Optics, Vision Sciences ..... Hermes
- G - Glaucoma ..... Hermes
- IM - Immunology / Microbiology ..... Rhodes 1
- LC - Lens and Cataract ..... Rhodes 4
- MBGE - Molecular Biology / Genetics / Epidemiology ..... Gallieni 5
- NSPH - Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History ..... Rhodes 3
- PO - Pathology / Oncology ..... Rhodes 2
- PBP - Physiology / Biochemistry / Pharmacology ..... Athena
- RV - Retina / Vitreous ..... Athena

## Agenda

1. Report of the chair of section
2. Report of the programme secretary
3. Next year's meeting:
  - nomination of the 2014 section programme secretary (different from the section chair)
  - proposals of 2014 Special Interest Symposia (SIS)
  - proposals of 2014 Courses
  - proposals for 2015 Keynote speakers
4. Comment on the EVER activities
5. Other business

**In addition to the agenda, the sections ACB, EOVS and MBGE will nominate at least 2 candidates for section chair.**

FRIDAY

**SIS  
RV/ACB****The myofibroblast: a key player of tissue repair**

Athena

Marie-Luce BOCHATON-PIALLAT, Constantin POURNARAS



16:45	3711	Myofibroblast biology and interactions with the environment DESMOULIERE A—Limoges
17:07	3712	Fibrotic alterations in glaucoma WALLACE D
17:29	3713	Regeneration of lymphatic vessels after lymphatic-specific photodynamic therapy is not dependent on lymphangiogenesis and tissue remodeling by myofibroblast KILARSKI W—Lausanne
17:51	3714	Role of myofibroblasts in epiretinal membrane development BOCHATON-PIALLAT ML—Geneva

**FP  
G****Free papers G 2/4: Glaucoma surgery part 1**

Hermes

Joaquin BARRAQUER, K. Sheng LIM

16:45	3721	Glaucoma surgery BARRAQUER J, CANUT M—Barcelona
16:57	3722	Reducing high intraocular pressure with hypertonic saline before eye surgery TORVINEN PIA—Helsinki
17:09 ★	3723	STARflo™ Glaucoma Implant: 12 month clinical results POURJAVAN S, COLLIGNON N, DE GROOT V—Brussels, Liege, Antwerp
17:21	3724	Trabeculectomy revision surgery with Ologen biodegradable collagen matrix implant PELOSINI L, ANSARI E—Maidstone, Kent
17:33	3725	Efficacy and safety of combined trans-scleral cyclophotocoagulation (TSCPC) and phacoemulsification surgery ANSARI E, HAWKES E—Maidstone
17:45	3726 <i>rf</i>	Argon laser trabeculoplasty (ALT) for advanced glaucoma: A 12 months follow-up study PELOSINI L, FAYEMI A, ANSARI E—Maidstone, Kent
17:51	3727 <i>rf</i>	Motion perception in early glaucoma FRANCOZ A, CARLINI A, CREUZOT C, POZZO T, BRON AM—Dijon



**Course 16 Stem cells for treatment of eye diseases**  
**COS/ACB** Vincent BORDERIE

Rhodes 1

Intermediate

To show recent developments of stem cell technologies in ophthalmology. Use of cultured cells for treating corneal and retinal diseases will be addressed from basic science to clinical results for the most advanced technologies.

16:45	3731	The limbal stem cell niche SHORTT AJ—London
17:00	3732	Assessment of the limbal condition GICQUEL JJ—Poitiers
17:15	3733	Transplantation of cultured limbal epithelial cells BORDERIE V—Paris
17:30	3734	Transplantation of cultured oral mucosal epithelium BURILLON C—Lyon
17:45	3735	Bioengineering and stem cells for corneal endothelial cell therapy THURET G, HE Z, SUFFEE N, BERNARD A, NAIGEON N, NANGOUM-FOSSO T, CROUZET E, PISELLI S, HA THI BM, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P—Saint Etienne
18:00	3736	Pluripotent stem cells (ES & iPS) for treatment of retinal dystrophies GOUREAU O—Paris

**SIS PO Cell migration and xenografting in ocular melanoma**  
 Laurence DESJARDINS, Martine J JAGER

Rhodes 2

16:45	3741	Animal models for ocular melanoma CAO J, JAGER M—Leiden
17:00	3742	Use of xenografts for preclinical drug testing DE LANGE MJ, NEMATI F, VERSLUIS M, JAGER MJ, LUYTEN GPM, DECAUDIN D, VAN DER VELDEN PA—Leiden, Paris
17:15	3743	Development of uveal melanoma xenografts: From patient tumours to patient derived xenografts characterization NEMATI F, LAURENT C, GENTEN D, PIPERNO-NEUMANN S, DESJARDINS L, MARIANI P, SASTRE X, ASSELAINE B, LANTZ O, ROMAN-ROMAN S, DECAUDIN D—Paris
17:30	3744	Orthotopic xenografts in ocular tumours CASSOUX N—Paris
17:45	3745	Stem cells in conjunctival melanoma xenografts KSANDER B—Boston
18:00	3746	miRNA and conjunctival melanoma migration MOULIN A, NICOLAS M—Lausanne

**Joint M. IM ARVO @ EVER: Molecular Imaging of the Retina**  
 Ashwath JAYAGOPAL, Justine SMITH

Rhodes 3



16:45	3751	Molecular Imaging of Protein and RNA Biomarkers in Retinal Vascular Disease JAYAGOPAL A—Nashville
17:05	3752	In Vivo Bioimaging of RPE cell death AMBATI J, KLEINMAN ME—Lexington
17:25	3753	Retinal Oximetry – Metabolic Imaging of the Retina STEFANSSON E, HARDARSON SK, GEIRSDOTTIR A, KRISTJANSDDOTTIR JV, SCHEVING T, OLAFSDOTTIR OB—Reykjavik
17:45	3754	DARC, Sick and Dying Cells CORDEIRO M—London

FRIDAY

**SIS** **Oxidative stress and cataract** **Rhodes 4**  
**LC** Stefan LÖFGREN, Vincent MONNIER

16:45	3761	Glutathione and Ascorbate: The balance between oxidant and carbonyl stress in the aging human lens MONNIER VM, FAN XJ—Cleveland, Cleveland
17:03	3762	Antioxidant delivery to the lens nucleus: A strategy to delay age related nuclear cataract DONALDSON PJ, VAGHEFI E, GREY AC, LIM JC—Auckland
17:21	3763	In vivo quantitative measurement of antioxidant effects in the lens SÖDERBERG P, KRONSCHLÄGER M, TALEBIZADEH N, YU Z, WANG J, XIAO Y—Uppsala
17:39	3764	Antioxidative properties of glutaredoxin 2 in the lens LOU MF, WU HL—Lincoln, NE
17:57	3765	Age-related human nuclear cataract. Blindness due to inexorable protein deterioration TRUSCOTT R—Wollongong

**FP** **Free papers NSPH 2/2: Neuro-ophthalmology** **Gallieni 1 & 2**  
**NSPH** Valerio CARELLI, Pierre Yves ROBERT

16:45	3771	Macular nerve-fiber-layer measurement in early stage Alzheimer's disease using optical coherence tomography GARCIA MARTIN E, DE HOZ R, ROJAS B, GIL P, YUBERO R, RAMIREZ JM—Madrid
16:57	3772	Age macular degeneration-alzheimer disease in-between correlations: One year screening, follow-up and outcome GONZALEZ C—Toulouse
17:09	3773	MR imaging in posterior ischemic optic neuropathy DEMAEREL P, VAN DEN EYNDE K, CASSIMAN C—Leuven
17:21	3774	Ophthalmological complications after treatment of carotid-ophthalmic artery aneurysms using flow diverter LECLERC O, BENAYOUN Y, ROUCHAUD A, AYOUB D, MOUNAYER C, ROBERT PY—Limoges
17:33	3775	Idiopathic optico-chiasmatic arachnoiditis (IOCA) – enigmatic or non existant disorder? GRZYBOWSKI A, LESSELL S—Poznan, Boston
17:45	3776	Melanopsin retinal ganglion cells and circadian dysfunction in Alzheimer's disease LA MORGIA C, GALLASSI R, SAMBATI L, PROVINI F, ROSS-CISNEROS FN, PAN B, BARBONI P, AVANZINI P, CANTALUPO G, HANNIBAL J, SADUN A, CARELLI V—Bologna, Los Angeles, Parma, Verona, Copenhagen

INDUSTRY-SPONSORED SYMPOSIUM **Hermes**

abbvie

Non-infectious uveitis.  
A short look back and a long look forward



The background features a complex pattern of thin, overlapping lines in shades of light blue and white, creating a sense of motion and depth. A large, white, rectangular area is positioned in the upper right, serving as a backdrop for the text. The text is rendered in a bold, dark blue, sans-serif font.

**SATURDAY  
SEPTEMBER 21  
2013**

SATURDAY

Advanced

**Course 17 Pseudophakic retinal detachment**  
**RV**

Tina XIROU

Athena

Pseudophakic Retinal Detachments have some unique characteristics, because they affect mostly older people. Affected eyes may have age related ocular changes. Vitreous body may be more synergetic. Posterior capsular opacification makes difficult visualization of retinal breaks that can be smaller and more peripheral. Intraocular lens in the presence of posterior capsular break can give intra-operative and post-operative problems. A carefully planned surgical approach is necessary for the management of the Pseudophakic Retinal Detachments. The available options to achieve our goal, a successful retinal reattachment, will be discussed.

08:30	4211	Vitrectomy for R.D. in eyes with different/unusual IOLs GEORGALAS I–Athens
08:45	4212	Problems in vitrectomy and gas for the treatment of Ps RDs THEOCHARIS IP–Athens
09:00	4213	Pars Plana Vitrectomy alone vs Vitrectomy with scleral buckling for PRDs ASTERIADIS S–Thessaloniki
09:15	4214	Scleral buckle vs primary vitrectomy in PRDs PARIKAKIS EA–Athens
09:30	4215	360 degrees prophylactic laser retinopexy during the surgery for the treatment of pseudophakic retinal detachment KOURENTIS C, XIROU T–Athens
09:45	4216	Macular problems in PsRD PAPPAS G–Heraklion

**FP**  
**G** **Free papers G 3/4: Medical treatment**

Anna - Maria STEVENS, Gordana SUNARIC MEGEVAND

Hermes

08:30	4221	Comparative study of the IOP-lowering effect of Xalatan vs generic latanoprost in normal subjects YUWEI (VINCENT) Q, POURJAVAN S–Woluwe Saint Lambert, Brussels
08:42 ★	4222	Efficacy of a preservative-free fixed combination of bimatoprost and timolol in treatment-naïve versus previously treated patients CORDEIRO MF, GOLDBERG I, SCHIFFMAN R, BERNSTEIN P, LIU C, BEJANIAN M–London, Sydney, Irvine, CA
08:54	4223	Does generic latanoprost measure up to the branded, well-known Xalatan? MARINESCU C, POURJAVAN S–Brussels
09:06	4224	24h IOP control by subchronic AMA0076 administration in Dutch Belted rabbits VAN DE VELDE S, VAN BERGEN T, HOLLANDERS K, SIJNAVE D, VANDEWALLE E, MOONS L, STALMANS I–Leuven
09:18	4225 <i>rf</i>	Patient behavior when prescribed non-affordable glaucoma medication in the medical unit, National Research Center, Cairo, Egypt SAEED IBRAHIM A–Cairo
09:24 ★	4226 <i>rf</i>	Removal of preservative from Ganfort improves intraocular pressure (IOP) lowering in patients – A timolol dose-response phenomenon SHEN J, BEJANIAN M, SCHIFFMAN R–Irvine
09:30 ★	4227 <i>rf</i>	SYL040012, a siRNA for the treatment of glaucoma PAÑEDA C–Tres Cantos, Madrid
09:36	4228 <i>rf</i>	Validation of Testvision, an internet-based test for the detection of visual field loss OLSEN AS, LA COUR M, SERUP L, ALBERTI M, DAMATO B, KOLKO M–Copenhagen, San Francisco

**SIS** **Therapeutics in the pipeline for unmet needs in ophthalmology** **Rhodes 1**  
**COS/RV** Thomas FUCHSLUGER, Einar STEFANSSON

08:30	4231	Biomaterials for ophthalmic implants - all for one and one for all? STORSBERG J, SCHMIDT C, FUCHSLUGER T, WEBER A, SEL S—Potsdam, Duesseldorf, Stuttgart, Heidelberg
08:48	4232	The LentiVector® gene therapy platform for ocular disease: A clinical update ELLIS S—Oxford
09:06	4233	Nanoparticles for drug delivery to the retina STEFANSSON E—Reykjavik
09:24	4234	Nanoparticles for delivery of therapeutical nucleic acids to corneal endothelium CZUGALA M, MYKHAYLYK O, SINGER BB, STEUHL KP, ERGÜN S, WESSELBORG S, EPPLER M, PLANK C, FUCHSLUGER T—Essen, Munich, Würzburg, Düsseldorf
09:42	4235	Nanoparticles incorporated collagen hydrogels for sustained release of EGF RAFAT M, MONDAL D, ISLAM M, LIEDBERG B, GRIFFITH M—Linköping

**SIS** **Advances in the treatment of retinoblastoma** **Rhodes 2**  
**PO** Laurence DESJARDINS, Francis MUNIER

08:30	4241	The treatment of retinoblastoma with intravenous chemotherapy + local treatment DESJARDINS L, LUMBROSOLEROUIC L, LEVY C, CASSOUX N, AERTS I, SAVIGNONI A, DENDALE R, SASTRE X—Paris
08:48	4242	Intravitreal chemotherapy: Indications and results MUNIER F, GAILLARD MC, BALMER A, BECK-POPOVIC M—Lausanne
09:06	4243	Intraarterial chemotherapy: Indications and results HADJISTILIANOU T—Sienna
09:24	4244	Management of locally advanced retinoblastoma LUMBROSO L—Paris
09:42	4245	Case reports DESJARDINS L, MUNIER F, HADJISTILIANOU T, LUMBROSO L—Paris



SATURDAY

**SIS**      **Optical and functional correlation of forward and backward scattering in the lens**      **Rhodes 3**

**LC**      Alfred WEGENER, Ralph MICHAEL

08:30 ★	4251	Basics of forward and backward scatter in the human eye lens VAN DEN BERG TJTP—Amsterdam
08:52	4252	Lens slitlamp image grading and nuclear hardness BARRAQUER R—Barcelona
09:14	4253	Pentacam HR and C-Quant – forward versus back-ward light scattering, what is the correlation? WEGENER A—Bonn
09:36	4254	Pentacam measurements and IOL scattering BAUMEISTER M—Frankfurt

**SIS**      **Controversies in history of ophthalmology**      **Rhodes 4**

**NSPH**      Andrzej GRZYBOWSKI, Francisco ASCASO

08:30	4261	Cataract surgery up to the age of Daviel DE LAEY JJ—Ghent
08:48	4262	Who really introduced pneumatic retinopexy for retinal detachment outpatient management? ASCASO F—Zaragoza
09:06	4263	Controversies in the history of glaucoma GRZYBOWSKI A—Poznan
09:24	4264	Trichromasy versus colour opponency: The controversy in 19th and 20th century's colour science and its solution KRASTEL H, UDODOV E, GRÜTZNER P—Mannheim, Nesvizh, Darmstadt
09:42	4265	Description of retinoblastoma by Pieter Pauw of Leiden in early 1600's KIVELÄ T—Helsinki



## KEYNOTE LECTURE

Hermes

Nicholas BAZAN

10:15		Introduction by Leopold Schmetterer
10:25	4321	Molecular sensors for the decoding of homeostasis disruptions in the retinal pigment epithelium: towards the understanding of retinal degenerative diseases BAZAN N—New Orleans
10:50		Award of the EVER certificate of honour

SATURDAY

**SIS** **Bench to bedside to registration - the intricate world of drug development** **Athena**

**RV** Marc D DE SMET, Mark VEZINA

11:00	4411	Introduction - The challenges to drug approval: Going from an idea, early data onto registration DE SMET MD—Lausanne
11:18 ★	4412	Pre-clinical testing: Good laboratory practice and the requirements imposed by the agencies VEZINA M—Senneville
11:36	4413	Designing clinical trials - How best to optimize ideas, resources and patients LEHMACHER W—Köln
11:54	4414	Running clinical trials - The challenges of international research ANGLADE E—Jersey City, NJ
12:12	4415	Facing the regulators - Partnership or opponent GRANZER U—München

**FP** **Free papers G 4/4: Glaucoma surgery part 2** **Hermes**

**G** Ejaz ANSARI

11:00	4421	Glaucoma surgery outcome in Rwanda DE SMEDT S, FONTEYNE Y—Muhanga
11:12	4422	Intracameral bevacizumab as an adjunct to trabeculectomy: A one year prospective, randomized study VANDEWALLE E, PINTO L, VAN BERGEN T, SPIELBERG L, SPILEERS W, ZEYEN T, STALMANS I—Leuven, Lisbon, Rotterdam
11:24	4423	Bevacizumab together with MMC may have complementary effects in the improvement of surgical outcome after glaucoma filtration surgery VAN BERGEN T, HOLLANDERS K, SIJNAVE D, VAN DE VELDE S, VANDEWALLE E, MOONS L, STALMANS I—Leuven
11:36	4424	What is the most optimal administration route of bevacizumab after glaucoma filtration surgery in mice? HOLLANDERS K, VAN BERGEN T, SIJNAVE D, VAN DE VELDE S, VANDEWALLE E, STALMANS I—Leuven
11:48	4425	Refractive and axial length changes after trabeculectomy for open angle glaucoma POPA CHERECHEANU A, CORBU C, COMAN C, IANCU R—Bucharest
12:00	4426	Risk factors for the development of glaucoma after vitreoretinal surgery DE VRIES MM, MÜSKENS RPHM, RENARDEL DE LAVALETTE VW, HOOYMANS JMM, JANSONIUS NM—Groningen

**SIS** **Cornea & Ocular surface: update** **Rhodes 1**

**COS** Thomas FUCHSLUGER, Sanjay PATEL, Haydee BAZAN

**BAUSCH + LOMB**

11:00	4431	Rigid gas-permeable contact lens correction of infant aphakia following congenital cataract surgery GRUENERT A, KLUEPPEL M, HAUSSER J, REINHARD T, SUNDMACHER R, GUTHOFF T, FUCHSLUGER T, GEERLING G—Duesseldorf, Moers, Freiburg
11:15	4432	Stem cells in the central cornea: To be or not to be? MAJO F—Lausanne
11:30	4433	The latest developments in the genetics of Fuchs corneal dystrophy BARATZ K—Rochester
11:45	4434	“No-touch” DMEK: Learning curve and outcomes DROUTSAS K—Marburg
12:00	4435	Silica-collagen hybrid artificial cornea PATEL SV, DIVITO MD, RUDISILL SG, STEIN A, MCLAREN JW, HUBEL A—Rochester, MN, Minneapolis, MN
12:15	4436	Modulators of corneal nerve regeneration BAZAN H—New Orleans

**Joint M. PO**    **OOG: Melanocytic lesions**

Sarah COUPLAND, Tero KIVELÄ

**Rhodes 2**



11:00	4441	C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions PARROZZANI R, BLANDAMURA S, ALESSANDRINI L, PERRINI P, FRIZZIERO L, MIDENA E—Roma, Padova
11:12	4442	Circulating tumour DNA (ctDNA) in metastatic uveal melanoma (MUM): Correlation with outcome in 87 patients (pts) from Institut Curie PIPERNO-NEUMANN S, MADIC J, MARIANI P, RAMPANOU A, SERVOIS V, BIDARD FC, MILDER M, CASSOUX N, DESJARDINS L, STERN MH, LANTZ O—Paris
11:24	4443	Uveal melanoma among Finnish octogenarians ALJAMAL R, KIVELÄ T—Helsinki
11:36	4444	Family relationships of recent familial uveal melanomas in Finland KIVELÄ T, TÄLL M, RAIVIO V, TUOMINEN J, LEHESJOKI AE—Helsinki, Jyväskylä
11:48	4445	Quantitative proteomic analysis of uveal melanoma reveals potential therapeutic targets ANGI M, KALIRAI H, DAMATO BE, COUPLAND SE—Liverpool
12:00	4446	Uveal metastases from carcinoid tumours: Clinical and therapeutic assessment MIDENA E, PILOTTO E, FRIZIERO L, PARROZZANI R—Padova, Roma
12:12	4447	Use of dexamethasone 0.7mg intravitreal implant in radiation macular edema BAILLIF S, MASCHI C, GASTAUD P, CAUJOLLE JP—Nice

**FP LC**    **Free papers LC 1/1: Cataract surgery**

Marie - José TASSIGNON, Andrzej GRZYBOWSKI

**Rhodes 3**

11:00	4451	Comparison of the biometric measurements obtained using IOL Master and ALADDIN systems MILKA M, WYLEGALA E, NOWINSKA A, JANISZEWSKA D, WEGLARZ B—Katowice
11:12	4452	Harmlessness of 1 mg cefuroxime intracameral injection at the end of cataract surgery BARREAU G, BOURMAULT L, DOST L, ADENIS JP, ROBERT PY—Limoges
11:24	4453	Intravitreal corticosteroids as first-line adjunctive treatment in acute post cataract surgery endophthalmitis KOEHRER P, BRON AM, CREUZOT C—Dijon
11:36	4454	Optimizing number of postoperative visits after cataract surgery – a safety perspective WESTBORG INGER, MÖNESTAM EVA—Umeå
11:48 ★	4455 <i>rf</i>	Mydriasset pupillary dilation for cataract surgery: A clinical and economic study SHAH A, JOHAL S, LEE N—Uxbridge, Luton
11:54	4456 <i>rf</i>	Cataract surgery and retinal vein occlusion: Is there an association? TING DSJ, HEGDE V—Carlisle
12:00	4457 <i>rf</i>	Morphological and proliferative studies on ex vivo cultured human anterior capsule lens epithelial cells ANDJELIC S, DRASLAR K, HAWLINA M, PETROVSKI G—Ljubljana, Szeged
12:06	4458 <i>rf</i>	Halo size after implantation of a multifocal intraocular lens PEREZ CARRASCO MJ, ÁLVAREZ-REMENTERÍA L, HURTADO-CEÑA FJ, HEREDIA-TEJADO L, DORADO-PALACIOS FI, PUELL MC—Madrid

SATURDAY

**FP** **Free papers RV 3/4: Retina imaging 2** **Rhodes 4**  
**RV** Pedro GUIMARAES, Rui BERNARDES

11:00	4461	Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial KODJIKIAN L, SOUIED EH, MIMOUN G, DECULLIER E, HUOT L, AULAGNER G—Lyon, Créteil, Paris
11:12	4462	Fast fully-automated multimodal image co-registration (optical coherence tomography, colour fundus photography, red-free, fluorescein angiography) GUIMARAES P, RODRIGUES P, LOBO C, SERRANHO P, BERNARDES R—Coimbra
11:24	4463	Non-invasive discrimination between perfused and occluded vessels by optical coherence tomography BERNARDES R, GUIMARAES P, RODRIGUES P, FIGUEIRA J, SERRANHO P—Coimbra
11:36	4464	Enhanced 3D retinal vascular network reconstruction from high-definition SD-OCT RODRIGUES P, GUIMARAES P, SERRANHO P, BERNARDES R—Coimbra
11:48	4465	En face 3D-SDOCT images and the saltmarshes sign THEOCHARIS IP—Athens
12:00	4466	Visualization of 3D retinal microcapillary network using OCT SIKORSKI B, BUKOWSKA D, RUMINSKI D, GORCZYNSKA I, SZKULMOWSKI M, KRAWIEC K, MALUKIEWICZ G, WOJTKOWSKI M—Bydgoszcz, Torun, Poznan
12:12	4467 <i>rf</i>	Swept source optical coherence tomographic findings in a case of bilateral macular coloboma CHENG C, CHAN JH, CHEUNG G—Singapore
12:18	4468 <i>rf</i>	Wide field imaging in Coat's disease ARNDT C, BENISTY D, MASSE S, VARDI K, DUCASSE A, ZAMBROWSKI O—Reims

**Joint M.** **Improved monitoring and treatment of endogenous uveitis is modifying disease management/outcomes II** **Gallieni 1 & 2**  
**IM** Piergiorgio NERI, Carl P HERBORT



11:00	4471	Early and sustained treatment modifies the phenotype of birdshot retinochoroiditis PAPADIA M, KNECHT P, HERBORT CP—Genova, Zurich, Lausanne
11:15	4472	Combined approach of inflammatory choroidal neovascularization indicates improved outcome NERI P, PIRANI V, ARAPI I, CAPUANO V, GIOVANNINI A, MARIOTTI C—Ancona
11:30	4473	Better monitoring of intraocular inflammation by laser flare photometry and diversified therapeutical approach could mean improved outcome for JIA BODAGHI B—Paris
11:45	4474	The use of laser flare photometry to assess therapeutical approaches for uveitis TAPPEINER C, HEINZ C, HEILIGENHAUS A—Bern, Muenster
12:00	4475	Uveitis has become a precise clinical science: Multimodal investigational approach and management HERBORT C—Lausanne
12:15	4476	Role of different imaging modalities in the differential diagnosis of inflammatory serous retinal detachments KHAIRALLAH M, KAHLOUN R—Monastir

INDUSTRY-SPONSORED SYMPOSIUM **Rhodes 2****Aflibercept: an innovation in health care  
for a chronic condition**

Moderator: Paolo LANZETTA

12:35	4541	Welcome and introduction LANZETTA P-Udine
12:40	4542	Aflibercept: innovation for wet AMD TADAYONI R-Paris
12:50	4543	Optimising anti-VEGF therapy for wet AMD LANZETTA P-Udine
13:10		Long-term treatment experience: beyond aflibercept initiation - TBD
13:25		Q & A

SATURDAY

**Joint M. FAN Club**

Athena

RV Anita LEYS



Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.

Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

[www.fan-int.org](http://www.fan-int.org)

**SIS  
G****Vitreous & Glaucoma: an unexpected Journey**

Hermes

Luís PINTO, Leopold SCHMETTERER

13:40	4621	Vitreomized patients: Are they at risk for glaucoma? VANDEWALLE E–Winksele
14:02	4622	Vitreous attachment to the optic disc: Strings pulling neurons? JONAS J–Mannheim
14:24	4623	Retinal oxygen: the good, the bad and the unknown? STEFANSSON E–Reykjavik
14:46	4624	Intravitreal drugs: What is happening to the ganglion cells? PINTO L–Lisbon

**Joint M.  
COS****Keratoprotheses 1: Indications and surgical techniques**

Rhodes 1

Christopher LIU, Thomas FUCHSLUGER



13:40	4631	Boston type 1 KPros in India - Indications, contraindications and device modifications SRINIVASAN B
13:58	4632	Results, complications, and future developments of the Boston type 1 KPro DE LA CRUZ J, CORTINA S–Chicago, Illinois
14:16	4633	Preventing complications of OOKP surgery AVADHANAM V, LIU C–Brighton
14:34	4634	Biomimetic developments to improve the OOKP AVADHANAM V, LIU C, LLOYD A, SANDERMAN S–Brighton
14:52	4635	Results of epicorneal keratoprotheses LIU C, AVADHANAM V–Brighton



**Joint M. PO**    **OOG: Retinoblastoma and others**  
 Laurence DESJARDINS, Theodora HADJISTILIANOU

Rhodes 2



13:40	4641	Proteomic analysis of aqueous humor in retinoblastoma: Final results MICHELI L, LANDI G, MORIGGI M, VANNONI D, VASSO M, MENICACCI F, GELFI C, LEONCINI R, HADJISTILIANOU T—Siena, Milan
13:52	4642	Direct intraarterial (ophthalmic artery) chemotherapy for advanced intraocular retinoblastoma: Five years experience DE FRANCESCO S, DE LUCA M, BRACCO S, GALLUZZI P, BORRI M, MICHELI L, HADJISTILIANOU T—Siena
14:04	4643	Alternating intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: First successful results without systemic chemotherapy HADJISTILIANOU T, DEFRANCESCO S, DE LUCA MC, BRACCO S, MENICACCI F, GALLUZZI P—Siena
14:16	4644	The treatment of bilaterally advanced retinoblastoma: The Institut Curie experience DESJARDINS L, LUMBROSOLEROUIC L, LEVY C, CASSOUX N, AERTS I, SASTRE X, SAVIGNONI A—Paris
14:28	4645	Molecular profiling of ocular surface squamous neoplasia identifies multiple DNA copy number alterations including recurring 8p11.22 amplicons ALKATAN H, EBERHART C—Riyadh, Baltimore
14:40	4646	IgG4-Positive orbitopathy HEEGAARD S—Copenhagen
14:52	4647	Pigmented basal cell carcinoma of the eyelid ROSNER M, PRIEL A, BEN SIMON1 G, ROSEN N—Tel Hashomer

**SIS LC**    **Controversies in Cataract Surgery**  
 Alfred WEGENER, Andrzej GRZYBOWSKI

Rhodes 3

13:40	4651	Do we have any effective measure to minimize PCO? TASSIGNON MJ, NI DHUBGHAILL S—Antwerp
13:58	4652	Is there any place for relaxing incisions in cataract surgery? COCHENER B—Brest
14:16	4653	What is important in present and future IOL materials & design? BARRAQUER R—Barcelona
14:34	4654	Pentacam nuclear staging versus LOCS III grading for cataract classification WEGENER A—Bonn
14:52	4655	Is preoperative antibiotic use justified by evidence based medicine? GRZYBOWSKI A—Poznan




FP  
ACB

## Free papers ACB 2/2: Cell biology of AMD and DR

Rhodes 4

Deborah A FERRINGTON, Heli SKOTTMAN

13:40	4661	Prevention of autophagy activates inflammasome signaling in ARPE-19 cells treated with a proteasome inhibitor KAUPPINEN A, PIIPPO N, HYTTI M, KINNUNEN K, SALMINEN A, KAARNIRANTA K—Kuopio
13:52 	4662	ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human ARPE-19 cells AMADIO M—Pavia
14:04	4663	Pro-inflammatory cytokines induce apoptosis of human retinal capillary endothelial cells through downregulation of Hsp27 NAGARAJ R, NAHOMI R—Cleveland
14:16	4664	Characterization of rafts subtypes in monocytes of diabetic patients with and without neovascular complication MATHIEU B, GAMBERT-NICOT S, BRETILLON L, BRON AM, CREUZOT C—Dijon
14:28	4665	Functional and molecular characterization of ex vivo cultured epiretinal membrane cells from proliferative diabetic retinopathy PETROVSKI G, VEREB Z, ANDJELIC S, LUMI X, GLOBOCNIK-PETROVIC M, URBANCIC M, HAWLINA M, FACSKO A—Szeged, Debrecen, Ljubljana
14:40 ★	4666 <i>rf</i>	The effect of hyperglycaemia on permeability and tight junction components in human retinal and choroidal endothelial cells STEWART EA, SAKER S, AMOAKU WM—Nottingham
14:46	4667 <i>rf</i>	Proteasome dysfunction in retinal pigment epithelium during aging contributes to the pathogenesis of Age-Macular related Degeneration GIRAO H, MARQUES C, SOARES A, FERNANDES R, PEREIRA P—Coimbra

FP  
MBGE

## Free papers MBGE 2/2: Genetics and epidemiology

Gallieni 1 &amp; 2

Bart LEROY, Marzena GAJECKA

13:40	4671	The UK Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Vision research questions prioritised by patients and health care professionals VOTRUBA M, THE SLV-PSP STEERING GROUP AT—Cardiff, UK
13:52	4672	Visual acuity thresholds associated with activity limitations in the elderly. The POLA study DAIEN V, PERES K, VILLAIN M, COLVEZ A, CARRIERE I, DELCOURT C—Montpellier, Bordeaux
14:04	4673	The KORA-AGE eye study: Eye diseases in the elderly GRAW J, STROBL R, HEIER M, LINKOHR B, PETERS A, HOLLE R, GRILL E—Neuherberg, Munich
14:16	4674	The effects of interleukin-8, VEGF and CFH polymorphisms on the long-term response to bevacizumab therapy in exudative age-related macular degeneration HAUTAMÄKI A, KIVIOJA J, VAVULI S, KAKKO S, SAVOLAINEN ER, SAVOLAINEN MJ, LIINAMAA MJ, SEITSONEN S, ONKAMO P, JÄRVELÄ I, LUOMA A, IMMONEN I—Helsinki, Oulu, Tampere
14:28	4675	Functional characterization of retinitis pigmentosa causing RPGR mutations SHU X, PATNAIK S, CRAFT J, MCCULLOCH D—Glasgow
14:40	4676 <i>rf</i>	Influence of refractive error and axial length on retinal vessel geometric characteristics LIM LS, CHEUNG C, LIM X, MITCHELL P, WONG TY, SAW SM—Singapore, Sydney
14:46	4677 <i>rf</i>	Early dietary therapy in preventing progression of retinopathy in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency caused by the homozygous G1528C mutation ROOMETS E, KIVELÄ T, TYNI T—Tallinn, Helsinki

SATURDAY

**Cornea / Ocular Surface****Moderators:****Gilles THURET, Thomas FUCHSLUGER,  
María Fideliz DE LA PAZ**

- S001 Mesenchymal stem cells as an alternative source of stem cells for ocular surface regeneration  
HOLAN V, JAVORKOVA E, TROSNAN P, KRULOVA M, ZAJICOVA A—Prague
- S002 Augmented dried versus cryopreserved amniotic membrane as an ocular surface dressing  
ALLEN C, CLARE G, STEWART E, BRANCH M, MCINTOSH O, VERMA M, DUA HS, HOPKINSON A—Nottingham
- S003 High doses of fatty acids for treating severe dry eye disease  
GEORGIOU T, NICOLAOU D, NEOKLEOUS A, MICHAEL S, IKONOMU C—Nicosia
- S004 Tear secretion impairment as a function of severity of herpetic keratitis  
LABETOULLE M, M'GARRECH M, ROUSSEAU A, KASWIN G, SAUER A, BOURCIER T, BARREAU E—Le Kremlin Bicêtre, Strasbourg
- S005 Corneal nerve structure and function in patients with non-Sjögren dry eye  
LABBE A, LIANG Q, XU L, BAUDOUIN C, SUN X—Paris, Beijing
- S006 The usefulness of corneal confocal microscopy to assessing and monitoring changes associated with hematopoietic diseases  
WOJCIK L, WYLEGALA E, SMEDOWSKI A—Katowice
- S007 Effects of cyclosporine in an experimental rat model of dry eye  
★ CIMBOLINI N, ANTONELLI S, FERAILLE L, MARGARON P, ELENA PP—La Gaude
- S008 Ocular tolerability of preservative-free prostaglandin eye drops  
★ PELLINEN P, ESAKI Y, SHIMAZAKI A—Tampere, Nara
- S009 Optimisation of a standardised chemical burn animal model for use in corneal wound healing  
MCINTOSH OD, ALLEN CL, HOPKINSON A, DUA HS—Nottingham
- S010 Treatment of Meibomian gland disease with the Lipiflow® system: A prospective study  
MICHEE S, RABUT G, BAUDOUIN C, LABBE A—Paris
- S011 Impact of two different prostaglandin preparations on human corneal epithelial cells (HCE-2) in vitro conditions  
SMEDOWSKI A, SEPPÄNEN A, KAARNIRANTA K, WYLEGALA E—Katowice, Kuopio
- S012 Tear levels of loteprednol etabonate following instillation of a novel gel formulation  
★ SIOU-MERMET R, ONG T, LOWE E—Montpellier, Madison, NJ, Rochester, NY
- S013 In vivo confocal microscopy of cystic lesions in corneal disorders  
ORSKI M, WYLEGALA E, TARNAWSKA D, SMEDOWSKI A—Katowice
- S014 Full-field optical coherence tomography of human donor and diseased corneas  
GHOUALI W, GRIEVE K, BELLEFQIH S, LAROCHE L, PAQUES M, BORDERIE V—Paris
- S015 Aquaporin expression in pterygium  
VIEL A, MOTULSKY E, PERRET J, GREGOIRE F, CASPERS L, DE SAINT AUBAIN N, DELPORTE C, WILLERMAIN F—Bruxelles
- S016 Expression of Huntingtons disease markers in the cornea of minipig transgenic for the human mutated huntingtin  
ARDAN T, JUHAS S, MOTLIK J—Libechov
- S017 Various epithelial manifestation of herpetic keratitis in corneal confocal microscopy imaging  
*rf* WOJCIK L, WYLEGALA E, SMEDOWSKI A—Katowice
- S018 Ocular surface dysfunction and tear osmolarity after cataract surgery  
KUZMIENE L—Kaunas
- S019 Ultrastructure features of dhub lizard (*Uromastix aegyptia*) cornea  
AKHTAR S, ALKHALAF M, KHAN A, ALMUBRAD T—Riyadh
- S020 Variability of oxidative stress-related genes in keratoconus and Fuchs endothelial corneal dystrophy  
SZAFLIK JP, SYNOWIEC E, WOJCIK K, SZAFLIK J, BLASIAK J—Warszawa, Lodz
- S021 Galilei Dual Scheimpflug Analyzer: Corneal thickness and anterior chamber characteristics in healthy human eyes  
SEGURA CALVO F, SANCHEZ-CANO A, LOPEZ DE LA FUENTE C, FUENTES-BROTO L, ORDUNA HOSPITAL E, PINILLA I—Zaragoza
- S022 Pragmatic approach in a case of unknown bilateral corneal opacity and staphyloma in a child in Timor Leste  
GRAEFF E, MEYER P—Basel
- S023 Semiology of patient derived to pterygium surgery at Fuan Noe c. Hospital in Arica city, Chile  
CHAVEZ C, VETTERLEIN V, FONTECILLA C, RAMIREZ JM, DE HOZ R—Arica, Barcelona, Madrid
- S024 Evaluation of transplanted oral epithelium by confocal microscopy correlates with success rate in aniridia patients  
WOWRA B, DOBROWOLSKI D, WROBLEWSKA-CZAJKA E, GROLIK M, WYLEGALA E—Katowice
- S025 Effects of acute in vivo exposure of rabbit cornea and conjunctiva to artificial sunlight  
ALMALIOTIS D, VARSAMIDOU E, GOULAS A, MARKOPOULOU S, KARAYANNOPOULOU G, VARSAMIDIS K, KARAMPATAKIS V—Thessaloniki
- S026 Prevalence of allergic conjunctivitis in allergic population in northern greece  
ALMALIOTIS D, MICHAILOPOULOS P, GIOULEKAS D, GIOULEKA P, PAPAOKOSTA D, SIEMPI T, KARAMPATAKIS V—Thessaloniki
- S027 Management of HSV-1 necrotizing keratitis with amniotic membrane transplantation combined with antiviral and steroid therapy  
GUEUDRY J, DUNCOMBE A, MARINGE E, MURAIN E—Rouen
- S028 Diagnosis of infectious keratitis by mass spectrometry  
HOFFART L, DRANCOURT M, DORNADIN A—Marseille
- S029 Chitosan-based biocompatible materials in ophthalmology  
WOWRA B, GROLIK M, SZCZUBIALKA K, NOWAKOWSKA M, DOBROWOLSKI D, ORZECZOWSKA-WYLEGALA B, WYLEGALA E—Katowice, Cracow
- S030 The use of tear osmolarity as a diagnostic tool for detection of dry eye prior to cataract surgery  
BAUMANN A, COCHENER B—Locmaria-Plouzane, Brest
- S031 Topical treatment with a new matrix therapy agent (RGTA) in combination with limbal allograft in ocular surface disease and corneal anesthesia  
MARINGE E, GUEUDRY J, AIFA A, DELCAMPE A, MURAIN E—Rouen

- S032 **Simulation of DSAEK in a new corneal bioreactor**  
TRONE MC, GAUTHIER AS, CAMPOLMI N, NAIGEON N, NANGOUM-FOSSO T, PATAIA G, FOREST F, PEOC'H M, DUMOLLARD JM, ACQUART S, THURET G, GAIN P—Saint-Etienne
- S033 **Risk factors for contact lens-related microbial keratitis: A case-control multicenter study**  
SAUER A, MEYER N, BOURCIER T, THE FRENCH STUDY GROUP FOR CONTACT LENS-RELATED MICROBIAL KERATITIS—Strasbourg
- S034 **Visual acuity outcomes after Descmet's stripping automated endothelial keratoplasty compared to penetrating keratoplasty**  
MOUNA ALI, PREMY S, AGAPIE A, JEAN-COLAS A, AMELOOT F, MANEA G, PERONE J—Metz
- S035 **Uniformity of the thickness of LASIK corneal flaps made by IntraLase FS 60 laser femtosecond (IntraLase, AMO USA) measured by OCT spectral domain (Heidelberg, Germany)**  
ABRIEU LACAILLE M, RAMBAUD C, CREPY P, FROUSSART F, RIGAL-SASTOURNE JC—Clamart
- S036 **Reproducibility of the thickness of Lasik corneal flaps made by IntraLase FS 60 laser femtosecond (IntraLase, AMO USA) measured by OCT spectral domain (Heidelberg, Germany)**  
ABRIEU LACAILLE M, RAMBAUD C, CREPY P, FROUSSART F, RIGAL-SASTOURNE JC—Clamart
- S037 **Extracellular matrix derived hydrogel for corneal tissue engineering**  
AHEARNE M, LYNCH A—Dublin
- S038 **Age-related changes in central corneal thickness and corneal endothelial characteristics**  
GALGAUSKAS S, NORVYDAITE D, STECH S, ASOKLIS R—Vilnius
- S039 **Differences in corneal epithelium in patients with diagnosed macular and granular corneal dystrophy**  
SMEDOWSKI A, WYLEGALA E, WOJCIK L—Katowice
- S040 **Outcome of phacoemulsification after Descemet membrane endothelial keratoplasty (DMEK)**  
YEH R, MUSA F, CABRERIZO J, QUILENDRINO R, DAPENA I, HAM L, MELLES GJ—Liège, Rotterdam, Manilla
- S041 **New Image Plugin for rapid and reproducible measurement of viable corneal endothelial cell density**  
BERNARD A, CAMPOLMI N, HE Z, PATAIA G, GAUTHIER AS, TRONE MC, NAGOUM-FOSSO T, PISELLI S, ACQUART S, GAIN P, THURET G—Saint-Etienne
- S042 **Analysis of fungal contamination in contact lens storage cases between 2000 and 2012**  
BOUHERAOUA N, TEMSTET C, GOLDSCHMIDT P, VAUDRAN P, LAROCHE L, BORDERIE V, CHAUMEIL C—Paris
- S043 **Expression levels of purinergic receptors in the endothelium of human and murine cornea**  
CZUGALA M, FUCHSLUGER T, FUNAKI T, CHAUHAN S, DANA R—Essen, Boston, MA
- S044 **Worldwide Eye Banking (WEB) project: International survey of demand and supply**  
JULIENNE R, CAMPOLMI N, ALDOSSARY M, THURET G, GAIN P—Saint-Etienne
- S045 **Improvement of delivery of molecules into corneal endothelium using nanoparticles activated by femtosecond laser pulses**  
JUMELLE C, CAMPOLMI N, BERNARD A, PISELLI S, BAUBEAU E, MAUCLAIR C, GRANIER J, EGAUD G, GAIN P, THURET G—Saint-Etienne
- S046 **Biomechanical consequences of keratoconus treatments**  
HUGNY LARROQUE C, COCHENER B—Brest


- S047 **Microbial keratitis after penetrating keratoplasty**  
EL MATRI L, LIMAIE M R, CHEBIL A, KORT F, MGHAIETH F—Tunis
- S048 **Viable endothelial cell density by triple HEC staining of a failed Descemet stripping automated endothelial keratoplasty**  
CAMPOLMI N, GAUTHIER AS, ACQUART S, THEILLIERE C, PEIRERA S, GARRAUD O, HE Z, PISELLI S, THURET G, DELBOSC B, GAIN P—Saint-Etienne, Besançon
- S049 **Corneal graft imaging by anterior segment OCT during storage in eye banks**  
PATAIA G, GAUTHIER AS, CAMPOLMI N, TRONE MC, HE Z, PISELLI S, FOREST F, ACQUART S, LEPINE T, GAIN P, THURET G—Saint-Etienne
- S050 **Femtosecond laser cutting of multiple ultrathin corneal stromal lamellae for endothelial graft bioengineering**  
BERNARD A, HE Z, CAMPOLMI N, PISELLI S, FOREST F, PEOC'H MC, DUMOLLARD JM, THURET G, GAIN P—Saint-Etienne
- S051 **Long-term outcomes of penetrating keratoplasty in children**  
DOBROWOLSKI D, WYLEGALA E, WROBLEWSKA-CZAJKA E, WOWRA B—Katowice
- S052 **Intrastromal corneal rings and corneal collagen crosslinking for progressive keratoconus: Comparison of 2 sequences**  
SAIB N, BONNEL S, ABRIEU M, RIGAL-SASTOURNE J—Clamart
- S053 **Ferrara ring's effects on corneal asphericity in keratoconus treatment**  
BONNEL S, LUSSATO M, FENOLLAND JR, SAIB N, RAMBAUD C, ABRIEU M, FROUSSART F, RIGAL-SASTOURNE JC—Clamart
- S054 **Intracorneal foreign body in the confocal microscopy in vivo images**  
WOJCIK L, WYLEGALA E, SMEDOWSKI A—Katowice

SATURDAY

**Immunology / Microbiology****Moderators:****Heping XU, Bahram BODAGHI,  
Nadia BOUCHENAKI**

- S055 Kyrieleis plaques in herpes zoster virus associated acute retinal necrosis  
KONIDARIS V, BRENT A, VARDARINOS A, DEANE J, EMPESLIDIS T—Leicester
- S056 Cytomegalovirus retinitis (CMVR)-related retinal detachment (RD) surgery in AIDS patients in an Asian population  
WONG J, WONG E, TEOH S—Singapore
- S057 High doses of fatty acids for reducing cystoid macular oedema secondary to inflammation or branch retinal vein occlusion  
GEORGIOU T, PHOTIOU DMF, NICOLAOU D, NEOKLEOUS A, MICHAEL S, IKONOMOU C—Nicosia
- S058 The regulatory effects of 1,  $\alpha$ , 25-dihydroxyvitamin D3 on the expression of inflammatory cytokines in diabetic retinopathy  
TOHARI A, CRAFT J, SHU X—Glasgow
- S059 Detection of antibodies against homologous Mycobacterium avium subspecies paratuberculosis and beta-cell antigen zinc transporter 8 epitopes in Sardinian type 1 diabetic patients with proliferative diabetic retinopathy  
PINNA A, MASALA S, BLASETTI F, MAIORE I, BRUNDU E, COSSU D, PACCAGNINI D, SECHI LA—Sassari
- S060 Uveitis and lyme disease: About two case reports  
NGUYEN KIM P, TOUITOU V, LEHOANG P, BODAGHI B—Paris
- S061 Can we consider syphilitic uveitis as neurosyphilis? A retrospective analysis of lumbar puncture results in a cohort of syphilitic uveitis patients  
LHOIR S, WILLERMAIN F, JANSEN J, LIBOIS A, VAN CALSTER J, CASPERS L, MAKHOUL D—Brussels, Leuven
- S062 Persistent macular edema with secondary neovascular membrane following a panuveitis in woman with Behçet's disease resolved by a switching to aflibercept injections  
TORO M, REIBALDI M, STELLA S, AMATO R, LONGO A, GAGLIANO C—Catania
- S063 Clinical characteristics of acute retinal pigment epitheliitis: Case series  
HAN J, YANG J—Uijeongbu, Gyeonggi
- S064 Adaptive optics imaging of retinal vasculitis  
ERRERA MH, PAQUES M—Paris
- S065 Hyperreflective dots detected in the retina using spectral domain optical coherence tomography  
KUOLIENE K, STECH S, CIMBALAS A, ASOKLIS R—Vilnius
- S066 Swept source-optical coherence tomography analysis of choroidal involvement in patients with uveitis  
DIWO E, RAZAVI S, LEHOANG P, BODAGHI B—Paris, Tours

**Lens and Cataract****Moderators:****Alfred WEGENER, Stefan LÖFGREN,  
Thomas JTP VAN DEN BERG**

- S067 Mydriasept pupillary dilation for cataract surgery: A clinical and economic study  
*rf*  
★  
SHAH A, JOHAL S, LEE N—Uxbridge, Luton
- S068 Cataract surgery and retinal vein occlusion: Is there an association?  
*rf*  
TING DSJ, HEGDE V—Carlisle
- S069 Risk factors for intraoperative floppy iris syndrome: One year prospective study  
CHATZIRALLI I, PARIKAKIS E, PEPONIS V, MANIATEA A, MITROPOULOS P—Athens
- S070 Cataract and uveitis: Comparison of two different anti-inflammatory protocols for the prevention of post-operative complications  
BUTEL N, FARDEAU C, LE HOANG P, BODAGHI B—Boulogne Billancourt, Paris
- S071 Cataractogenesis and surgical outcome in patients with uveitis  
REMOND A, LE HOANG P, BODAGHI B—Paris
- S072 Femtosecond laser capsulotomy versus manual technique: A clinico-morphological study of the resected capsules  
MEYER P, PRUENTE CH—Basel, Binningen bei Basel
- S073 Morphological and proliferative studies on ex vivo cultured human anterior capsule lens epithelial cells  
*rf*  
ANDJELIC S, DRASLAR K, HAWLINA M, PETROVSKI G—Ljubljana, Szeged
- S074 Transporters of glycine, cystine, glutamate and glutamine in canine lens epithelial cells  
OCHIAI H—Sagamihara
- S075 Active caspase-3 expression in healthy lens epithelium  
TALEBI ZADEH N, YU Z, KRONSCHLÄGER M, SÖDERBERG P—Uppsala
- S076 In vivo analysis of protein quality control in response to aging using transgenic mice  
*rf*  
MARQUES C, MATAFOME P, SANTOS A, LOBO C, SHANG F, PEREIRA P, GIRAO H—Coimbra, Boston
- S077 The effects of actomyosin inhibitors on cytoskeletal distributions in the lens  
  
WON G, CHO H—Waterloo
- S078 Absence of beta-amyloid in cortical cataracts of donors with and without Alzheimer's disease  
ROSANDIC J, MONTENEGRO G, BARRQUER RI, VRENSSEN G, MICHAEL R—Barcelona, Leiden
- S079 Absence of amyloid beta in human lens opacities: A confocal Raman study  
MICHAEL R, OTTO C, GELPI E, MONTENEGRO G, ROSANDIC J, BARRAQUER RI, VRENSSEN G—Barcelona, Enschede, Leiden
- S080 Elastic properties of human lens zonules as a function of age in presbyopes  
MIKIELEWICZ M, MICHAEL R, MONTENEGRO G, PINILLA L, BARRAQUER RI—Barcelona

- S081 Comparison of different techniques to evaluate the biomechanics of the accommodative apparatus in human eyes  
PINILLA L, BURD HJ, MONTENEGRO GA, MIKIELEWICZ M, BARRAQUER RI, MICHAEL R—Barcelona, Oxford
- S082 Retinal straylight and the yellow Bag in the Lens IOL  
JONGENELEN S, ROZEMA JJ, TASSIGNON MJ—Edegem
- S083 *rf* Halo size after implantation of a multifocal intraocular lens  
PEREZ CARRASCO MJ, ÁLVAREZ-REMENTERÍA L, HURTADO-CEÑA FJ, HEREDIA-TEJADO L, DORADO-PALACIOS FI, PUELL MC—Madrid
- S084 Do multifocal intraocular lens implants allow spectacle independence?  
O’GALLAGHER MK, CHAKRABARTI M, FRAZER DG—Belfast
- S085 Quality of vision with traditional monovision versus modified monovision  
VANDERMEER G, LEGRAS R, GICQUEL JJ, PISELLA PJ—Tours, Orsay, Poitiers


**Pathology / Oncology**

**Moderators:**

**Martina ANGI, Inge BRONKHORST,  
Rob DE KEIZER**

- S086 *rf* A novel imaging approach to periocular basal cell carcinoma: In vivo optical coherence tomography and histological correlates  
PELOSINI L, SMITH HB, SCHOFIELD J, DHITAL A, KHANDWALA M—Maidstone, Kent
- S087 *rf* Strabismus and diplopia revealing rhabdomyosarcoma in a 7-year-old girl  
AZIZ A, MATONTI F, FAKHOURY O, DENIS D—Marseille
- S088 *rf* Unique morphology of the human orbit among the Hominoidea  
DENION E, HITIER M, GUYADER V, DUGUE AE, MOURIAUX F—Caen
- S089 *rf* Orbital melanocytosis and OTA naevus  
DE KEIZER RJW, LAUWERS N, DE GROOT V—Antwerp
- S090 Different assessments of immunohistochemically stained Ki-67 ocular malignancies  
PAULAVICIENE R, PETROSKA D, ASOKLIS R—Vilnius
- S091 Rare iridociliary pediatric tumours and pseudotumours: Cases report and literature review  
HADJISTILIANOU T, TSYGANKOV A, DE LUCA MC, DEFRANCESCO SONIA, MICHELI L, BORRI M, MENICACCI F—Siena, Moscow
- S092  Expression of stem cell markers in human uveal melanoma  
STEIBER Z, HALMOS G, CSERHATI Z, TRESZL A—Debrecen
- S093 Metastases inhibition and cellular damage in melanoma cells irradiated with proton beam  
ROMANOWSKA DIXON B, KEDRACKA-KROK S, SKALNIAK L, JURA J, ZUBA-SUMA E, JASINSKA K, PAWLAK A, SOWA U, OLKO P, URBANSKA K, ELAS M—Krakow
- S094 Trans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy  
KONSTANTINIDIS L, DAMATO B—Liverpool
- S095 Photodynamic therapy for juxtapapillary retinal capillary hemangioma: A case report  
CHATZIRALLI I, PARIKAKIS E, PEPONIS V, TSIOTRA V, MITROPOULOS P—Athens
- S096 Cases of choroidal metastasis revealing lung cancer  
BARCATALI M, MIOCQUE S, HADDAD M, MOURIAUX F—Caen
- S097 Synchronous malignant transformation of bilateral symmetrical retinocytoma  
DE FRANCESCO S, DE LUCA M, GALIMBERTI D, CAINI M, HADJISTILIANOU T—Siena
- S098 Case of primary neuroendocrine carcinoma in lacrimal gland  
DAISUKE Y, TOSHIYUKI O, SHUICHI Y—Chibacity
- S099 Mucormycosis is a rare etiology of ophthalmoplegia: How to diagnose and to manage it, about one exceptional case  
LAGENAITE C—Lyon
- S100 A time-line model of developmental events within the human fovea based on imaging and histology data  
SJÖSTRAND J, POPOVIC Z—Göteborg





**FP RV** **Free papers RV 4/4: Medical retina** **Athena**  
Catherine CREUZOT, Tassos GEORGIOU

16:15	4711	Macular choroidal thickness profile in healthy population measured by swept-source optical coherence tomography RUIZ MORENO JM, RUIZ-MEDRANO J, FLORES-MORENO I, PEÑA-GARCÍA P, MONTERO JA—Albacete, Madrid, Alicante, Valladolid
16:27★	4712	Combination of ranibizumab and navigated retinal photocoagulation in diabetic macular edema, compared to ranibizumab mono-therapy: Twelve month results KERNT M—Munich
16:39	4713	High doses fatty acids for improving vision in patients with dry and wet macular degeneration GEORGIOU T, NICOLAOU D, NEOKLEOUS A, MICHAEL S, IKONOMU C—Nicosia
16:51★	4714 <i>rf</i>	Intravitreal aflibercept (IVT-AFL) for macular edema secondary to CRVO: Results of COPERNICUS and GALILEO studies CREUZOT C—Dijon
16:57	4715	Direct versus indirect ophthalmoscopy: Medical student assessment of retinal pathology ZIELICKA Z, HULL S, DAVIES N—London

**SIS G** **Modern glaucoma surgery: efficacy and safety** **Hermes**  
Andrew MCNAUGHT, Alain BRON

16:15	4721	Modern Trabeculectomy: Technique, and results from a UK multicentre study KIRWAN JF, LOCKWOOD A, MCNAUGHT AI, MACLEOD A, SHAH P, KING AJ, BROADWAY DC, AGRAWAL P—Portsmouth
16:37	4722	Viscocalanostomy and canaloplasty: Technique and results SUNARIC MEGEVAND G—Geneva
16:59	4723	Novel glaucoma surgery techniques ZEYEN T—Leuven
17:21	4724	UK National Ophthalmology database: optimising surgical safety JOHNSTON R—Gloucestershire

**Joint M. COS** **Keratoprotheses 2 - Tissue and bioengineering approaches** **Rhodes 1**  
Thomas FUCHSLUGER, Christopher LIU



16:15	4731	Microbiological, Chemical, and Mathematical Analysis of Alexidine-Polyethylene Interaction: Implications for the Fusarium Keratitis Epidemic of 2004-2006 BULLOCK J—Kettering, Ohio
16:30	4732	Biomaterials in ophthalmic applications - IOL's and keratoprosthesis STORSBERG J, SCHMIDT C, DUNCKER G, SCHRAGE N, SEL S—Potsdam, Halle, Cologne, Heidelberg
16:45★	4733	In vivo integrity of intra-corneal bioengineered discs in rabbit models RAFAT M, LAGALI N, KOULIKOVSKA M, GRIFFITH M, FAGERHOLM P—Linköping
17:00	4734	Nanofibrous scaffolds for corneal tissue engineering FUCHSLUGER T, BAHNERS T, CZUGALA M, GUTMANN J, SALEHI S—Düsseldorf, Krefeld
17:15	4735	Ocular surface reconstruction SHORTT AJ—London
17:30	4736	Immunomodulatory effects of gene therapy in composite corneal grafts PASTAK M, SINGER BB, SCHWARTZKOPFF J, SABAN D, CZUGALA M, DANA R, STEUHL KP, ERGÜN S, FUCHSLUGER T—Essen, Freiburg, Durham, Boston, Würzburg, Düsseldorf

SATURDAY

**Joint M. OOG: Business meeting  
PO**

Rhodes 2



1. Minutes of previous Business Meeting (Lapland, February 2013)
2. Financial report
3. OOG Website update
4. OOG YIN update
5. Nominations for membership to OOG
6. Update on current collaborative studies/new proposals
7. Details of next OOG Meetings
8. Any Other Business (AOB)
9. Closure of Business Meeting

**Course 18 Femtosecond laser cataract surgery  
LC**

Rafael I. BARRAQUER, Zoltan NAGY

Rhodes 3

The course will review the basic aspects of femtosecond laser cataract surgery, the special features of the different available platforms for this procedure, the different aspects of the surgical techniques relative to the standard cataract (phaco) procedure, the published and emerging evidence on the advantages of this technology, as well as the complications and a discussion of special cases.

16:15	4751	The basics of femtosecond laser cataract surgery NAGY Z–Budapest
16:33	4752	Current available platforms for femtosecond laser cataract surgery ALVAREZ DE TOLEDO J, BARRAQUER RI, NAGY Z–Barcelona, Budapest
16:51	4753	Femtosecond cataract surgery: The basic procedure and surgical details BARRAQUER R, NAGY Z, ALVAREZ DE TOLEDO J–Barcelona, Budapest
17:09	4754	Proven advantages of femtosecond laser cataract surgery NAGY Z–Budapest
17:27	4755	Complications & special cases of femtosecond laser cataract surgery BARRAQUER R, NAGY Z, ALVAREZ DE TOLEDO J–Barcelona, Budapest

Intermediate

**FP COS**      **Free papers COS 5/5: Corneal miscellaneous**      **Rhodes 4**  
 Jean-Jacques GICQUEL, Haydee BAZAN

16:15	4761	Endothelial graft precutting from the epithelial and endothelial side with the femtosecond laser, on cornea stored in a new corneal bioreactor BERNARD A, MAUCLAIR C, BAUBEAU E, GRANIER J, EGAUD G, HE Z, CAMPOLMI N, PISELLI S, FOREST F, PEOC'H M, DUMOLLARD JM, THURET G, GAIN P—Saint-Etienne
16:27	4762	Ultrastructural 3D imaging of collagen fibrils and proteoglycans of macular dystrophy cornea AKHTAR S, KHAN A, KIRAT O, ALKATAN H, ALMUBRAD T—Riyadh
16:39	4763	Integrin alphavbeta5 identifies human corneal epithelial stem cells DI GIROLAMO N, ORDONEZ P, CHOW S—Sydney
16:51	4764	Predictive value of optical coherence tomography in graft attachment after Descemet membrane endothelial keratoplasty YEH RY, QUILENDRINO R, MUSA F, LIARAKOS V, DAPENA I, MELLES GJ—Ans, Liège, Manilla, Rotterdam
17:03	4765	Filamentary keratitis epidemiology PRONKIN I, MAYCHUK D, VASILJEVA O—Moscow
17:15	4766	Cultivation and characterisation of human peripheral cornea derived endothelial cells ALBERT R, FARAJ L, YEUNG A, BRANCH M, SIDNEY L, WILSON S, MCINTOSH O, HOPKINSON A, PETROVSKI G, DUA HS—Nottingham, Szeged
17:27	4767	Adeno-associated viral vector serotypes for gene transfer to corneal endothelial cells FUCHSLUGER T, MUELLER C, DANA R—Düsseldorf, Worcester MA, Boston MA

**FP PBP**      **Free papers PBP 2/2: Retina toxicity and RPE**      **Gallieni 1 & 2**  
 Leopold SCHMETTERER, Gerhard GARHOFER

16:15	4771	Iron antagonism of DICER1 promotes NLRP3 inflammasome priming due to enhanced Alu RNA stability GELFAND B, KIM Y, YASUMA T, LI S, FOWLER B, KLEINMAN M, AMABTI J—Lexington
16:27	4772	Quercetin counteracts the cellular damage caused by HNE and inhibits inflammation in ARPE-19 cells HYTTI M, PIIPPO N, SALMINEN A, KAARNIRANTA K, KAUPPINEN A—Kuopio
16:39	4773	In vivo toxicity evaluation of mannitol included in freeze-dried PEA-III microparticles ROJAS B, DE HOZ R, SALAZAR JJ, RAMIREZ AI, GALLEGO BI, TRIVINO A, ANDRÉS-GUERRERO V, HERRERO R, RAMIREZ JM—Madrid
16:51	4774	Retinal pigment epithelium cell-derived microparticles mediate oxidative stress-induced retinal cells dysfunction TAHIRI H, YANG C, DUHAMEL F, CHEMTOB S, HARDY P—Montreal
17:03 ★	4775	Hepatocyte growth factor in neovascular age related macular degeneration: In vitro study of its effects on choroidal endothelial cells STEWART EA, SAMARANAYAKE GJ, AMOAKU WM—Nottingham
17:15	4776	Plasma gangliosides and age-related macular degeneration DOSSARPS D, MASSON EA, BERDEAUX O, BRON A, CREUZOT C, BRETILLON L—Dijon





## EVER General assembly and prize giving

### Agenda

1. President's address, Philippe Kestelyn
2. Minutes of the General Assembly 2012
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Marcela Votruba
5. Report of the Treasurer, Jean-Jacques Gicquel
  - approval of the accounts 2012
  - discharge to the directors
  - approval budget for 2013
6. Results of the elections
7. Presentation of the board 2014
8. President Elect, Vice President Elect (2)
9. Presentation and report of the Business Meetings of the Scientific Sections meetings
10. Future congresses
11. Prize giving
12. Miscellanea
13. Acknowledgments
14. Handover of chain of office

### Hermes



19:30-21:00

EVER FAREWELL  
COCKTAIL

Mykonos area



# EVER 2014 NICE

OCTOBER 1-4  
SCIENCE FOR SIGHT  
[www.ever.be](http://www.ever.be)



EVER  
EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH





**EUPO**

**EUPO 2014**  
**RETINA**  
Sept 30 - Oct 1  
NICE, France  
In conjunction with **EVER 2014**

EUP0 Office • Kapucijnenvoer 33 • 3000 Leuven • Belgium • [www.eupo.eu](http://www.eupo.eu) • [office@eupo.eu](mailto:office@eupo.eu)





**EVER**

[www.ever-f.eu](http://www.ever-f.eu)

Awardees of the  
EVERf Research Fellowships 2013  
Dr. Reka ALBERT, Hungary  
Dr. Minika JASIELSKA, Poland

*European Association for Vision and  
Eye Research Foundation*

# Acta Ophthalmologica

Edited by: Einar Stefánsson


**Why should you be reading?**

- Impact – our impact factor now stands at 2.345\*, placing us amongst the most highly-cited ophthalmology journals.
- Coverage that's relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye.
- Official publication of EVER and all five Nordic Ophthalmological Societies.

Members of EVER receive FREE online access to *Acta Ophthalmologica* as part of their membership.

Visit [www.actaophthalmologica.com](http://www.actaophthalmologica.com) for more information

\*2012 JCR, Thomson Reuters



# ARVO 2014

MAY 4 – 8 | ORLANDO, FLORIDA LEADING EYE AND VISION RESEARCH


## ARVO 2014 Key Dates

- **Hotel reservations**  
Now open at [arvo.org/hotels](http://arvo.org/hotels)
- **Early meeting registration**  
Opens September 16, 2013
- **Abstract submission**  
Opens October 15 – December 6, 2013
- **Abstract acceptance notification**  
February 18, 2014
- **ARVO Imaging Conference/ARVO Education Courses**  
May 3, 2014 — Orlando, Fla.
- **ARVO Annual Meeting**  
May 4 – 8, 2014 — Orlando, Fla.

Travel grants are available. Apply when submitting your abstract.

+1.240.221.2900; [arvo@arvo.org](mailto:arvo@arvo.org)


[arvo.org/am](http://arvo.org/am)




## KEYNOTE LECTURES

SCHMETTERER L	> Wednesday, 17:15
GRZYBOWSKI A	> Wednesday, 17:50
KIVELÄ T	> Wednesday, 18:25
CHAUHAN B	> Thursday, 10:15
OSBORNE N	> Thursday, 13:40
SADUN A	> Friday, 10:10
BAZAN N	> Saturday, 10:15

Four digit numbers refer to oral presentations



One letter and three digit numbers refer to posters



ABOU SAMRA W: 3431  
 ABRIEU LACAILLE M: S035, S036  
 ABU EL ASRAR A: 1753, 2254, 2256  
 ACAR N: 1613  
 AGARD E: T038  
 AHEARNE M: S037  
 AKHTAR S: S019, 4762  
 AKNIN I: T089  
 ALAVI M: 2662  
 ALBERT R: 4766  
 ALEKSEEV O: 2651  
 ALI ALJASIM L: T039  
 ALJAMAL R: 4443  
 ALKATAN H: 4645  
 ALLEN C: S002  
 ALMALIOTIS D: S025, S026, 3674  
 AL-SWAILEM S: 3432  
 ALVAREZ DE TOLEDO J: 4752  
 AMADIO M: T006, 4662  
 AMBATI J: 2231, 3752  
 AMBROSIO AF: 1742  
 ANDJELIC S: S073, 4457  
 ANDROUDI S: 1452  
 ANGI M: 4445  
 ANGLADE E: 4414  
 ANSARI E: 2223, 2224, 3725  
 AOYAMA Y: T032  
 APTEL F: T033, T047  
 ARDAN T: S016  
 ARJAMAA O: T005  
 ARMITAGE J: 2672, 2673  
 ARNDT C: F039, F063, 3656, 4468  
 ASCASO F: F034, T080, 2711, 4262  
 ASLAM T: 2541  
 ASNAGHI L: 1772

ASPINALL P: 3665  
 ASTERIADIS S: 4213  
 AU L: 1731  
 AVADHANAM V: 4633, 4634  
 AZIZ A: F065, S087, 2645, 3658  
 BACHMANN B: 2676  
 BAILLIF S: 4447  
 BALASKAS K: F041, 3466  
 BARATZ K: 4433  
 BARCATALI M: S096  
 BARRAQUER J: 3721  
 BARRAQUER R: 4252, 4653, 4753, 4755  
 BARREAU G: 4452  
 BASTOS CARVALHO A: F049  
 BATH C: 2434  
 BATTI B: F089  
 BAUDOT A: F006  
 BAUMANN A: S030  
 BAUMEISTER M: 4254  
 BAZAN H: 4436  
 BAZAN N: 4321  
 BEHAR-COHEN F: 3615  
 BENISTY D: F023  
 BENNAI D: F086  
 BERENDSCHOT T: 1443  
 BERNARD A: S041, S050, 4761  
 BERNARDES R: 4463  
 BERROD JP: 1712, 2413  
 BEUERMAN R: 2652, 2772  
 BIDAUT GARNIER M: F067, 3462  
 BIGOT K: F002  
 BLASETTI F: F090  
 BOCHATON-PIALLAT ML: 3714  
 BOCK F: 2431  
 BODAGHI B: 1655, 1755, 2451, 4473

BOLTZ A: 1746  
 BONNEAU D: 2264  
 BONNEL S: S053  
 BONNIN N: T084  
 BORDERIE V: 2674, 3433, 3733  
 BORRUAT F: 2755  
 BOUAKAZ S: T052  
 BOUCHENAKI N: 2252  
 BOUHERAOUA N: S042  
 BOUILLOT A: 3453  
 BRANCH M: 1625  
 BREMOND-GIGNAC D: 1421, 1723, 3273  
 BRERETON N: T040, T041  
 BRON A: 1431, 1541, 2222, 2724  
 BRONKHORST IHG: 1771  
 BULLOCK J: 2653, 4731  
 BURILLON C: 3734  
 BUSHUYEVA NN: F071  
 BUTEL N: S070  
 CALCAGNI A: F046  
 CAMPOLMI N: S048, 3232  
 CAO J: 3741  
 CARAMELLO C: F051, F082  
 CARELLI V: 2265  
 CASSOUX N: 3643, 3744  
 CASTELO-BRANCO M: 3652  
 CAUJOLLE JP: 2441  
 CELLINI M: T053  
 CHAE JB: F045  
 CHAKER N: F022, F031  
 CHATZIRALLI I: S069, S095  
 CHAUHAN B: 2321, 2622, 3223  
 CHAVEZ C: S023, T068  
 CHEBIL A: F030, T016  
 CHENG C: F058, 4467

- CHEOUR M: F036  
 CHIAMBARETTA F: 1422, 3272  
 CHIQUET C: 2656  
 CHUNG SH: 2765  
 CIMBOLINI N: S007  
 COCHENER B: 3661, 4652  
 CORDEIRO M: 2621, 3754, 4222  
 COSCAS F: 3213  
 COSCAS G: 3211  
 COUPLAND S: 2244, 2741, 2745, 3645  
 CRABB D: 3221  
 CREUZOT C: F038, 1615, 1711, 2214, 2542, 2714, 3465, 4714  
 CROWSTON JG: 2262  
 CZUGALA M: S043, 4234  
 DAIEN V: 4672  
 DAISUKE Y: S098  
 DALLONGEVILLE J: 1612  
 DAMATO B: 2445, 3244, 3441, 3443, 3644  
 DARUGAR A: 3456  
 DEBELLEMANIERE G: 3464  
 DE FRANCESCO S: S097, 4642  
 DEGOUMOIS A: T051  
 DE HOZ R: F005, T010  
 DE KEIZER RJW: S089, 1777, 2243  
 DE LA CRUZ J: 4632  
 DE LAEY JJ: 4261  
 DE LANGE MJ: 3742  
 DE LA PAZ M: 3434  
 DELBARRE M: T057  
 DELCOURT C: 1611  
 DELMAS D: 2543  
 DEMAEREL P: 3773  
 DENION E: S088, 2644  
 DESJARDINS L: 2444, 3243, 4241, 4245, 4644  
 DE SMEDT S: 4421  
 DE SMET MD: T031, 1714, 4411  
 DESMOULIERE A: 3711  
 DEV BORMAN A: 1776  
 DE VRIES MM: 4426  
 DE ZAEYTIJD J: F052  
 DICK A: 1451, 1456, 1751  
 DICKMAN M: 2675  
 DI GIROLAMO N: 4763  
 DIWO E: S066  
 DOBROWOLSKI D: S051, 3635  
 DONALDSON PJ: 3762  
 DONOVAN K: 2764  
 DOSSARPS D: 4776  
 DROUTSAS K: 4434  
 DURIEUX P: F035  
 EL CHEHAB H: T055  
 ELLIS S: 4232  
 EL MATRI L: S047, T083  
 ERMOLAEV A: 2725  
 ERRERA MH: S064  
 ESPINASSE M: 2641  
 FACON G: F068  
 FALCK A: T054  
 FAUQUERT J: 3271  
 FEL A: 3651  
 FERRINGTON D: 2273, 3253  
 FISCH AL: 2646  
 FLORES M: 3463  
 FOWLER B: T081  
 FRANCOZ A: T066, 3727  
 FRANCOZ M: T056  
 FRIMPONG-ANSAH K: 1413  
 FRUSCHELLI M: F050  
 FUCHSLUGER T: 4734, 4767  
 GAJECKA M: 2763  
 GALGAUSKAS S: S038  
 GALLEGO B: T009, 1741  
 GANDORFER A: 2415  
 GARCIA-ARUMI J: 2716, 3245, 3246  
 GARCIA MARTIN E: F083, F084, F085, 3771  
 GARHOFER G: 1641, 3521, 3522  
 GARWAY-HEATH D: 3224  
 GAUTHIER A: 3234  
 GAVARD PERRET A: 2241  
 GELFAND B: 4771  
 GEORGALAS I: 1415, 4211  
 GEORGIU T: S003, S057, 4713  
 GHOUALI W: S014  
 GICQUEL J: 1424, 1621, 1622, 1721, 1724, 2631, 2634, 2732, 3662, 3732  
 GIMBERT A: T058  
 GIOCANTI-AUREGAN A: T071  
 GIRAIO H: T002, 4667  
 GIRAUD JM: T064  
 GIRMENS JF: 3413  
 GOCHO K: 2762  
 GONI F: 1542  
 GONZALEZ C: F043, F044, 3772  
 GOTZARIDIS S: 1414  
 GOUREAU O: 3736  
 GRAEFF E: S022  
 GRANZER U: 4415  
 GRAW J: 4673  
 GRIVET D: F093, 2642  
 GRUENERT A: 4431  
 GRUS F: 2452  
 GRZYBOWSKI A: 2712, 3775, 4263, 4655  
 GUAGLIANO R: F087  
 GUEUDRY J: S027  
 GUILLEMOT C: F029  
 GUIMARAES P: 4462  
 GUTIÉRREZ BONET R: F088  
 HADJISTILIANOU T: S091, 4243, 4643  
 HAN J: S063  
 HANNULA V: F070  
 HARDARSON S: 1442  
 HAUTAMÄKI A: 4674  
 HEEGAARD S: 2744, 2746, 4646  
 HEITMAR R: F059  
 HERAVIAN J: F080, T022  
 HERBERT C: 1455, 1654, 2251, 2255, 4475  
 HERON E: 3412  
 HERRERA L: F078, T076  
 HIRN C: T062, 2727  
 HOFFART L: S028, 1664  
 HOLAN V: S001  
 HOLDER G: 1464, 1762, 1764  
 HOLLANDERS K: 1471, 4424  
 HOMMER A: 1432  
 HONDEGHEM K: 2421  
 HOPKINSON A: 1623, 2432  
 HUGNY LARROQUE C: S046, 1632  
 HYTTI M: 4772  
 IBANEZ J: T046, T048  
 IMMONEN I: T077  
 IOMDINA E: F072  
 ITO Y: T082  
 JANISZEWSKA D: 3634  
 JANSONIUS NM: 3222

- JANUSCHOWSKI K: F094  
 JÄRVINEN T: 2774  
 JAYAGOPAL A: 3751  
 JOHNSTON R: 4724  
 JONAS J: F062, T061, 1433, 2211, 2723, 2726, 3655, 4622  
 JONGENELEN S: S082  
 JULIENNE R: S044  
 JUMELLE C: S045  
 JUNG S: F076  
 KAARNIRANTA K: 2272, 3254  
 KAMEYA S: T075  
 KATARGINA L: F092  
 KAUPPINEN A: 4661  
 KAWASAKI A: 1463, 2751, 2754, 3471, 3473, 3474  
 KENGO T: T019  
 KERNT M: F057, 3467, 4712  
 KHAIRALLAH M: 1653, 4476  
 KILARSKI W: 3713  
 KIM Y: F061  
 KIRWAN JF: 4721  
 KIVELÄ T: 2442, 3442, 3444, 4265, 4444  
 KLIJANIENKO J: 3641  
 KODJIKIAN L: 4461  
 KOEHRER P: 4453  
 KOEV K: T078, T079  
 KOH L: F021  
 KOLKO M: 2623  
 KONIDARIS V: S055  
 KONSTANTINIDIS L: S094  
 KOSHY Z: F027, 2414, 2416  
 KOTECHA A: 2424, 3424  
 KOURENTIS C: 4215  
 KOVARSKI C: F074  
 KRASTEL H: T029, T030, 4264  
 KSANDER B: 3745  
 KUBOVA Z: T026, 1661  
 KUOLIENE K: S065  
 KUZMIENE L: S018  
 LABBE A: S005, 2454  
 LABETOULLE M: S004, 1722  
 LAGENAITE C: S099  
 LA MORGIA C: 3776  
 LAMPE M: 2722  
 LANZETTA P: 4541, 4543  
 LECLERC O: 3774  
 LEE DW: T015  
 LEHMACHER W: 4413  
 LE MER Y: 2614  
 LEMIJ H: 3225  
 LENAERS G: 2661  
 LEROY B: 1462, 1761, 1763  
 LEUNG C: 3622  
 LHOIR S: S061  
 LI-FONG LF: 2773  
 LIGHTMAN S: 2234  
 LIM K: 1733  
 LIM LS: T073, 4676  
 LIPSKI D: 1472  
 LISKOVA P: T086, 2766  
 LIU C: 4635  
 LOEWENSTEIN A: 2233, 3614  
 LONGSTAFF S: 1732  
 LOU MF: 3764  
 LUJAIN I: 3653  
 LUK S: F060  
 LUMBROSO L: 4244  
 LUX AL: 3654  
 LYNCH A: 3436  
 MAJO F: 4432  
 MANDAL N: F019  
 MANU MD: T017, T018  
 MARCHESI N: T004  
 MARINESCU C: 4223  
 MARINGE E: S031  
 MARKOSSIAN G: F028  
 MARQUES C: S076  
 MARSOVSZKY L: 1636  
 MARTENS T: 1473  
 MARTIN L: 1663  
 MASSIN P: 1715, 2212  
 MASSON EA: F001  
 MATET A: 2654  
 MATHIEU B: 4664  
 MATONTI F: T025  
 MAUGET-FAYSSE M: 3216, 3415  
 MCINTOSH O: S009  
 MEIER T: 2665  
 MELSOM H: T088  
 MENCUCCI R: 2632  
 MENDES-JORGE L: T012, T013, 2475  
 MESQUIDA M: 3455  
 MEYER P: S072  
 MICHAEL R: S079  
 MICHEE S: S010  
 MICHELI L: 4641  
 MIDENA E: 2213, 2443, 3642, 4446  
 MIKIELEWICZ S: S080  
 MILANO G: T063  
 MILKA M: 4451  
 MIRONOVA E: F009  
 MOE MC: 3672  
 MONNIER VM: 3761  
 MORGAN J: 3624  
 MOTTET B: T037  
 MOULIN A: 3746  
 MOUNA ALI: S034  
 MUNIER F: 4242  
 MURAINÉ M: 2842, 3673  
 NAGARAJ R: 4663  
 NAGY Z: 4751, 4754  
 NAIGEON N: 3675  
 NAKAI K: 2253  
 NAVARRO J: 1743  
 NEMATI F: 3743  
 NERI P: 1453, 1754, 4472  
 NGUYEN KIM P: S060  
 NI DHUBHGHAILL S: 1474  
 NIELSEN K: 3633, 3636  
 NOWAK DM: T085, 2767  
 NOWINSKA A: 3632  
 OCHIAI H: S074  
 O'GALLAGHER MK: S084  
 OGATA N: F042  
 OHTA K: F025  
 OLMIERE C: F015  
 OLSEN AS: T067, 4228  
 ORSKI M: F091, S013  
 OSBORNE N: 1644, 2261, 2621  
 OSHITARI T: F032  
 OSTADIMOGHADDAM H: T070  
 OSTRI C: F024  
 OVERBY D: 1734  
 PALKOVITS S: 1745



- PAÑEDA C: T044, 4227  
 PAPADIA M: 4471  
 PAPPAS G: 1416, 4216  
 PAQUES M: 1444, 3411, 3414  
 PARIKAKIS E: 4214  
 PARROZZANI R: 4441  
 PASTAK M: 4736  
 PATAIA G: S049, 3233  
 PATEL SV: 4435  
 PAULAVICIENE R: F033, S090  
 PELLINEN P: S008  
 PELOSINI L: S086, T050, 2643, 3724, 3726  
 PENAUD B: 3454  
 PEREZ-CARRASCO MJ: S083, 4458  
 PEREZ-MARTIN S: F026, 2417  
 PETROVSKI G: 4665  
 PHILIPPAKIS E: 2412  
 PICAUD S: 1642  
 PIIPPO N: T003  
 PINILLA I: F016, F017  
 PINILLA L: S081  
 PINNA A: S059  
 PINTO L: T065, 4624  
 PIPERNO-NEUMANN S: 4442  
 PISELLA P: 2731  
 PISON A: 1631  
 PLEYER U: 1454, 1652  
 POJDA-WILCZEK D: 1666  
 PONZIN D: 2671  
 POPA CHERECHEANU A: T035, T059, 4425  
 PORTEOUS C: 3423  
 POULTON J: 2663  
 POURJAVAN S: 2422, 3723  
 POURNARAS CJ: 2215, 2611, 3212  
 POURNARAS JA: 1412, 2613, 2616  
 PRIOT AE: T024  
 PROMELLE V: F073  
 PRONKIN I: 4765  
 PUCHE N: 3215  
 PUELL MC: T021  
 PUK O: 2761  
 RAFAT M: 4235, 4733  
 RAMULU P: 3421  
 REDMOND T: 3623  
 REHAK MATUS: 2713  
 REIS A: 1662  
 REMOND A: S071  
 REPPUCCI V: 1417  
 RESCH M: F004  
 REUS NJ: 3663  
 ROBERT P: 2242, 2647  
 RODRIGUES P: 4464  
 ROJAS B: 4773  
 ROMANOWSKA DIXON B: S093  
 ROMERO J: T011  
 ROOMETS E: T074, 4677  
 ROSANDIC J: S078  
 ROSNER M: 4647  
 ROSSETTI L: 1543, 1643  
 ROULAND J: T042, T049  
 ROUSSEAU A: T034  
 RUBIN GS: 3422  
 RUIZ HIDALGO I: 1475  
 RUIZ MORENO JM: F048, F056, 4711  
 RUPENTHAL I: 1744  
 SADUN A: 2664, 3321  
 SAEED IBRAHIM A: T045, 4225  
 SAIB N: S052  
 SALIK D: F007, 1476  
 SALLO F: F055  
 SALVADOR CULLA B: 3435  
 SAUER A: F064, S033, 2655, 3657  
 SCHALENBOURG A: 3242  
 SCHMETTERER L: 1441, 2841  
 SCHMIDL D: 1635  
 SEGURA CALVO F: S021, T072  
 SENNLAUB F: 1614  
 SESHADRI S: F014  
 SHAH A: S067, 4455  
 SHAMS F: T008, 2476  
 SHEN J: T043, 4226  
 SHIMIZU A: F003  
 SHORTT AJ: 3731, 4735  
 SHU X: 4675  
 SIAPICH SA: T027  
 SIDNEY L: 2472  
 SIISKONEN M: F069  
 SIJNAVE D: 1478, 1633  
 SIKORSKI B: 4466  
 SINHA D: 2271, 3252  
 SIOU-MERMET R: S012  
 SJÖSTRAND J: S100  
 SKOTTMAN H: 2473  
 SMEDOWSKI A: S011, S039, 1634  
 SÖDERBERG P: 3763  
 SONG JH: F053  
 SOO GEUN JOE: F040, 3468  
 SOUBRANE G: 3612  
 SPALLONE L: F066  
 SPILEERS W: 1461  
 SRINIVASAN B: 4631  
 STAPPLER T: 1411  
 STEFANSSON E: 3753, 4233, 4623  
 STEIBER Z: S092  
 STEINMETZ P: T060  
 STEVENS AM: 2423  
 STEWART E: T007, 4666, 4775  
 STINGLHAMBER A: T036  
 STORSBERG J: 4231, 4732  
 STRUBLE C: F018  
 SULEMAN H: 2735  
 SUNARIC MEGEVAND G: 1435, 1544, 4722  
 SUZUKI N: 3461  
 SZAFLIK JP: S020  
 SZATMARY G: 2752, 2753, 3472  
 TADAYONI R: 1713, 2232, 2612, 4542  
 TAGUCHI C: F008  
 TAHIRI H: 4774  
 TAKETANI Y: F020  
 TALEBIZADEH N: S075  
 TAPPEINER C: 4474  
 TARIKHT N: 3671  
 TARUTTA E: T020  
 TASSIGNON MJ: 4651  
 THANOS S: 3621  
 THEOCHARIS IP: 4212, 4465  
 THURET G: 2677, 3735  
 TING DSJ: S068, 4456  
 TODOROVA M: 1665  
 TOHARI A: S058  
 TOLD R: F010  
 TORO M: S062  
 TORVINEN PIA: 3722  
 TOTH-MOLNAR E: 1637  
 TRONE MC: S032, 3231

TRUSCOTT R: 3765  
TÜRKSEVER C: T023  
UDAONDO P: 2715  
UDZIELA M: 2843  
UUSITALO H: 2771, 3251  
UZZAN J: 3214  
VAINIO I: 2474  
VAN BERGEN T: 1477, 4423  
VAN CAUWENBERGH C: 1671  
VAN DEN BERG TJTP: 2733, 3664, 4251  
VAN DE PUT M: 2411  
VANDERMEER G: S085, 2734  
VAN DE VELDE S: 1672, 4224  
VANDEWALLE E: 4422, 4621  
VAN ESSEN TH: 2435  
VAN GINDERDEUREN R: 1775, 2742, 2743  
VAN HOUCKE J: 1673  
VAN HOVE I: 1674  
VAN LOOVEREN J: 1675  
VAN PELT S: 1774  
VARGA BE: F079  
VEKRIA P: T014  
VELDMAN E: 3452  
VERDIN H: 1676  
VEREB Z: T001, 2477  
VERSLUIS M: 1773  
VERTICCHIO VERCELLIN AC: F011  
VEZINA M: 4412  
VIDAL-SANZ M: 2453  
VIEL A: S015  
VILA J: F077  
VOTRUBA M: 4671  
WALLACE D: 3712  
WASILEWICZ R: 2721  
WEGENER A: 4253, 4654  
WESTBORG INGER: 4454  
WILLERMAIN F: 1651, 1752  
WILSON S: 1624, 2471  
WIRTH M: T028  
WOJCIK L: S006, S017, S054, 3676  
WOLFENBERGER TJ: 2615, 3611  
WOLF-SCHNURRBUSCH U: 3613  
WON G: S077  
WONG J: S056  
WOWRA B: S024, S029  
WROBEL-DUDZINSKA D: T087  
WYLEGALA E: 3631  
XIROU T: F037, F081  
XU H: 3451  
YASUMA R: F012  
YASUMA T: F013  
YEH R: S040, 4764  
YEKTA A: F075, T069  
YEUNG A: 1423, 2633  
YU-WAI-MAN P: 2263  
YUWEI (VINCENT) Q: 4221  
ZABADANI K: F047, F054  
ZAKARIA N: 1677, 2433  
ZEYEN T: 1434, 2221, 4723  
ZIELICKA Z: 4715  
ZOGRAFOS L: 3241



**WOC2014**

Tokyo | April 2-6

**World Ophthalmology Congress®**  
of the International Council of Ophthalmology

**Host:** Japanese Ophthalmological Society

**Co-Host:** Asia-Pacific Academy of Ophthalmology

- Attend hundreds of scientific sessions led by internationally renowned experts.
- Participate in cutting-edge continuing education opportunities.
- Learn about over 100 exhibiting companies.
- Connect with more than 10,000 attendees from over 120 countries.
- Discover Tokyo during the beautiful cherry blossom season.

WOC2014: Delivering world-class education, insight, and inspiration to a global ophthalmology community for improving quality eye care and preventing visual loss.

**Register Today at [woc2014.org](http://woc2014.org) for Early Bird Rates**



**April 2-6, 2014**

**[www.woc2014.org](http://www.woc2014.org)**



[facebook.com/woc2014](https://www.facebook.com/woc2014)



[twitter.com/woc2014](https://twitter.com/woc2014)



Australia .....	4
Austria.....	7
Belgium .....	29
Bulgaria .....	1
Canada.....	4
Chile.....	1
Cyprus .....	1
Czech Republic.....	4
Denmark.....	7
Egypt .....	2
Estonia.....	2
Finland.....	18
France.....	138
Germany.....	22
Greece .....	12
Hong Kong.....	1
Hungary.....	9
Iceland.....	2
India.....	1
Iran.....	3
Ireland.....	3
Israel.....	2
Italy .....	23
Japan.....	15
Lithuania.....	4
Luxembourg.....	1
Netherlands .....	15
New Zealand.....	2
Norway.....	1
Poland .....	19
Portugal .....	11
Romania .....	2
Russia .....	7
Saudi Arabia.....	6
Singapore .....	6
Slovenia .....	1
South Korea .....	6
Spain .....	31
Sweden.....	7
Switzerland.....	26
Tunisia .....	5
Ukraine.....	1
United Kingdom.....	64
United States .....	30

ATHENA		HERMES		RHODES 1		RHODES 2		RHODES 3		RHODES 4		GALLIENI 1 & 2	
<b>Wednesday 18 September 2013</b>													
11:00 - 12:30	RV: Macular Hole Georgios PAPPAS	COS/NSPH: Update on limbus disorders in children Dominique BREMOND-GIGNAC Jean-Jacques GICQUEL	G: Glaucoma? Yes I can! Alain BRON	PBP: Ocular Imaging Gerhard GARHOFER Leopold SCHMETTERER	IM: EBO review course: Intraocular inflammation and infection - Part I Bahram BOBAGHI Carl P. HERBERT	EOVS: Doctor, The eyes won't keep still Graham HOLDER	FRO - Belgian Fund for Research in Ophthalmology - part 1 Marie - José TASSIGNON Laure CASPERS	Rhodes 2					
12:30 - 13:30	Industry-sponsored symposium 1: Glaucoma and the Ocular Surface												
13:05 - 15:00	RV: Dietary fatty acids: from mechanisms to epidemiology and clinical application in the prevention of Age-related Macular Degeneration (AMD) Lionel BRETILLON	COS: The amniotic membrane: new regenerative therapies and their potential impact on the clinical management of ocular surface diseases Jean-Jacques GICQUEL Andrew HOPKINSON	COS: Free papers 1/5: Corneal inflammation and wound healing Philippe KESTELYN Dominique BREMOND-GIGNAC	PBP: Neuroprotection: past and future strategies Gerhard GARHOFER Neville OSBORNE	IM: EBO review course: Intraocular inflammation and infection - Part II Bahram BOBAGHI Carl P. HERBERT	EOVS: Free papers 1/1: Visual function and neurophysiology Miguel CASTELO-BRANCO Werner SPIELERS	FRO - Belgian Fund for Research in Ophthalmology - part 2 Marie - José TASSIGNON Laure CASPERS	Rhodes 2					
15:05 - 16:35	RV: Retinal detachment Catherine CREUZOT Jean-Paul BERROD	COS: An update on corneal infectious diseases Jean-Jacques GICQUEL Dominique BREMOND-GIGNAC	G/ACB: New frontier in glaucoma surgery: Trans-trabecular meshwork K. Sheng LIM Sayeh POURAVAN	PPP: Free papers 1/2: Neuroprotection and ocular blood flow Gerhard GARHOFER Jonathan CROWSTON	IM: How biologic agents are changing the story of uveitis: anti-TNF- $\alpha$ agents and more Piergiorgio NERI Andrew DICK	EOVS: Visual electrophysiology Graham HOLDER Bart LEROY	PO: Free papers 1/2: New insights into uveal melanoma Martine JÄGER Nathalie CASSOUX	Rhodes 2					
16:45 - 16:55	Welcome by the President EVER 2013 - Philippe KESTELYN												
17:15 - 17:50	EVER Lecture - Leopold SCHMETTERER												
17:50 - 18:20	European Ophthalmic Heritage Lecture - Andrzej GRZBYBOWSKI												
18:25 - 19:00	EVER-Acta Lecture - Tero KIVELÄ												
19:00 - 21:00	EVER Welcome Reception												
<b>Thursday 19 September 2013</b>													
08:30 - 10:00	RV: Macular edema Catherine CREUZOT Pascale MASSIN	G: Dealing with advanced glaucoma Ejaz ANSARI	ME and Retinal Disease Susan LIGHTMAN Anat LOEWENSTEIN	PO: Non-Graves' Orbital Inflammation Pierre Yves ROBERT Rijw DE KEIZER	IM: Improved monitoring and treatment of endogenous uveitis is modifying disease management/outcomes: YKH disease Piergiorgio NERI Carl P. HERBERT	MBGE/NSPH: Mitochondria and the eye: mitochondrial dysfunction and disease Marcela VOTRUBA Alfredo SADUN	ACB: Clearance systems in the RPE cells-implications to AMD Kai KAARNIRANTA Hannu UUSTALO	Hermes					
10:15 - 11:00	Keynote Lecture: Why what you have been taught about the optic disc may not be entirely true, Balwantray CHAUHAN												
11:05 - 12:35	RV: Free papers 1/4: Surgical retina Zachariah KOSHY Ramin TADAYONI	G: Myths and misconceptions in glaucoma Miriam KOLIKO M. Francesca CORDEIRO	COS: Developments in corneal regeneration - NEXCR Herbert VAN ESSEN Marie - José TASSIGNON	PO: The management of pigmented fundus lesions Laurence DESJARDINS Bertil DAWATO	IMG: Inflammation and glaucoma: good or bad? Francis WILLERMAIN Heping XU Alain BRON	MBGE: Grand rounds in ophthalmic genetics Bart LEROY Christian HAMEL	ACB: Free papers 1/2: Modelling corneal epithelium and cell biology of retina Roger W. BEUERMAN Goran PETROVSKI	Hermes					
12:35 - 13:35	Industry-sponsored symposium 2: Micronutrition: Part of the retinal specialists' armamentarium ?												
13:40 - 14:15	Ophthalmic Research Lecture: The neuroscience of glaucoma in relation to the possibility for neuroprotection, Neville OSBORNE												
14:15 - 15:45	RV: Vitreoretinal interface disorders Jean - Antoine C POURVARAS Ramin TADAYONI	G: New angles in glaucoma- neuroprotection Miriam KOLIKO M. Francesca CORDEIRO	COS: An update on corneal procedures Jean-Jacques GICQUEL Rita MENCUCCI	PO: Free papers 2/2: Diagnostic tools in eyelid and orbital pathology Steffen HEEGAARD Eduardo MIDEVA	IM: Free papers 1/2: Ocular infections "pole to pole": new perspectives Piergiorgio NERI Andrew DICK	MBGE/NSPH: Mitochondrial dysfunction in optic neuropathies: from disease mechanisms to therapeutic strategies Marcela VOTRUBA Patrick YU-WAI-FMAN	COS: EEBa symposium: storage and processing of donor tissue before transplantation Vincent BORDERIE	Hermes					
15:45 - 16:30	Poster session 1: Anatomy-Cell Biology / Electrophysiology-physiological Optics-Vision Sciences / Glaucoma / Molecular Biology-Genetics-Epidemiology												
16:30 - 18:00	RV: Controversies in the pathogenesis and treatment of retinal vein occlusion Andrzej GRZBYBOWSKI Francisco ASCASO	G: Free papers 1/4: IOP measurements / Epidemiology Jost B JONAS Philippe KESTELYN	COS: The quality of vision: the new frontier of modern ophthalmology Jean-Jacques GICQUEL Pierre Jean PISELLA	PO: Practical ophthalmic pathology - basics, updates and new insights Sarah COUPLAND Steffen HEEGAARD	NSPH: Neuro-ophthalmic complications in the patient with cancer Aki KAWASAKI Gabriella SZATMARY	MBGE: Free papers 1/2: Genetics; Genotypes and Phenotypes Christian HAMEL Jochen GRAW	ACB: Mechanisms of wound healing Hannu UUSTALO Roger BEUERMAN	Rhodes 2					
18:00 - 19:30	Industry-sponsored symposium: Ocular surface and corneal damage: new outcomes												

ATHENA		HERMES		RHODES 1		RHODES 2		RHODES 3		RHODES 4		GALLIENI 1 & 2	
<b>Friday 20 September 2013</b>													
08:30 - 10:00	RV: Recent Advances in OCT exploration of choroid in normal and diseases Gabriel COSCAS Constantin POURNARAS	G: Intelligent follow-up for glaucoma David F GARWAY-HEATH Balwantraj CHAUHAN	COS: Free papers 2/5: Eye banking and corneal bioengineering Gilles THURET Christopher LIU	PO: Tumours and pseudo-tumours of the pigment epithelium Leonidas ZOGRAFOS Ann SCHALENBORG	ACB: Cell biological techniques for eye research Hannu UUSTALO Ulla AAPOLA							NSPH: GOA Jean-Luc FAUJQUERT Hermes	
10:10 - 10:55	Keynote Lecture: Why is the optic nerve the canary in the coal mine of mitochondrial diseases? Alfredo SADUN												
11:00 - 12:30	RV: Retinal vein occlusions: new concepts for clinical management Michel PAQUES	G: Patient Perceptions in Glaucoma- what the doctor (thinks he) knows, and what the patient can tell us Aachal KOTECHA Pradeep RAMULU	COS: Free papers 3/5: Keratoconus and corneal diseases Vincent BORDERIE María Ideliz DE LA PAZ	PO: Don't panic Hitchhiker's guide to statistics Tero KIVELÄ Bertil DAMATO	IM: Free papers 2/2: Hot topics in ocular immuno-infectology François WILLERMAIN Heping XU					RV: Free papers 2/4: Retina imaging 1 Melanie BIDAUT GARNIER Catherine CREUZOT		NSPH: Visual fields: Back to basics Aki KAWASAKI François-Xavier BORRUAT Hermes	
12:35 - 13:35	Industry-sponsored symposium 3: Enhanced Oxidative Stress and ocular surface												
13:40 - 15:10	RV: Fluid accumulation in the retina Anat LOEWENSTEIN	G: Retinal ganglion cell degeneration and dysfunction in glaucoma James Edwards MORGAN	COS: Corneal Dystrophies – from molecular basis to therapeutic approach Edward WYLEGALA Anna NOWINSKA	PO: FNAB for the diagnosis and management of intraocular tumours Nathalie CASSOUX Laurence DESJARDINS	NSPH: Free papers 1/2: Pediatric ophthalmology Carl ARNDT Bahram BODAGHI			LC: Functional indicators for cataract surgery Rafael J. BARRAQUER Ralph MICHAEL		COS: Free papers 4/5: Infected and ocular inflammatory surface Philippe KESTELYN Marc MURAINÉ			
15:10 - 16:00	Poster session 2: Physiology-Biochemistry-Pharmacology / Retina-Vitreous / Neuro-ophthalmology-Strabismology-Paediatric Ophthalmology-History of Ophthalmology												
16:00 - 16:40	Business meetings of the scientific sections												
16:45 - 18:15	RV/ACB: The myofibroblast: a key player of tissue repair Marie-Luce BOCHATON-PIALLAT Constantin POURNARAS	G: Free papers 2/4: Glaucoma surgery part 1 Joaoquin BARRAQUER K. Sheng LIM	COS/ACB: Stem cells for treatment of eye diseases Vincent BORDERIE	PO: Cell migration and xenografting in ocular melanoma Laurence DESJARDINS Martine JAGER	IM: ARVO @ EVER: Molecular imaging of the Retina Ashwath JAYAGOPAL Justine SMITH			LC: Oxidative stress and cataract Stefan LÖFGREN Vincent MONNIER		NSPH: Free papers 2/2: Neuro-ophthalmology Valerio CARELLI Pierre Yves ROBERT Hermes			
18:15 - 19:15	Industry-sponsored symposium 4: Non-infectious uveitis: A short look back and a long look forward												
20:30 - 23:00	Congress dinner in Negresco - Registration required												
<b>Saturday 21 September 2013</b>													
08:30 - 10:00	RV: Pseudophakic retinal detachment Tina XIROU	G: Free papers 3/4: Medical treatment Anna - Maria STEVENS Gordana SUNARIC WEGEVAND	COS/RV: Therapeutics in the pipeline for unmet needs in ophthalmology Thomas FUCHSLUGER Einar STEFANSSON	PO: Advances in the treatment of retinoblastoma Laurence DESJARDINS Francis WUNIER	LC: Optical and functional correlation of forward and backward scattering in the lens Alfred WEGENER Ralph MICHAEL			NSPH: NSPH: Controversies in history of ophthalmology Andrzej GRZYBOWSKI Francisco ASCASO				Hermes	
10:15 - 10:55	Keynote Lecture : Molecular sensors for the decoding of homeostasis disruptions in the retinal pigment epithelium: towards the understanding of retinal degenerative diseases, Nicholas BAZAN												
11:00 - 12:30	RV: Bench to bedside to registration - the intricate world of drug development Marc D DE SMET Mark VEZINA	G: Free papers 4/4: Glaucoma surgery part 2 Ejaz ANSARI	COS: Cornea & Ocular Surface: Update Thomas FUCHSLUGER Sanjay PATEL Haydée BAZAN	PO: OOG: Melanocytic lesions Sarah COUPLAND Tero KIVELÄ	LC: Free papers 1/1: Cataract surgery Marie - José TASSIGNON Andrzej GRZYBOWSKI			RV: Free papers 3/4: Retina imaging 2 Pedro GUIMARAES Rui BERNARDES		IM: Improved monitoring and treatment of endogenous uveitis is modifying disease management/ outcomes II Piergiorgio NERI Carl P HERBERT		Hermes	
12:35 - 13:35	Industry-sponsored symposium 5 : Afibercept: an innovation in health care for a chronic condition												
13:40 - 15:10	RV: FAN Club Anita LEYS	G: Vitreous & Glaucoma: an unexpected Journey Luís PINTO Leopold SCHMETTERER	COS: Keratoprosthesis 1: Indications and surgical techniques Christopher LIU Thomas FUCHSLUGER	PO: OOG: Retinoblastoma and others Laurence DESJARDINS Theodora HADJISTILIANOU	LC: Controversies in Cataract Surgery Alfred WEGENER Andrzej GRZYBOWSKI			ACB: Free papers 2/2: Cell biology of AMD and DR Deborah A FERRINGTON Hell SKOTTMAN		MBGE: Free papers 2/2: Genetics and epidemiology Bart LEROY Marzena GAJECKA		Rhodes 2	
15:15 - 16:10	Poster session 3: Cornea-Ocular Surface / Immunology-Microbiology / Lens and Cataract / Pathology-Oncology												
16:15 - 17:45	RV: Free papers 4/4: Medical retina Catherine CREUZOT Tassos GEORGIOU	G: Modern glaucoma surgery: efficacy and safety Andrew MCNAUGHT Alain BRON	COS: Keratoprosthesis 2 - Tissue and bioengineering approaches Thomas FUCHSLUGER Christopher LIU	PO: OOG: Business meeting	LC: Femtosecond laser cataract surgery Rafael J. BARRAQUER Zoltan NAGY			COS: Free papers 5/5 : Corneal miscellaneous Jean-Jacques GICQUEL Haydée BAZAN		PBP: Free papers 2/2: Retina toxicity and RPE Leopold SCHMETTERER Gerhard GARHOFER Hermes			
18:00 - 19:30	EVER General Assembly and Prize Giving												
19:30 - 21:00	EVER Farewell cocktail Mykonos area												

# THANK YOU SPONSORS

EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2013. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

## MAIN SPONSORS



## MAJOR SPONSOR



## CIS SPONSORS

abbvie



## SIS SPONSORS



## SPONSORS IN EXHIBITION



## NON PROFIT SPONSORS

